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ABSTRACT 
Recombinant protein therapeutics have transformed modern medicine in the past decade 
and will continue to provide treatments for a wide range of life-threatening illnesses. 
Mammalian cells have been the major workhorse to produce therapeutic proteins owing to 
their capability to perform complex post-translation modifications that are essential to the 
pharmacological activities of these proteins. The performance of mammalian cell culture 
is greatly affected by cell metabolism, while the robustness of glycosylation patterns of the 
product proteins still needs improvement. A meta-analysis of cell culture bioprocess data 
revealed a correlation between lactate metabolism, productivity, and glycosylation 
patterns. Using the system biology approach that integrates computational modeling with 
transcriptomic resources, we explored different behaviors of energy metabolism and 
glycosylation in mammalian cells, contrived strategies for more robust control of cells 
physiology to achieve desired process outcomes. 
In a continuous culture of mammalian cells, different steady states have been observed 
even under the same operating conditions. Some cultures reach a high glycolysis flux state 
whereas others reach a low flux state. The two steady states exhibit different cell 
concentrations. A multi-scale model was constructed, integrating the intracellular 
metabolism with macroscopic cell growth. Using the model, we demonstrate that multiple 
steady states exist in a certain range of dilution rate. At a high flux state, most of the glucose 
consumed is converted to lactate whereas, at a low flux state, glucose is mainly utilized for 
biomass synthesis. The difference in the steady state of glycolysis flux is marked by 
different cell concentrations due to their distinct metabolic efficiencies.  
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Cultured mammalian cells during growth consume glucose at a high rate and convert most 
of it to lactate. As the growth rate tapers, cells may switch to a state of low glucose 
consumption and low lactate production, some cells even start to consume lactate. Among 
cultures that have reduced lactate production, some may resume its high lactate production 
rate during the late stage of culture. Cultures with a switch-up from a low to a high lactate 
production state have been correlated with low productivity. The metabolic model is used 
to explain the mechanism behind this switch-up. We show that the switch-up behavior 
changes as the lactate and glucose concentration vary. Importantly, AMPK-mediated stress 
response also alters the switch-up behavior. Cells in culture may undertake a switch-up or 
not, depending on the concentrations of glucose and lactate and the stress level of the cells. 
During hepatocyte differentiation, a metabolic switch from a high to a low glycolytic flux 
occurred. Using gene expression microarray data of stem cell-derived hepatocytes, we 
examine changes in the transcript levels of key glycolysis enzymes and incorporate such 
change to the kinetic model of energy metabolism in mammalian cells. Model predictions 
reveal the role of isoform levels of glycolysis isozymes in the switch of metabolism. 
Obtaining proper and consistent glycosylation of the protein products is of high importance 
in cell culture process. It has been known that N-glycans affect the efficacy of protein 
therapeutics and mucin-type O-glycans influence the structure and stability of 
glycoproteins. The synthetic pathway of O-glycans involves a large number of enzymes 
whose expression pattern is cell specific. We develop an integrated platform to study the 
O-glycosylation network in a cell-specific fashion. The versatility of this platform can 
facilitate the development of strategies in glycoengineering.  
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1 INTRODUCTION 
1.1 MAMMALIAN CELL CULTURE 
Recombinant protein therapeutics (also known as biologics) had a profound impact on 
modern medicine by providing innovative and effective treatments for a wide range of life-
threatening diseases. These recombinant proteins are mainly produced in mammalian cells 
because of their capability to perform complex post-translation modifications that are 
essential to the pharmacological activities of the proteins. A number of mammalian cells 
have been used to produce biologics; among those, Chinese hamster ovary (CHO) cells are 
the major workhorse, accounting for nearly 70% of therapeutic proteins produced today.  
The performance of mammalian cell culture is greatly affected by cell metabolism, while 
the robustness of glycosylation patterns of the product proteins still needs improvement. A 
meta-analysis of cell culture bioprocess data revealed a correlation between lactate 
metabolism, productivity, and glycosylation patterns. In this study, we use various 
modeling techniques to understand the behavior of cell metabolism and the O-
glycosylation patterns of protein therapeutics. Mathematical modeling of energy 
metabolism of mammalian cells provides us with a more holistic understanding of the cell 
physiology and reveals the underlying mechanism of the somewhat erratic behavior of cell 
metabolism. In addition, we combined a rule-based network generator with a network 
visualization tool to explore the highly complex reaction network of O-glycan synthesis. 
Insights from the current study can be employed to devise strategies for robust control of 
cell physiology to achieve desired process outcomes. 
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1.2 SCOPE OF THESIS 
This thesis research focuses on the development and application of mathematical modeling 
approaches to understanding the physiology of the cells. Two types of models were 
considered in the current study: a kinetic model and a rule-based model. 
In the first part of the thesis, we focus on explaining the mechanism behind the steady state 
multiplicity in continuous culture. Besides fed-batch culture, continuous culture is another 
cultivation method practiced in the industry. In continuous culture, nutrients are fed 
continuously to the culture and the reactor content is withdrawn at the same rate. The 
working volume of reactor thus remains constant throughout the culture. Under seemingly 
identical operating conditions, some cultures reside at a high glycolysis flux state whereas 
some others reside at a low glycolysis flux state. Different metabolic states of glycolysis 
lead to distinct outcomes of the culture. At a high flux state, most of the glucose consumed 
is converted to lactate, leading to a low cell concentration and thus low productivity.  At a 
low flux state, most of the glucose consumed is utilized for biomass synthesis, which 
results in high cell concentration and high productivity. Understanding the conditions at 
which culture can be steered towards a desired steady state is of high interest. In this 
section, we develop a multi-scale model that links the intracellular metabolism with 
macroscopic cell growth in the reactor and use the model to explain the nature of multiple 
steady states in continuous culture. 
The second part of this thesis is devoted to conceiving the mechanism of a somewhat erratic 
behavior of glucose metabolism in the fed-batch culture of mammalian cells. Fed-batch 
culture is the prevailing method for cell cultivation. In fed-batch cultures, glucose is 
regularly added to the medium to sustain its concentration within a certain range. During 
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growth, cells consume glucose at a high rate and convert the majority of glucose consumed 
to lactate. Once the growth phase is over, lactate production rate may vary; some cultures 
have a transition to a state of low lactate production or even start to consume lactate 
whereas others continue to produce lactate towards the end. Among cultures that have a 
reduced lactate production rate, some resume high lactate production after a period of time. 
Cultures that exhibit metabolic switch from low to high lactate production have been 
correlated with decreased viability and low productivity [1, 2].  The diversity of metabolic 
switches discussed above has been observed even for the same cell line, under seemingly 
identical culture conditions and using the same standard operating protocol. The underlying 
mechanism of such metabolic switches has been of interest for decades yet not well 
understood.  We have previously studied the mechanism of a switch from lactate 
production to lactate consumption [3]. In this study, we aim at identifying the mechanism 
of the other switch in which cell changes from a low to a high lactate production state. 
Insights from this study will help contrive strategies for robust control of metabolism and 
prevent an unfavorable switch from occurring.  
In the third part of this thesis, we demonstrate the mechanism of a switch in glucose 
metabolism occurred during hepatocyte differentiation from human embryonic stem cells 
(hESCs). Using gene expression microarray data of stem cell-derived hepatocytes, we 
examine changes in the transcript levels of key glycolysis enzymes and incorporate such 
change to the kinetic model of energy metabolism in mammalian cells. Using this model, 
we reveal the potential association between the levels of glycolysis isozymes and the 
behavior of glycolysis flux during differentiation.  
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In the final part of this thesis, we focus on studying the mucin-type O-glycosylation 
network. Obtaining proper and consistent glycosylation of the protein products is of high 
importance in cell culture process. N-glycans have been known to affect the biologics 
efficacy; mucin-type O-glycans, on the other hand, have profound effects on the structure 
and stability of glycoproteins. The synthetic pathway of O-glycans involves a large number 
of enzymes with diverse substrate specificity. The expression pattern of these enzymes is 
cell specific, thus making the pathway highly diverse. To facilitate the analysis of the 
pathway in a cell-specific fashion, we develop an integrated platform of a rule input 
network generator and a network visualization program. We use the platform to generate 
the O-glycosylation networks of different cell lines, compare the predicted network with 
the reported O-glycan profiles of the same cell lines, and then predict the synthetic route 
for each reported glycan species. The versatility of this platform in projecting the network 
and tracing the reaction path can facilitate the development of strategies in 
glycoengineering. 
1.3 THESIS ORGANIZATION 
This thesis is organized into five chapters. Chapter 2 focuses on development and 
application of a multi-scale kinetic model to the analysis of multiple steady states in 
continuous culture of mammalian cells. The multiple steady states behavior of glycolysis 
flux is exploited to devise strategies to guide cells towards the desired flux state with higher 
cell concentration. Chapter 3 examines the mechanism of the metabolic switch to high 
lactate production in fed-batch cultures of mammalian cells. We also investigated the 
important parameters for stimulating the switch. Chapter 4 discusses the effect of isoform 
composition of key glycolysis enzymes on the glycolysis activity. Chapter 5 presents an 
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integrated platform for generation and visualization of the O-glycosylation network.  
Finally, chapter 6 provides a brief conclusion of this study and future directions.  
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2 MECHANISM FOR MULTIPLICITY OF STEADY STATES WITH DISTINCT 
CELL CONCENTRATION IN CONTINUOUS CULTURE OF MAMMALIAN 
CELLS 
Reproduced from: Yongky A, Lee J, Le T, Mulukutla BC, Daoutidis P, Hu WS, 
Mechanism for multiplicity of steady states with distinct cell concentration in continuous 
culture of mammalian cells. Biotechnology and Bioengineering, 2015. 112(7): p. 1437-
1445. 
TL constructed the ODE model. AY derived the algebraic model from the ODE model. 
AY and TL performed simulations and analyzed the results. 
2.1 SUMMARY 
Continuous culture for the production of recombinant proteins enables steady state 
operations, which provides more consistent product quality and increased productivity. The 
multiplicity of steady states has been observed in continuous cultures of mammalian cells. 
With the same dilution rate and feed nutrient composition, steady states with very different 
cell and product concentrations may be reached; in a high glycolysis ﬂux state, cells 
produce lactate with a high specific rate and have low cell concentration, whereas cells at 
a low ﬂux state have a lower rate of lactate production and higher cell concentration. These 
different steady states also have different productivity. A mechanistic understanding of the 
multiple steady states behavior in continuous culture facilitate the development of 
strategies to guide the culture toward the desired steady state. We established a multi-scale 
kinetic model that links the intracellular metabolism with the cultivation conditions in a 
continuous bioreactor. We showed that the bistable behavior of glycolysis flux leads to the 
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occurrence of steady state multiplicity in a range of dilution rate. The model was also used 
to devise strategies to steer the culture toward the desired steady state.  
2.2 INTRODUCTION 
Mammalian cells are the predominant host cells for the production of therapeutic 
recombinant proteins. In the past three decades, fed-batch culture, wherein feed containing 
nutrients are regularly added to the culture to replenish those consumed to sustain longer 
cell growth and production period, has become the prevailing form of process. While the 
continuous process has been explored as a process technology and for kinetic studies of 
cell growth and metabolism [4-13], its industrial applications are mostly in the case that 
the product is labile or is produced at a rather low concentration, such as Factor VIII and 
Protein C. 
Continuous cell culture processes operated at steady states allow a stable cell concentration 
and productivity to be sustained in the reactor for an extended period. The increased 
productivity also allows a small manufacturing facility to be used. In addition, continuous 
cell culture processes offer the advantage of a steady state operation, where none of the 
parameters such as the concentrations and rates of glucose, lactate and cell changes 
throughout time. Such steady state operation possibly enables a better control of the cells’ 
physiological state, thereby enhancing our ability to control product quality. Because of 
this potential beneﬁt and the increasing emphasis on product quality in biopharmaceutical 
processes, there has been increasing interest in exploring continuous culture for 
mammalian cell culture [14]. 
However, the growth and metabolic behavior of mammalian cells differ signiﬁcantly from 
those of most microbial cells. The growth of microorganisms can often be adequately 
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described by a Monod growth model and be shown experimentally to have a unique steady 
state where the concentration of cells, nutrients and other process parameters such as 
growth and metabolic rates all reach a unique set of steady state values under a set of 
nutrient input conditions and at a ﬁxed dilution rate. In contrast, under identical operating 
conditions, mammalian cells can metabolize glucose differently depending on their 
physiological states. Such capability was demonstrated in the form of a metabolic shift of 
glucose catabolism in many types of cultured cells [15, 16]. Under those different 
metabolic states, cells may consume glucose at a high rate and convert a large proportion 
of glucose to lactate or consume glucose at a low rate and produce little lactate. The 
metabolic shift resulted in a lower proportion of carbon sources being directed toward 
lactate, redirecting more carbon sources to cell growth. Through the control of glucose at 
low levels to shift cell metabolism prior to the initiation of continuous culture, the culture 
reached a steady state with higher cell concentration compared to the culture started from 
batch mode without alteration in cell metabolism [17, 18]. Those continuous cultures 
reached distinct steady state marked by distinct cell concentration, even though the feed 
and operating dilution rate were the same, thus suggesting the existence of steady state 
multiplicity. Similar demonstrations of steady state multiplicity in continuous culture were 
reported in other studies [19, 20]. 
This steady state multiplicity was experimentally attained by exploiting the plurality of the 
ﬂux of glycolysis observed in cultured cells. The cause of steady state multiplicity and the 
range of conditions that multiplicity exists were not known. Those multiple steady states 
are marked not only by different glycolysis ﬂuxes but also by different cell concentrations 
and thus the productivity. The ability to control the culture to consistently reach the desired 
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steady state, usually the one with higher cell concentration, will be critical for production 
processes. Therefore, a better understanding of the root cause of such steady state 
multiplicity and ways to control the culture trajectory is essential. 
We have previously shown that steady state multiplicity exists in the glycolysis of 
mammalian cells as a result of the feedback and feed-forward regulations imparted by the 
set of isozymes they express [21]. The glycolysis ﬂux increases with increasing 
extracellular glucose concentration as in most metabolic pathways, but in a range of 
glucose concentrations, multiple steady states exist for a given glucose concentration. In 
the bistable region, the glycolysis ﬂux may be at either a high ﬂux state or a low ﬂux state. 
In the late growth phase of a fed-batch culture, the culture can transit from a high ﬂux state 
to a low ﬂux state as a result of reduced AKT activation due to slower growth rate and 
lactate inhibition of glycolysis [3]. The glycolysis behavior predicted by the metabolic 
model is supported by experimental observations in fed-batch cultures and in continuous 
cultures, providing a mechanistic foundation for the metabolic shift. 
In this study, we constructed a multi-scale model that integrates the intracellular metabolic 
model with the macroscopic cell growth model in a continuous bioreactor. Through model 
simulations, we show that multiplicity of steady states is present in a range of dilution rates 
in continuous culture and demonstrate the trajectory that one can employ to guide the 
culture to the desired steady state. 
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2.3 MATERIALS AND METHODS 
2.3.1 Multi-Scale Model 
A kinetic metabolic model of mammalian metabolism including glycolysis, pentose 
phosphate pathway (PPP), tricarboxylic acid (TCA) cycle, malate-aspartate shuttle 
pathway and citrate shuttle between the cytosolic and the mitochondrial compartments was 
constructed as described previously [3, 21]. The rate expressions for all enzymatic 
reactions were based on mechanistic derivation [22, 23]. The allosteric regulations of the 
enzymes phosphofructokinase (PFK), pyruvate kinase (PK) and 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase (PFKFB) have been considered in detail based on the 
Monod-Wyman-Changeaux method [24]. For cases where multiple isozymes are expressed 
in the mouse-mouse hybridoma cell line, MAK, the dominant form based on microarray 
data [25] namely the muscle isoform of PFK (PFKM), the M2 isoform of PK (PKM2) and 
PFKFB3 isoform of PFKFB, were considered. In this study, the model was extended to 
include the macroscopic cell growth and mass balances for extracellular glucose and lactate 
in the reactor in a continuous operation (Figure 1) 
 
Figure 1. Schematic of the multi‐scale model. 
The model takes into account the intracellular metabolism of the cell and substrate utilization 
for macroscopic cell growth in the reactor. Notations: V, reactor volume; F, volumetric 
flowrate; Glcex, glucose; Lacex, lactate; x, cell concentration. 
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The multi‐scale ordinary differential equation (ODE) model consists of mass balance 
equations for 37 reaction intermediates of the intracellular metabolism as well as three 
macroscopic mass balance equations. The rate expressions for the intracellular enzyme 
kinetics and the differential equations for those intracellular metabolic intermediates have 
been described previously [3, 21]. The equations describing macroscopic cell growth, 
glucose and lactate concentrations in the bioreactor are as follow: 
Equation 1. The rate of change of extracellular glucose concentration. 
( )  ex feed ex GLUT
dGlc D Glc Glc r x
dt
= − − ×  
Equation 2. The rate of change of extracellular lactate concentration. 
ex
ex MCT
dLac D Lac r x
dt
= − × + ×  
Equation 3. The rate of change of cell concentration. 
( D)dx x
dt
µ= − ×  
Equation 4. The specific growth rate of the cells. 
( )
,
max 2
, ,
i Lacex
m Glc ex i Lac ex
KGlc
K Glc K Lac
µ µ= × ×
+ +
 
The reactor balance model shown above is linked to the intracellular metabolic model 
through the rates of consumption of glucose (rGLUT) and production of lactate (rMCT). rMCT 
and rGLUT (i.e the glycolysis flux) are related to the concentrations of glucose (Glcex) and 
lactate (Lacex). The specific growth rate of the cells is assumed to follow Monod type 
kinetics with respect to glucose concentration and an inhibitory effect of lactate in Equation 
4 as described previously [26]. Thus, the cell growth rate is indirectly affected by the 
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intracellular metabolism through glucose and lactate. One of the major determinants of the 
rate of intracellular metabolism is the AKT signaling pathway activity which modulates 
the kinase‐to‐phosphatase ratio (K/P) of the PFKFB [27-29]. AKT phosphorylation of 
PFKFB positively affects the rate of glycolysis. AKT activity is correlated to the growth 
rate of the cells. However, for the range of dilution rates considered in this study, the 
growth rate is high and AKT is assumed to be fully active in all dilution rates. 
2.3.2 Model Simulation 
An algebraic model comprising of steady state mass balance equations for the cell 
concentration, extracellular glucose and lactate concentrations and all the intracellular 
metabolites concentrations was derived from the multi‐scale ODE model. The steady state 
solutions were obtained from the algebraic model using numerical solver fsolve in Matlab 
(Mathworks, Inc.). Positive and real‐valued solutions were calculated using initial guesses, 
which were pseudorandom values drawn from the standard uniform distribution. All the 
possible steady states and the corresponding eigenvalues were calculated initially at fixed 
feed glucose concentration of 5 mM and dilution rate of 0.033 h−1. The feed glucose 
concentration and dilution rate were then expanded to find other steady state conditions. 
The steady state concentrations of the cell and all metabolites were examined to ensure 
they are within the same order of magnitude as the physiological range. The local stability 
of a steady state was investigated using the standard approach of calculating the 
eigenvalues of the Jacobian evaluated at the steady state. The Jacobian matrix was 
calculated as part of the output of Matlab's fsolve function. The eigenvalues of the Jacobian 
matrix were evaluated using Matlab's eig function. If all the eigenvalues have a negative 
real part, the steady state is stable, if not it is unstable. 
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Transient simulations of the ODE model were performed using the implicit numerical ODE 
solver ode15 in Matlab (Mathworks, Inc). Initial cell and lactate concentrations were 
1.5 × 105 cells/mL and 0 mM, respectively. For the batch culture simulation, the dilution 
rate was set to zero and the initial glucose concentration used was 15 mM. For the fed‐
batch culture, the dilution rate was set to zero and the extracellular glucose concentration 
was fixed at 0.5 mM by setting the right-hand side of the differential equation for 
extracellular glucose Equation 1 to zero. Upon switching to continuous mode, the dilution 
rate was set at 0.033 h−1 and the feed glucose concentration was 7 mM. Changes in the 
extracellular concentrations of glucose, lactate, and cell and the intracellular concentrations 
of all metabolites were followed. 
2.4 RESULTS 
2.4.1 Multiplicity of Steady States in Continuous Culture 
The multi‐scale model was used to first simulate the steady state reached in continuous 
culture. Figure 2 depicts the steady state concentrations of cells, glucose, and lactate as 
well as the fluxes (i.e. specific consumption rate) of glucose and lactate at different dilution 
rates. The glucose concentration in the feed was fixed at 5 mM (Figure 2A–C). The figures 
show classical bistable behavior where two stable metabolic steady states exist in the 
dilution rate ranging from 0.029 to 0.039 h−1. The middle steady states are unstable and 
cannot be realized in the culture. The glucose flux and lactate flux data in the bistable 
region indicate that a set of stable steady states corresponds to high flux state and the other 
set correspond to low flux state. At high flux states, glucose is mostly converted towards 
lactate as indicated by the ratio of lactate flux and glucose flux into glycolysis (JL/JG) which 
is in the range of 1.45‐1.6 mol/mol. In contrast, the low flux states have (JL/JG) 
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<0.8 mol/mol. In addition, the high flux states have lower cell concentrations and higher 
lactate levels, while the low flux states have higher cell concentrations and lower lactate 
levels. Thus, glucose is more efficiently metabolized to support cell proliferation at low 
flux states. Outside of the bistable region, only one steady state exists for a given dilution 
rate: at dilution rate <0.029 h−1 only the low metabolic flux state (high cell concentration) 
exists whereas at dilution rate >0.039 h−1 only the high metabolic flux state (low cell 
concentration) exists. 
 
Figure 2. Multiple steady states in continuous culture. 
Bistability is observed in the profiles of cell concentration (A, D, G), extracellular 
concentrations of glucose and lactate (B, E, H), rates of glucose consumption and lactate 
production and the ratio of the two rates(C, F, I). Feed glucose concentration was 5 mM (A‐
C), 8 mM (D‐F) and 12 mM (G‐I), respectively. The steady states corresponding to low 
metabolic flux are in blue, while those corresponding to the high metabolic flux are in red. 
15 
 
The unstable steady states are in black. Note that the steady states with low metabolic flux 
confer high cell concentration and vice versa. 
The effect of increasing the feed glucose concentration on the steady state behavior was 
then investigated by varying the feed glucose concentrations from 5 mM to 8 mM (Figure 
2D–F) and 12 mM (Figure 2G–I), respectively. At a low flux steady state increasing feed 
glucose concentration gives rise to a higher steady state cell concentrations as well as 
somewhat elevated residual glucose and lactate concentrations (comparing Figure 2B,E,H), 
although the extent of cell concentration increase diminishes somewhat at the high dilution 
rate region at a feed glucose concentration of 12 mM. This is due to the higher levels of 
residual glucose concentration (thus lower amounts of glucose taken up by cells) at those 
steady states. In contrast, increasing feed glucose concentration at high flux states does not 
increase the cell concentration substantially, rather the residual lactate concentration 
increases significantly. At the low feed glucose concentration of 5 mM, the high flux state 
extends only to a dilution rate of 0.029 h−1, below that only the low flux state is observed. 
Whereas at higher feed glucose concentrations the high flux metabolic steady states reach 
into lower dilution rate range. 
2.4.2 Effect of Feed Lactate on Steady State 
Consumption of lactate typically occurs in the late stage of fed‐batch cultures. It happens 
when the glycolysis flux is low [30]. In continuous culture, while steady states with low 
lactate production rate are possible under normal feed condition as seen above, steady 
states with lactate consumption do not occur unless lactate is present in the feed.  
The steady state profiles of continuous cultures with a feed glucose concentration of 5 mM 
and lactate supplemented at 2 mM and 5 mM are shown in Figure 3. In both cases, lactate 
consumption only occurs at dilution rate <0.021 h−1. Glucose is still being consumed even 
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when lactate consumption occurs at dilution rate <0.021 h−1, resulting in negative values 
for JL/JG ratio (Figure 3C&F). In this range of dilution rate in which lactate consumption 
is observed, cell concentration is hardly affected compared to the case of no lactate 
supplementation (Figure 2A). In the lactate consumption state a significant residual lactate 
concentration is present in order to drive lactate uptake by cells; thus the net amount of 
lactate consumed is too small to substantially change cell concentration. 
 
Figure 3. Effect of feed lactate on the bistable behavior in continuous culture. 
Lactate concentration in the feed was 2 mM (A‐C) and 5 mM (D‐F), respectively. Lactate is 
consumed only at dilution rate <0.021 h−1. 
2.4.3 Trajectory to Steady State in Continuous Culture 
We next ask the question of how to direct a continuous culture to a different steady state in 
the bistable region. The key is to “guide” cells to the desired flux state before it reaches the 
steady state. For increasing the productivity, the desired steady state is the low flux state 
with a higher cell concentration compared to the high flux state. In a batch culture of 
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mammalian cells the default steady state is always the high flux state as cells in culture, 
without intervention, always consume glucose at a high rate and convert a large portion of 
glucose to lactate. To “guide” the system toward a low flux steady state in continuous 
culture, one strategy is to first culture them in fed‐batch with glucose maintained at low 
concentration. Such strategy allows the culture to move to a region in which only the low 
flux state exists (Appendix Figure 1). Once the metabolic state is in a low flux state, one 
can switch the culture to a continuous mode. 
This scenario is illustrated by two simulated cultures: in one case a batch culture is switched 
to a continuous mode without guiding cells to a low flux state; in the other, a low glucose 
concentration is imposed in fed‐batch culture to first guide cells to a low flux state (Fig. 4). 
The initial conditions used are 1.5 × 105 cells/mL and 0 mM lactate in both cases. Upon 
switching to continuous mode, the dilution rate is 0.033 h−1 and feed glucose concentration 
is 7 mM in both.  
The batch culture is initiated with a glucose concentration of 15 mM. It consumes glucose 
and produces lactate at very high rates and reached 11.8 mM and 4.9 mM of glucose and 
lactate respectively at 50 h (Figure 4A&B). The ratio of glucose to lactate conversion 
(JL/JG) is 1.55 mol/mol, indicating that the culture operated at high metabolic flux state. At 
this time, with a cell concentration of 1.8 × 106 cells/mL, the culture is switched to a 
continuous mode. The culture continues at a high flux state (JL/JG) is 1.53 mol/mol) to reach 
a steady state with a relatively low cell concentration of 3.2 × 106 cells/mL. 
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Figure 4. Transient simulations of continuous culture that reaches steady states with distinct 
cell concentrations. 
(A‐B) Culture started from batch mode exhibits high metabolic flux and remains at high flux 
state upon initiation of continuous culture. Such culture reaches steady state with high 
metabolic flux and lower cell concentration. (C‐D) Culture started from fed‐batch with 
glucose maintained at low level exhibits a metabolic shift to low flux state. Upon initiation of 
continuous mode, the culture remains at low flux state and reaches steady state with higher 
cell concentration. Arrow (↑) indicates the time at which continuous mode is initiated. In the 
continuous mode, dilution rate and feed glucose concentration were fixed at 0.033 h−1 and 
7 mM, respectively. 
For the fed‐batch culture, glucose concentration is maintained at 0.5 mM. Over time, the 
culture undergoes a metabolic shift to a low flux state. After 110 h (Figure 4C&D) JL/JG 
was 0.22 mol/mol indicating low metabolic state. Cell concentration reaches 5.1 × 106 
cells/mL. At this point, the culture is switched to continuous mode, where it continues at a 
low flux state as indicated by the low JL/JG. Glucose and lactate concentrations settled down 
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to 1.7 mM and 3.6 mM, respectively, and the cells continued to grow before reaching a 
final steady state concentration of 5.6 × 106 cells/mL. 
2.5 DISCUSSION 
In this study, we constructed a multi‐scale model combining intracellular metabolic 
pathways with the macroscopic cell concentration in a continuous bioreactor. From a 
modeling perspective, biological systems are intrinsically multi‐scale, involving time and 
length scales spanning over many orders of magnitude, from microsecond and nanometer 
at submolecular level, millisecond to submicrometer in biochemical reactions, to 
centimeter and minutes in tissue and even organism levels. In this multi‐scale model, the 
time constants involved range from the order of seconds in enzyme reactions to multiple 
of hours in the reactor, and the material quantities range from the order of 10−5 moles per 
L for metabolites to 1010 per L for cells. Due to the ill‐conditioned nature of the model, i.e. 
the span of over many orders of magnitude between distinct variables, appropriate scaling 
was necessary to solve the system. 
The steady state multiplicity predicted by the mechanistic metabolism model is manifested 
in the continuous bioreactor. In the bistable region, for a given dilution rate, the culture can 
exist at either a high glycolysis flux steady state or a low glycolysis flux steady state. The 
two kinds of steady states have different metabolic efficiency. At a high flux state, the vast 
majority of glucose is converted to lactate, whereas at a low flux state more glucose 
consumed is converted to biomass. Thus different steady states are marked by distinct 
steady state cell concentrations. With the feed glucose concentration used in the simulation, 
multiple steady states are observed only in a range of dilution rates. Outside of the bistable 
region, in the high dilution rate region, only the high flux states are present. Whereas in the 
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low dilution rate region, only the low flux states exist. It is notable that the model predicts 
that in the range of lactate production rate to glucose consumption rate ratio (JL/JG) between 
0.8–1.45 no stable steady state exists. The experimental data in the literature are in close 
agreement to this finding [4, 5]. 
In the bistable region, which steady state (high flux state or low flux state) a culture will 
reside in is dependent on the history of the culture. One can thus influence the steady state 
to be reached by controlling the cell's metabolic state before steady state is reached. Since 
the “default” state of cells in culture under typical culture conditions is a high flux state, at 
issue is thus “guiding” the cell to a low flux state before steady state is reached. 
This was illustrated by two approaches: one by eliciting a metabolic shift to a low flux state 
in fed‐batch culture via controlling glucose at low levels (Figure 4), and the other by 
operating at a low dilution rate region in which only the low flux steady state exists before 
gradually increasing the dilution rate to the bistable region (Appendix Figure 2). Indeed 
these two approaches were used to reach a low flux steady state in two experimental studies 
[17, 20]. 
The bistable behavior observed in continuous culture is reminiscent of that observed in fed‐
batch cultures. Cells in the later stage of fed‐batch cultures can switch their metabolism 
from high rate of lactate production to lactate consumption. The metabolic shift to lactate 
consumption in fed‐batch cultures has been shown to be correlated with a higher 
productivity [1, 2]. In continuous culture, a steady state with lactate consumption does not 
exist without lactate supplementation in the feed. Addition of lactate to the feed medium 
of a continuous culture may not be used in practice, but the result does show its feasibility 
as a steady state operation. 
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In culture, mammalian cells also consume glutamine and other amino acids. These amino 
acids are building blocks for cellular proteins, nucleotides, etc. Glutamine also contributes 
to the energy metabolism through anaplerotic pathway [31]. The rate of glutamine 
consumption at the high flux state is higher compared to that at low flux state. Overall 
glutamine consumption rate is almost one order of magnitude lower than glucose. For the 
purpose of demonstrating the mechanism of multiple steady states in continuous culture, 
glutamine effect is considered small and was not included in the model. 
In our model, the specific growth rate is expressed as a Monod type kinetics with respect 
to the concentrations of glucose and lactate (Equation ). Thus, we implicitly assume that 
all other nutrients, including glutamine and other amino acids, are in ample supply. While 
a few amino acids, including glutamine, are essential for the growth of cells in culture, 
none of them are depleted in the spent media; indicating no amino acid limitation in the 
cultures. Thus, the use of Equation 4 as a first approximation is appropriate in this case. In 
cases where some amino acids may be depleting, a modified form which includes those 
amino acids will be required. 
There has been a resurgence of interest in using continuous culture for recombinant 
therapeutic protein production [14]. The prospect of producing biosimilars in different 
regions of the world has provided incentives for constructing regional manufacturing 
facilities. Many new facilities will aim to be smaller and more flexible in terms of the 
product it produces while sustaining a high throughput similar to the facility designed for 
fed‐batch manufacturing. Continuous processes are well suited to such purposes. 
Furthermore, continuous processes offer the possibility of steady state operation in which 
the metabolic state of cells is kept relatively constant as opposed to the constantly changing 
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nature in fed‐batch cultures. Increasingly, biopharmaceutical production is focusing on 
controlling product quality in addition to the productivity. The glycosylation pattern of the 
product protein is a key product attribute that process engineers strive to control and is 
reported to be affected by many environmental factors that fluctuate in typical fed‐batch 
cultures [32-35]. Steady state operation of continuous cultures may minimize such culture 
variations and provides greater control of product quality. 
The multi‐scale model presented demonstrates that multiple steady states exist under some 
culture conditions. Since those different steady states represent different metabolic states, 
they may also elicit different glycosylation patterns or other product quality attributes with 
some being the preferred. In view of such possibilities, controlling the culture condition to 
ensure it follows the trajectory to reach the desired steady state is thus critical. The model 
we established should provide mechanistic understanding to prescribe such trajectories to 
enhance process performance. 
3 MECHANISTIC STUDY OF THE METABOLIC SHIFT TO LACTATE 
PRODUCTION IN MAMMALIAN CELL CULTURE 
3.1 SUMMARY 
Cultured mammalian cells invariably exhibit high glycolysis flux and high lactate 
production during their growth. As the growth rate tapers, cells may switch to a state of 
low glycolysis flux with low lactate production or even lactate consumption. The switch to 
lactate consumption has been shown in correlation with productivity. Cultures that 
underwent a switch to lactate consumption had higher tiers than those did not. In fed-batch 
cultures, cells sometimes switch back to a high glycolysis flux state and resume lactate 
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production. Such metabolic switch occurs at the late stage of cultures when the cultivation 
conditions represent a high-stress environment. The metabolic homeostasis of cells is 
tightly regulated through the AMPK signaling pathway, which is stimulated in response to 
energy, nutrient, and high-osmotic stresses.  We have previously shown that the glycolysis 
flux of proliferating cells exhibits a hallmark of bistability in distinct high and low flux 
states. In this study, we use mathematical modeling to demonstrate the effect of AMPK on 
the bistability of glycolysis flux, and thus the topology of steady states. The transition from 
the low to the high flux state occurs in a certain region of the steady state topology. The 
metabolic outcome of the cells depends on the trajectory that they undertake in the steady 
state topology.  Cells encountering the region that allows a switch in the metabolic state 
will adopt high glycolysis flux with elevated lactate production. Insights into this switch 
behavior provide a guideline principle in control of cell metabolism in fed-batch cultures.  
3.2 INTRODUCTION 
The extensive regulation of the glycolysis pathway in mammalian cells gives rise to very 
complex metabolic behavior. The metabolic behavior is affected by the isoform 
composition of several key enzymes in the glycolysis pathway. Glucose metabolism is 
further affected by cell’s growth rate mediated through various signaling pathways. The 
complex regulation of glucose metabolism has a profound effect on the productivity of 
therapeutic proteins produced in cell culture. Cells invariably produce lactate from glucose 
when growing rapidly. However, under some conditions, for example in the stationary 
phase of fed-batch culture, they may consume lactate. It is not unusual that the same cell 
line may have different metabolic behavior, even under seemly identical culture conditions.   
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When analyzing data from a biomanufacturing plant, we found that the top productivity 
runs switched from lactate production to lactate consumption, while low productivity runs 
remained in the lactate production mode throughout the culture [1]. Such observations 
attest to the significant influence of glucose metabolism on productivity. Using a 
mechanistic kinetic model, we have previously attributed the “unpredictability” in glucose 
metabolism to the multiple steady state behavior of glycolysis flux in mammalian cells 
[21]. The topology of the glycolysis flux at different glucose and lactate concentration 
changes as the growth rate varies, due to changing levels of AKT activation of PFKFB 
enzyme [3]. In a fed-batch culture, the difference in the timing of glucose addition may 
cause cultures at the same initial conditions to diverge to different metabolic fates [3].  
The multiple steady states behavior has also been observed in the continuous bioreactor. In 
the previous section (Section 2), a multiscale model that links the intracellular metabolism 
with the bioreactor cultivation conditions is described [36]. The model was used to 
demonstrate the occurrence of steady state multiplicity in a range of dilution rates in 
continuous culture. The low flux steady state is the desired state for increasing productivity 
because it provides a higher cell concentration as compared to the high flux state. In order 
to attain the metabolic shift to a low flux state in continuous culture, a low dilution rate is 
necessary. Intriguingly, model prediction shows that at a low flux state, lactate 
consumption occurs only under the presence of lactate in the feed. 
In addition to AKT, another major player of signaling pathways that affect cell metabolism 
is AMPK. AMPK is activated by energy [37], nutrient [38-42], and hyperosmotic stresses 
[43]. During late stage of culture, many metabolites may accumulate to a high level, 
representing a high osmolality environment [1]. Under such conditions, AMPK might be 
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activated, leading to a stimulation of glycolysis flux through PFKFB activation. This 
chapter discusses the effect of AMPK activation on the topology of glycolysis flux at 
various levels of lactate and glucose. Glucose addition during high AMPK activity may 
shift the culture from a low flux state to a high flux state with a concurrent increase in 
lactate production. Through model simulations, we show that with the presence of lactate 
in the feed, one can prevent the occurrence of the metabolic switch-up and retain the culture 
at a low glycolysis flux state. 
3.3 MATERIALS AND METHODS 
A kinetic metabolic model of the central metabolism pathway in mammalian cells was 
previously constructed [3]. It includes glycolysis and pentose phosphate pathways, TCA 
cycle, malate-aspartate shuttle, and other inter-compartmental shuttles. The mass balance 
equations of 40 reaction intermediates involved in these pathways were incorporated into 
an ordinary differential equation (ODE) model. The rate expressions for all enzymatic 
reactions were derived based on the mechanistic understanding of enzyme kinetics [44]. 
The kinetic parameters were obtained from the previous literature.  
Many reactions in the glycolysis pathway are catalyzed by multiple isozymes, which are 
subjected to diverse regulatory mechanisms [21].  The model used in this study considers 
the dominant isoforms expressed across different CHO cell lines as shown in our 
transcriptome data. Specifically, the HK1 isoform of hexokinase, the liver isoform of 
phosphofructokinase-1 (PFKL), the M2 isoform pyruvate kinase (PKM2), and the 
inducible isoform of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) 
were considered. Both PFKM and PKM2 are highly sensitive to activation by fructose-1,6-
biphosphate (F16BP). The PFKFB3 isoform displays the highest kinase/phosphatase (K/P) 
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ratio among other PFKFB isoforms. Figure 5 shows the allosteric regulations that these 
isoforms are subjected to [3].  
 
Figure 5. Allosteric regulations of glycolysis isoenzymes that are predominantly expressed in 
CHO cells. 
The regulation of glycolysis flux by AMPK is modeled as an increase in the kinase activity 
(or K/P ratio) of the bifunctional enzyme PFKFB. 
3.3.1 Steady state simulation 
An algebraic model that consists of steady-state mass balance equations for all the reaction 
intermediates was derived from the ODE model [3]. The model was used to explore 
possible steady states.  The inputs into the model are the K/P ratio and the concentrations 
of glucose and lactate. The extracellular concentrations of glutamine, the intracellular 
concentrations of energy nucleotides and a number of other metabolites were set to be 
constant [3]. The steady state solutions were obtained using the numerical solver fsolve in 
Matlab (Mathworks, Inc.). For each combination of K/P ratio, glucose and lactate 
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concentrations, positive and real-valued solutions were calculated using initial guesses, 
which are drawn from the standard uniform distribution using the pseudo-random number 
generator (rand) in Matlab. 
3.3.2 Transient simulation 
Transient simulations were performed using the ODE solver ode15s in Matlab. The initial 
extracellular lactate concentration is 25 mM. Cell concentration was assumed to be 
constant at 2x107 cells/mL throughout the course of the simulation. The K/P ratio was held 
constant at 45 when simulating the effects of glucose on the metabolic switch, which 
restrains the simulation to the moment when the switch occurs. In another case, when the 
effects of K/P ratio on the switch are investigated, extracellular glucose was held constant 
at 5 mM.  
3.4 RESULTS 
3.4.1 Bistability in Glycolysis Flux and the Diversity of Lactate Behavior 
The glycolysis flux behavior was simulated when lactate concentration and K/P ratio was 
held constant at 20 mM and 40, respectively (Figure 6A). In the glucose concentration 
range of  around 3-21 mM, glycolysis flux exhibits the bistable behavior with three types 
of steady states: the two representing high (red) and low flux states (blue) are stable; the 
other is unstable (orange), which cannot be realized experimentally. Outside this range, 
glycolysis flux has only one steady state for one glucose concentration; below 3 mM, only 
the low flux state is observed, whereas above 21 mM, only high flux state exists. Glycolysis 
flux states play an important role in dictating the behavior of lactate. In the high flux states, 
lactate is rapidly produced at a high rate. In the low flux region, it is produced a slow rate 
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in the bistable region and consumed when the glucose concentration further decreases (i.e. 
the lactate consumption region is colored in green).  
A transition from lactate consumption to lactate production and then a surge in the 
production rate is usually accompanied by increasing levels of glucose, and even a switch 
of flux state. Starting from a low glucose concentration (< 3 mM, thus the low flux state 
with lactate consumption), as the glucose concentration increases, the flux moves along the 
stable steady states line, and then enters the lactate production region. Further increase of 
glucose levels (> 21 mM) causes a switch from a low flux state to a high flux state, 
characterized by an abrupt increase in lactate production rate. The glucose concentration at 
which the switch happens hereinafter will be referred to as the “switch-up” concentration 
of glucose.  
The concentration of lactate also affects its behavior. As an allosteric inhibitor of 
phosphofructokinase (PFK) (Figure 5), lactate exerts an inhibitory effect on glycolysis flux 
[45, 46]. In our previous work, we have demonstrated that an increase in the levels of 
lactate shifts the “switch-up” concentration to higher glucose levels [3]. At very high levels 
of lactate (> 40 mM), the “switch-up” concentration of glucose far exceeds those seen in 
culture, which becomes near lethal to cells due to high osmolality. In this study, we further 
examined the effects of lactate concentration on the lactate consumption region (Figure 
6B). At low levels of lactate concentration, lactate is consumed only at a notably low level 
of glucose and outside the physiological range. With increasing levels of lactate, the lactate 
consumption region extends to a higher concentration of glucose. At 45 mM of lactate, 
lactate is consumed throughout the entire low flux region (in the glucose concentration 
range of ~0.5 – 40 mM). 
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Figure 6. Bistability in glycolysis activity and diversity of lactate behavior.  
(A) Glycolysis flux plotted against extracellular glucose concentration. High flux states are 
colored in red. Low flux states with lactate production and consumption are colored in blue 
and green, respectively. Unstable steady states are colored in orange. (B) Effects of lactate 
concentration on the “switch-up” concentration of glucose and the shape of the lactate 
consumption region (solid lines). (C) Glycolysis flux plotted against extracellular lactate 
concentration. High flux states are colored in red. Low flux states with lactate production and 
consumption are colored in blue and green, respectively. (D) Effects of glucose concentration 
on the “switch-up” concentration of lactate and the shape of the lactate consumption region 
(solid lines). 
3.4.2 Effects of Glucose Concentration on Lactate Behavior 
In the previous section, we examined the switch-up concentration of lactate at a given 
glucose level (Figure 6C). The simulation was performed when glucose concentration was 
held constant at 2 mM, at which condition, the lactate is consumed (as shown in the 
previous section). In the lactate concentration range of ~6-16 mM, glycolysis flux confers 
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the hallmark of bistability. In this bistable region, depending on the previous state of 
glycolysis flux, the system can be at a high or a low flux state [3]. When the lactate 
concentration changes, the system traverses along the stable steady states lines. Starting at 
a high concentration of lactate (thus the low flux state with lactate consumption), as the 
lactate level decreases, the flux gradually moves away from the lactate consumption region 
and enters the bistable region, where lactate starts to produce at a slow rate. In the bistable 
region, glycolysis flux remains at the low state. Further decrease in the lactate level to 6 
mM (“switch-up” lactate concentration) causes an abrupt shift to a high flux state 
accompanied by high lactate production rate.  
The behavior shown in Figure 6C was obtained at a constant concentration of extracellular 
glucose. Such behavior may vary at different glucose concentration. We thus investigated 
the effects of a wide range of glucose levels on the switch-up concentration of lactate 
(Figure 6D). At low levels of glucose, the switch-up concentration of lactate is also low. 
Increasing glucose levels shifts the “switch-up” to higher lactate concentrations. At high 
levels of glucose, the effects of glucose concentration on the switch-up become saturated; 
at 32 and 48 mM glucose, the switch-up concentrations of lactate are largely similar. 
The extracellular concentration of glucose also affects the lactate consumption region. At 
a low glucose concentration, lactate is consumed at a wide range of lactate concentration 
(~ 16 to 50 mM and higher). As the glucose levels increase, the lactate consumption region, 
marked by the solid lines in Figure 6D, shifts to higher concentrations of lactate. At a very 
high glucose concentration of 48 mM, lactate is consumed only when its concentration 
exceeds 34.5 mM.  
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The synergistic effects of glucose and lactate concentrations on the “switch-up” are 
presented in a three-dimensional plot with the flux plotted against glucose and lactate 
concentrations (Figure 7). The plot shows the top (red) and bottom (blue or green) surfaces 
representing high and low flux states with lactate production or consumption, respectively. 
A slice of the plot at a fixed lactate concentration of 20 mM along the glucose axis yields 
the curve shown in Figure 6A. Similarly, the curve shown in Figure 6B is a slice of the plot 
at a fix glucose concentration of 2 mM along the lactate axis.  
 
Figure 7. Synergistic effect of lactate and glucose concentrations on metabolic “switch-up” 
and the lactate consumption region.  
The effect of lactate and glucose on the “switch-up” and on the shape of the lactate 
consumption region is examined by model simulation for a wide range of lactate and glucose 
concentrations (0-50 mM for both). 
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3.4.3 Effect of AMPK on Lactate Behavior 
We have previously demonstrated the regulatory effects of growth on glycolysis, which 
influences the metabolic switch from high to low flux state during the late stage of the 
culture. In the current study, we investigated the effects of cellular stresses on glycolysis 
flux through AMPK. The AMPK signaling pathway regulates cellular energy homeostasis 
and promotes glycolysis activity [47]. Under cellular stresses, AMPK is activated and its 
active form (pAMPK) stimulates glycolysis through the activation of the kinase activity of 
PFKFB2, 3 [41, 48, 49] and induction of GLUT1, 4 and HK [50, 51] (Figure 8). The 
concurrent increase in the pAMPK level (and thus K/P ratio) causes a stimulation of 
glycolysis. Among three targets regulated by pAMPK, PFKFB is stimulated at the activity 
level, whereas the other two are regulated either at the transcriptional or translocational 
level. In order to examine the stability and steady state behavior, we only consider the 
system in which enzymes are uniformly distributed inside the cells with constant levels. 
Therefore, the effect of AMPK on glycolysis flux is thus described as its regulation on 
PFKFB.  
Figure 9A demonstrates the effects of K/P on the glycolysis flux behavior at a constant 
lactate concentration of 20 mM. At low K/P ratios (10-30), a shift from the low flux state 
to the high flux state cannot occur for the entire range of glucose concentration examined. 
Higher K/P ratios bring the “switch-up” concentration of glucose to lower levels. At very 
high K/P ratios, the “switch-up” become very likely because glycolysis flux only has high 
flux states throughout most of the glucose concentration. An opposite trend for the “switch-
up” concentration of lactate was observed when glucose concentration is held constant at 
2 mM (Figure 9B). At low K/P ratios, the switch-up occurs only when lactate is not present. 
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Interestingly, at a very low level of K/P ratio, the switch-up is not possible even at zero 
lactate. With increasing K/P ratios, the “switch-up” moves to higher lactate concentrations.  
 
 
Figure 8. Regulation of AMPK on glycolysis.  
The AMPK signaling pathway is involved in regulation of cellular energy homeostasis. In 
response to energy, nutrient, and hyperosmotic stresses, AMPK is activated, leading to the 
induction of GLUT1,4 and HK. In addition, AMPK can phosphorylate PFKFB2, 3 to promote 
the production of fructose-2,6-biphosphate levels, which in turns further activates PFK 
activity and thus increases glycolysis flux. 
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Figure 9. Effect of pAMPK level, represented as K/P ratio, on the metabolic “switch-up” and 
the shape of lactate consumption region (solid lines).  
The glycolysis flux is plotted against glucose (A) and lactate (B) concentrations. 
Figure 10 shows the three-dimensional curves of glycolysis flux plotted against glucose 
and lactate at four discrete values of K/P ratio. At a low K/P ratio, the top (high flux) plane 
is present only at very low levels of lactate. At higher lactate concentration, glycolysis flux 
can operate only at a low flux state with lactate consumption, shown in the green region 
that dominates the bottom (low flux) plane. The metabolic “switch-up” moves to a region 
where lactate is almost not present (shown in the slim blue region) and glucose are at 
extremely high levels, outside the examined range.  Such condition is not relevant in 
culture, and thus not considered in this study. As the K/P ratio increases, the bottom plane 
recedes towards lower glucose and higher lactate concentrations such that a metabolic shift 
from the low flux plane to the high flux plane becomes possible. As the bottom plane 
regresses, the lactate consumption occurs only at high lactate concentration or very low 
levels of glucose, outside the physiological range. At a very high K/P ratio (≥ 70), 
glycolysis flux is mostly in its high flux states throughout the examined range of glucose 
and lactate concentrations. The low flux states are only at very low levels of glucose (near 
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depletion). The “switch-up”, therefore, becomes feasible for almost all the glucose and 
lactate levels that have been seen in cell culture. 
 
Figure 10. Effect of glucose and lactate on the metabolic “switch-up” and lactate consumption 
region at different K/P ratio.  
The top (red) and bottom (blue or green) surfaces are stable steady states representing high 
and low glycolysis flux states. The bottom surface is divided into two regions: lactate 
production (blue) and lactate consumption (green). Orange surfaces are unstable steady 
states, which cannot be realized experimentally. (A) K/P = 10, (B) K/P = 30, (C) K/P = 50, (D) 
K/P = 70. 
3.4.4 Trajectory of the Metabolic “Switch-up” Resulted from Glucose 
Addition 
During the growth phase of cells in culture, lactate is produced at a high specific rate. As 
the growth rate diminishes, lactate production rate decreases with a concurrent switch from 
a high to a low glycolysis flux state. As time progresses, some cultures may start to 
consume lactate whereas others resume to the high lactate production rate, which is also 
marked by a high rate of glucose consumption [1]. The variation in lactate behavior during 
late stages of culture suggests two possible metabolic fates of cultures while cells progress 
on the low flux plane. 
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Figure 11. Transient simulations of cultures with and without a metabolic switch-up.  
At t = 0, cells are positioned on the bottom (low flux) plane in a low-stress condition (low 
pAMPK, and thus low K/P ratio), with low glucose and medium-high lactate concentrations 
(graph on the right-hand side of the figure). As the culture progresses with the appearance of 
cellular stresses, pAMPK activity increases (denoted by an increase of K/P ratio from 10 to 
45), glucose is consumed and lactate is produced at low specific rates. The culture trajectory 
follows the line (A-B). Glucose is added slowly to the culture, leading to an increase in its 
concentration, as shown by the (B-C) line. After a certain time, it encounters a receded section 
of the bottom (low flux) plane, which leads to a shift from the low to the high flux state (C-D 
line) where cells start to consume glucose and lactate at high specific rates. No metabolic shift 
is observed when lactate is added to the culture (B-F line) along with glucose addition. The 
simulation shows that with lactate feed, a metabolic switch-up can be avoided. 
A set of transient simulations was performed to demonstrate that different feeding 
strategies might diverge the metabolic fates of cultures (Figure 11). Cells are initially on 
the low flux plane of low K/P ratio of 10. As the culture progresses, cells consume glucose 
and produce lactate, as denoted by a path with decreasing glucose concentration and 
increasing lactate concentration. The path is depicted by the line AB in the two-
dimensional plots of Figure 11. Line AB also represents a simultaneous increase in the K/P 
ratio from 10 to 45. The surface plot shown in Figure 11 corresponds to K/P ratio of 45 
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(pAMPK activation, as demonstrated in Figure 10). In the first scenario, glucose 
concentration is gradually increased due to glucose feeding to the culture starting at 6 h 
(line BC, Figure 11). During the feed, the path encounters the receded section of the low 
flux plane, leading to a switch up from the low flux plane to the high flux plane (line CD, 
Figure 11). In the other scenario, both glucose and lactate are added to the culture (line BF, 
Figure 11), leading to an increase in their concentrations. This feeding strategy diverges 
the path away from the receded plane by shifting the culture towards a higher lactate 
concentration. A metabolic switch-up thus cannot occur and the cells remain in the low 
flux plane. In the first scenario, upon switching to a high flux state, cells start to produce 
lactate and consume glucose at a high specific rate. Such culture only switches back to a 
low flux state at a notably low glucose concentration, which is not usually seen in culture 
[3]. In the second scenario, further addition of glucose to the culture (data not shown) will 
not cause the culture to switch to a high flux state unless the K/P ratio increases further. 
The difference in the feeding strategy, wherein lactate is either present or not in the feed, 
leads to variation in lactate behavior of cultures with very similar metabolic behavior. 
3.4.5 Trajectory of the Metabolic “Switch-up” Caused by AMPK Activation 
We performed another set of transient simulation to further demonstrate that lactate feeding 
helps prevent the metabolic “switch-up”. In this study, cells are initially in the low flux 
plane of low K/P ratio and consume lactate. As the culture progresses, cells move along a 
path with decreasing lactate concentration (line AB, Figure 12). When cells are subject to 
certain energy or nutrient stresses, AMPK is activated, leading to an increase of K/P ratio 
(line BC, Figure 12). In the first case, while moving along AB line, as a result of the surge 
of K/P ratio (or pAMPK), cells encounter a receded section of the low flux plane and 
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undergo a metabolic switch from the low to the high flux plane (line CD, Figure 12). In 
this case, cells start to produce lactate at a high specific rate towards the end of the culture 
(line DE, Figure 12). In another case, lactate is added to the culture, which diverges the 
culture trajectory away from the receded region (line BF, Figure 12). Because the metabolic 
“switch-up” does not occur, cells remain at the low flux plane where lactate is produced at 
a low rate (line FG, Figure 12).  
 
Figure 12. Transient simulations of cultures with and without a metabolic switch-up.  
At t = 0, cells are positioned on the bottom (low flux) plane in a low-stress condition (low 
pAMPK, and thus low K/P ratio), with low glucose and medium-high lactate concentrations 
(graph on the right-hand side of the figure). As the culture progresses, glucose is consumed 
and lactate is produced at low specific rates. The culture trajectory follows the line (A-B) with 
an increase in lactate concentration (glucose is assumed to be constant throughout the 
culture). With the appearance of cellular stresses, pAMPK activity increases (denoted by an 
increase of K/P ratio from 10 to 50, line B-C-D and B-F). After a certain time, it encounters 
a receded section of the bottom (low flux) plane, which leads to a shift from the low to the 
high flux state (C-D line) where cells start to consume glucose and lactate at high specific 
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rates. No metabolic shift is observed when lactate is added to the culture (B-F line). The 
simulation shows that with lactate feed, a metabolic switch-up can be avoided. 
3.5 DISCUSSION 
We have previously demonstrated that the multiplicity of steady states in glycolysis flux 
arises from the expression of glycolytic isozymes commonly seen in many rapidly growing 
cells, including cultured mammalian cells  [21]. We also showed that the metabolic switch 
from a high glycolysis flux state to a low flux state in fed-batch culture is a reflection of 
the bistable behavior of glycolysis flux [3]. In this study, using the concept of bistability, 
we investigated the mechanism of the metabolic switch from a low flux to a high flux state 
(“switch-up”), with a concomitant increase in lactate production. The metabolic switch-up 
was attributed to the increase in the kinase activity of PFKFB enzyme because of AMPK 
activation. The switch-up was examined for different combinations of AMPK activity (or 
K/P ratio), glucose, and lactate concentrations. 
The metabolic “switch-up” has been observed in cultured mammalian cells during the late 
stage of culture [1]. The culture conditions at its late stage usually represent a high-stress 
environment with the accumulation of several by-product metabolites, elevation of 
osmolarity and sometimes, limitation of certain types of nutrients. AMPK has been known 
for its important role in regulating cellular homeostasis in response to energy, nutrient, and 
hyperosmotic stress. Under a high-stress environment, AMPK is activated, leading to the 
simulation of glycolysis activity [41, 48, 50]. Using the mechanistic metabolism model, we 
demonstrated that as the levels of activated AMPK varies, the topology of the glycolysis 
flux at different glucose and lactate concentration changes due to changing PKKFB kinase 
activity. At a high level of activated AMPK (thus high kinase activity of PFKFB), the low 
flux plane recedes towards lower glucose and higher lactate concentrations. As a result, the 
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system can only have a high glycolysis flux steady state for a wide range of glucose and 
lactate concentration. When the system is operated near this receded region, even a small 
perturbation can diverge it to drastically different metabolic fates. 
The model simulation also demonstrated the possibility of lactate addition to prevent the 
metabolic switch-up. As we described above, the levels of active AMPK govern the 
topology of glycolysis flux, and thus the switch-up behavior. The active form of AMPK 
enhances the kinase activity (K/P ratio) of PFKFB, resulting in an increase of F26BP 
production and thus the stimulation of PFK activity. Lactate counteracts the AMPK-
mediated activation of PFK through its inhibitory effect on this enzyme. Increase in lactate 
concentration leads to an increase in the switch-up concentration of glucose. Interestingly, 
the result does show that lactate addition to the culture may help avoid the switch-up, 
although this might not be used in practice. 
The mechanistic metabolic model presented here provides insights into the possible cause 
of metabolic switch to a high flux state with a surge in lactate production. This somewhat 
unpredictable behavior of metabolism has been observed in cell culture bioprocessing. The 
simulation result supports that the multiple steady state behavior of glycolysis flux may be 
at play. With a bettering understanding of the root cause of such metabolic switch, one can 
devise strategies to control the metabolism in a robust manner and avert the unfavorable 
switch.  
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4 MECHANISM FOR SHIFT OF GLUCOSE METABOLISM DURING STEM 
CELLS DIFFERENTIATION TOWARDS HEPATOCYTE-LIKE CELLS  
Reproduced from: Chau D, Le T, Park Y, O’Brien C, and Hu W-S. Energy Metabolism 
of Human Embryonic Stem Cells during Hepatocyte Differentiation. (In preparation). 
DC and TL analyzed microarray data. TL and CO constructed the ODE model. TL 
performed model simulation and analyzed the simulation results. 
4.1 SUMMARY 
The metabolic phenotype of human embryonic stem cells changes as they differentiate 
towards hepatocyte-like cells (HLC). At the very early stage, stem cells rely on glycolysis 
for energy generation, marked by the high specific rates of glucose consumption and lactate 
production. During HLC differentiation, glucose consumption rate decreases progressively 
with a concurrent decrease in lactate production, which suggests a switch of metabolic flux 
states. In this study, the mechanistic kinetic model of energy metabolism in mammalian 
cells [3] was extended to include the rate equations for isoforms of key glycolysis enzymes. 
The model was used to demonstrate the existence of multiple steady states of glycolysis 
flux at certain stages of differentiation. Model prediction showed that during the course of 
differentiation, a switch from a high to a low glycolytic flux state occurred due to changes 
in the isoform compositions of key glycolysis enzymes. The simulation results are in 
agreement with the metabolic profile of HLC during differentiation.  
4.2 INTRODUCTION 
Human embryonic stem cells are the pluripotent stem cells derived from the inner cell mass 
that possesses the ability to self-renew and differentiate into highly specialized cell types 
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found in the body. Using different growth factors and cytokines to mimic embryonic 
signaling cues, stem cells can be guided through different developmental stages to become 
hepatocytes in a manner similar to embryonic development [52-55].  
A number of studies have shown the resemblance of stem cell-derived hepatocytes (SDHC) 
to primary hepatocytes at the global gene expression and proteome levels [56-58]. Despite 
these similarities, SDHCs still lack key markers and functionalities shown in fully matured 
hepatocytes. Certain metabolic functions of the liver such as cytochrome P450 (CYP) 
activity were either nonexistent or present at very low levels [52, 56]. Baxter et al. 
demonstrated that SCDHs are more representative of fetal hepatocytes than adult 
hepatocytes at the transcript, protein, and functional level [56]. Li et al. examined the time-
course transcript dynamics of embryonic development from embryo to post-natal liver, and 
found that the transcript levels of genes involved in metabolic processes and cell cycle were 
significantly altered [59]. Although the role of metabolism for cellular growth and 
maintenance during development has been well studied, its impact on the differentiation of 
SCDHs remains elusive. 
Stem cells have been shown to rely mainly on glycolysis for energy generation [60-62]. In 
more differentiated cell types, the energy demand is typically met with the upregulated 
oxidative phosphorylation (OxPhos) activity [63]. Primary hepatocytes have been shown 
to exist in a low glycolytic flux state [64, 65], and utilize mitochondrial respiration for 
bioenergetic demands [66-69]. The preference between glycolysis and oxidative 
phosphorylation have often been used as a marker of differentiation status.  
In this study, we aimed to understand the metabolic properties of PSCs during the 
differentiation process to become SCDHs. In accordance with previous reports, our results 
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demonstrated that hESCs had high glycolytic activity as compared to their SCDHs 
counterpart. We also observed a switch of metabolic states during differentiation, which 
resembles the reported changes of metabolism during embryonic liver development. Using 
a mechanistic kinetic model of cellular energy metabolism, we predicted that such 
metabolic switch might result from the change in the transcript levels of key glycolysis 
isozymes.  
4.3 MATERIALS AND METHODS 
4.3.1 Human Embryonic Stem Cell Culture. 
The human embryonic stem cell (hESC) H9 cell line was cultured in feeder-free condition 
using TeSR™-E8™ media (STEMCELL-Technologies). The cells were maintained on 2% 
hESC-qualified Matrigel® (Corning) at 37°C and 5% CO2. Cells were routinely passaged 
using 0.5 mM EDTA (Corning) after reaching 50-70% confluency and replated onto 2% 
hESC-qualified Matrigel for continued expansion. 
4.3.2 Hepatocyte Differentiation. 
After reaching approximately 70% confluency, differentiation was initiated as described 
previously [70]. Briefly, H9 cells were harvested using 0.5 mM EDTA and replated onto 
2% Growth Factor Reduced Matrigel® (Corning) in TeSR™-E8™ media for 24h or until 
70% confluency was reached. Differentiation was started by switching to the hepatocyte 
differentiation medium which consists of a mixture of low glucose DMEM (Gibco) and 
MCDB-201 (Sigma) (60:40 v/v). The differentiation medium was further supplemented 
with 26 µg/mL ascorbic acid 3-phosphate (Sigma), linoleic acid and bovine serum albumin 
(LA-BSA; Sigma; 0.25 mg/mL BSA, and 2.35 µg/mL linoleic acid), insulin-transferrin-
selenium (ITS (Sigma), 2.5 µg/mL insulin, 1.38 µg/mL transferrin, 1.25 ng/mL sodium 
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selenium), 0.4 µg/mL dexamethasone (Sigma), 4.3 µg/mL β-mercaptoethanol (Hyclone), 
100 IU/mL penicillin, and 100 µg/mL streptomycin (Gibco).  
The differentiation medium was supplemented with stage specific growth factors: Stage 1, 
Activin A (100 ng/mL) and Wnt3a (50 ng/mL); stage 2, FGF2 (10 ng/mL) and BMP4 (50 
ng/mL); stage 3, FGF8b (25 ng/mL), FGF1 (50 ng/mL), and FGF4 (10 ng/mL); and stage 
4, HGF (20 ng/mL) and Follistatin (100 ng/mL). The differentiations were carried out at 
21% O2 and 5% CO2. 
4.3.3 Metabolite Measurement. 
Spent medium was collected every other day to assess the concentration of different 
metabolites. Glucose level was measured using Infinity Glucose Hexokinase (Thermo), 
following the manufacturer’s instruction. Lactate measurement was carried out using a 
lactate assay kit (Sigma), following the manufacturer’s instruction. Oxygen concentration 
was measured with the NeoFox Software viewer using the NeoFox-GT fluorimeter coupled 
with the FOSPOR-R Oxygen Sensor probe (NeoFox). The metabolic consumption or 
production rates for each metabolite was calculated for each stage by measuring the 
concentration of the metabolites on different days throughout the stages of differentiation. 
The viable and total cell concentration were measured by cell counting using 0.4% trypan 
blue exclusion assay.  
The specific rates of glucose consumption and lactate production were determined by: 
Equation 5. Specific rates of glucose consumption and lactate production 
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where S is the concentration of glucose or lactate in the medium at time t (St) or t0 (St0), V 
is the volume of spent medium at time t (Vt) or t0 (Vt0), X is the average cell number 
between time t and t0. 
4.3.4 Model Simulation 
In this study, the kinetic metabolic model described previously [3, 21] was extended to 
include the rate expressions of the isoforms of key glycolysis enzymes, including glucose 
transporter (GLUT1-4), hexokinase (HK1-3 and GCK), phosphofructokinase (PFKL, 
PFKM and PFKP), pyruvate kinase (PKM1, PKM2, PKL and PKR), and lactate 
dehydrogenase (LDHA and LDHB). The net rate for each enzyme reaction was a weighted 
summation of all individual rates by its isozymes. The weighting factors (see Section 8.3.1) 
were estimated from the transcript levels of the corresponding isozymes using gene 
expression microarray data. The isozyme-specific kinetic parameters are described in detail 
in Section 8.3.1 of the Appendix Materials. The steady state solutions were obtained from 
the algebraic model using the same method described in Section 2.3.2. 
4.4 RESULTS 
4.4.1 Changes in Energy Metabolism during Differentiation 
During HLC differentiation, glucose consumption on a per cell basis (i.e. specific glucose 
consumption rate) decreased progressively, accompanied by the decrease in lactate 
production. The molar ratio of lactate production to glucose consumption (∆L/∆G) also 
decreased from 1.30 ± 0.35 to 0.50 ± 0.18, and 0.26 ± 0.06 (mol/mol) in the first, second, 
and last stages of differentiation, respectively (Figure 13A). The drastic change in ∆L/∆G 
between the first two stages suggests a metabolic switch from the high to the low glycolytic 
flux state. Interestingly, this switch occurred with a simultaneous upturn in oxygen 
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consumption. The oxygen consumption rate increased from 1.50 × 10-10 mmol O2/cell/h in 
the first stage to 2.29 × 10-10 mmol O2/cell/h when cells were at the end of the 
differentiation (Figure 13B). The molar ratio of oxygen and glucose consumption increased 
from 1.21 ± 0.20 to 3.46 ± 0.41 (mol/mol), indicating a change from a high glycolytic to 
an oxidative metabolism.  
 
Figure 13. Metabolism Profiling of Cells during HLC Differentiation.  
(A) Rates of glucose consumption (black bar) and lactate production (white bar) for cells 
during different stages of differentiation. The solid red line represents the molar ratio of 
lactate: glucose. (B) Rates of glucose consumption (black bar) and oxygen consumption (white 
bar) for cells during different stages of differentiation. The solid red line represents the molar 
ratio of oxygen: glucose. (C, E) Different metabolic isozyme levels were measured using qRT-
PCR at different stages of differentiation. All error bars are represented as the standard 
deviation of three replicates. (D) Model predictions for rates of glucose consumption (black 
bar) and lactate production (white bar) during different stages of differentiation. The solid 
red line represents the molar ratio of lactate: glucose (F) Schematic of change in bioenergetic 
profiling for cells in early and late stages of differentiation. In the early stage, the rates of 
glucose consumption and lactate production were high. In the late stage, glucose consumption 
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decreased with a concomitant reduction of lactate production. At the same time, pyruvate 
transport into the mitochondria increased. 
4.4.1 Effect of Isoform Composition on Flux State during Differentiation 
Using the gene expression data of HLC differentiation, we examined the transcript 
dynamics of key glycolysis enzymes including their isoforms (Figure 14). A switch in 
isoform composition was not observed for most of the key glycolysis enzymes. Their 
predominant isoforms remained the same throughout the differentiation. The isozyme 
switch only occurred for phosphofructokinase and lactate dehydrogenase. In the first stage 
of differentiation, the muscle form of PFK (PFKM) was expressed at the highest level 
among three isoforms. However, as the differentiation progressed, the transcript level of 
this isoform decreased with an increasing level of the brain isoform PFKP. At the second 
stage, PFKP already became the predominant isoform and its expression increased 
monotonically towards the final stage of differentiation. The transcript dynamics of LDH 
isoforms were rather intriguing. In the first stage of differentiation, LDHB and LDHA were 
expressed at comparable levels. In the second and third stages, the expression level of 
LDHA decreased rapidly, making LDHB the predominant isoform. At the final stage of 
differentiation, LDHA transcript level increased markedly and became the dominant 
isoform of lactate dehydrogenase.  
Incorporation of the transcript dynamics of key glycolysis isoenzymes into the kinetic 
model revealed multiple steady states behavior of glycolysis flux (Appendix Table 2). We 
first examined the effect of isoform levels of each enzyme on glycolysis flux. Despite the 
significant change in isoform level of GLUT3, the topology of glycolysis flux remained 
unchanged through different stages of differentiation. A decrease in the transcript levels of 
both HK1 and HK2 in the second stage led to the loss of bistability in glycolysis flux. For 
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a range of glucose concentration from 0.5 to 10 mM, the system could only operate at low 
flux states, marked by the low specific rates of glucose consumption and lactate production. 
In the third and fourth stages, both HK1 and HK2 were upregulated, the bistable region of 
glycolysis flux returned. The increase in PFKP and decrease in PFKM levels also caused a 
loss of bistability. Interestingly, because of the monotonic trends of these two isoforms, 
this metabolic behavior remained unchanged towards the final stage of differentiation. 
Changes in the PK isoform levels did not significantly alter the bistable region of glycolysis 
flux. However, the high flux state adopted a slightly lower glycolysis rate, which can be 
attributed to the changes in PKM1/2 levels (Figure 13C). Changes in LDH isoform levels 
did not affect the glycolysis flux behavior. When considering the changes in isoform levels 
of all of these enzymes, the behavior of glycolysis flux resembled the one obtained by only 
changing PFK isoform levels. The simulation result at the glucose concentration of 5 mM 
showed a switch from a high to a low glycolytic flux in the second stage (Figure 13D), 
similar to our experimental observations (Figure 13A).    
 
Figure 14. Transcript dynamics of glycolysis enzymes and their isoforms during HLC 
differentiation. 
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4.5 DISCUSSION 
In this study, we showed that during hepatocyte differentiation of hESCs, the glycolytic 
activity decreases with a concurrent switch of metabolic states. The most drastic drop of 
glycolytic activity occurred during the transition between the first two stages of 
differentiation, wherein cells switched from a high to a low glycolytic flux state. Using the 
mechanistic metabolism model, we attributed this switch to the change in the isoform levels 
of key glycolysis enzymes, especially hexokinase and phosphofructokinase. Interestingly, 
in another study, a change in the expression of HK and PFK isozymes was shown to 
accompany the switch from a low flux state of somatic cells to a high flux state of induced 
pluripotent stem cells  (iPSCs) [71].  
The simulation result shows that a decrease in the expression levels of HK1 and HK2 
caused the loss of high flux states in the examined range of glucose concentration (0.5-10 
mM). Inside this range, glycolysis flux can thus only operate at a low flux state at any given 
glucose concentration. Attest to this result is the switch from a high to a low metabolic flux 
state observed in the second stage of differentiation.  
A decrease in PFKM and an increase in PFKP levels also led to a loss of high flux states.  
Among three PFK isoforms, PFKM is the most sensitive to activation by fructose-1,6-
biphosphate (F16BP, Ka = 0.35 mM) whereas PFKP is not activated by F16BP. In our 
previous study, we showed that feedback activation of PFK (M, L) by F16BP gives rise to 
the multiple steady state behavior [21]. Without this activation loop (i.e. in cells that do not 
express either PFKM or PFKL), glycolysis flux is less likely to confer multiple steady state 
behavior. In the current study, we further demonstrated that the multiple steady state 
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behavior remained unchanged even when cells have PFKM or PFKL given that the 
expression levels of these enzymes are low.  
During the transition of hESCs towards the hepatic lineage, switch in isoform composition 
of key glycolysis enzymes is essential for certain metabolic functions of hepatocytes. The 
mechanistic metabolic model presented above provides insights into the role of isoform 
composition in regulating glycolytic activity and more importantly, metabolic switches 
during differentiation. At later stages of differentiation when hepatic cells begin to exhibit 
more active lipid metabolism, the glycolysis activity diminishes with a concurrent increase 
in TCA flux. The work conducted in this study can lay a foundation for the development 
of strategies to manipulate hESCs fate and lineage commitment to achieve more mature 
HLCs.   
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5 AN INTEGRATED PLATFORM FOR MUCIN-TYPE O-GLYCOSYLATION 
NETWORK GENERATION AND VISUALIZATION 
5.1 SUMMARY 
Mucin-type O-glycans have profound effects on the structure and stability of glycoproteins. 
O-glycans on the cell surface proteins also modulate the cell’s interactions with the 
surrounding environments and other cells. The synthetic pathway of O-glycans involves a 
large number of enzymes with diverse substrate specificity. The expression pattern of these 
enzymes is cell and tissue-specific, thus making the pathway highly diverse. To facilitate 
the analysis of the pathway in a cell and tissue-specific fashion, we developed an integrated 
platform of RING (Rule Input Network Generator) and O-GlycoVis, a newly developed 
visualization program. RING uses an English-like reaction language to describe the 
substrate specificity of enzymes and additional constraints on the formation of the glycan 
products. Using this information, RING generates a list of possible glycans, which is used 
as input into O-Glycovis. O-GlycoVis displays the glycan distribution in the pathway and 
potential reaction paths leading to each glycan. With the input glycan data, O-Glycovis 
also traces all possible reaction paths leading to each glycan and outputs pathway maps 
with the relative abundance levels of glycans overlaid. O-glycan profiles from Chinese 
Hamster Ovary cells, Human Umbilical Vascular Endothelium cells, and two other breast 
cancer cell lines were used to illustrate the application of O-Glycovis. 
5.2 INTRODUCTION 
Mucin-type O-glycans (hereinafter referred to as O-glycans) are oligosaccharide moieties 
that are covalently attached to the serine or threonine residues of the protein. O-glycans are 
52 
 
abundantly present on cell surface proteins. They modulate the cell’s interactions with the 
surrounding environment and other cells. O-glycans play an important role in cell-cell 
recognition in the immune system [72, 73]. Aberrant O-glycans on surface proteins of 
cancer cell lines change their adhesion characteristics and promote migration, invasion, 
and metastasis [74, 75]. O-glycans on secreted mucins contribute to the physical and 
chemical properties of mucins, enabling them to act as a general shield, protecting cells or 
tissues from direct contact with microorganisms [76].  
O-glycans are also present in a number of glycoprotein therapeutics including recombinant 
erythropoietin [77], factor VIII [78], von Willebrand factor [79], and tumor necrosis factor 
receptor-Fc fusion protein [80]. They affect the stability, propensity to aggregation and 
pharmacokinetic properties of protein therapeutics (reviewed in [81]). In general, O-
glycosylation of proteins is less characterized than N-glycosylation, largely because of the 
highly diversified nature of O-glycans and the technical challenges involved in the 
structural analysis of O-glycosylation. 
O-glycosylation occurs mainly in the Golgi apparatus, albeit in tumor cells the initiation 
step might occur in the endoplasmic reticulum (ER) [82]. O-glycosylation is initiated by 
the transfer of an N-acetylgalactosamine (GalNAc) residue to the hydroxyl group of Ser or 
Thr in a peptide sequence, forming the Tn antigen structure (GalNAcαSer/Thr). The 
extension of the Tn antigen structure forms four major core structures (core 1-4). Core 1 is 
formed by the addition of a galactose to Tn antigen. The addition of an N-
acetylglucosamine to the GalNAc of core 1 forms core 2. Core 3 results from the addition 
of a GlcNAc to Tn antigen. Core 4 is formed by branching of core 3 from its GalNAc with 
a β1-6GlcNAc. Core structures can be further extended to form complex O-glycans with 
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linear or branched chains. A typical O-glycan structure may contain ABO and Lewis blood 
group determinants, polysialic, i and I antigens. Repetition of LacNAc (type 1, type 2 and 
type 3) chains provides frameworks for further elaboration of O-glycan with additional 
monosaccharides or the described functional groups (see Table 1 for a list of common 
antigens).  
Most O-glycosylation enzymes belong to one of the five groups: N-
acetylgalactosaminyltransferases (GalNAcTs), N-acetylglucosaminlyltransferases 
(GlcNAcTs), galactosyltransferases (GalTs), sialyltransferases (SiaTs), and 
fucosyltransferases (FucTs). Each enzyme group can be further divided into several 
subgroups with distinct substrate specificities. For example, the polypeptide α-GalNAcT 
enzyme family catalyzes the addition of GalNAc to a Ser/Thr residue to initiate O-glycan 
synthesis on the protein backbone, while other GalNAcTs transfer GalNAc to GlcNAc or 
Gal to extend core structures. Similarly, some GlcNAcTs add GlcNAc to the GalNAc 
residue of Tn antigen to form core structures while others add GlcNAc to Gal, forming I 
or i antigen. GalTs add Gal to GalNAc or GlcNAc to form core 1 structure or type 1 and 
type 2 chains. SiaTs add N-Acetylneuraminic acid (Neu5Ac) to GalNAc and Gal to form 
α6- and α3-sialyl antigens. FucTs add fucose (Fuc) to Gal or GlcNAc to form various blood 
group antigens. The wide array of O-glycosylation enzymes and their manifold substrate 
specificities make O-glycosylation a highly diversified and complex biochemical network. 
The expression pattern of O-glycosylation enzymes is cell and tissue-specific, making the 
O-glycosylation network also cell and tissue-specific. Computational tools prove useful to 
generate tissue- or cell-specific networks. A MATLAB-based framework was developed 
to construct the O-glycosylation network from five different glycosyltransferase activities 
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using a machine-readable definition for enzyme class with functional groups, linkages and 
substrate specificity [83, 84]. The resulting network was used to predict possible reaction 
paths leading to O-glycans on P-selectin glycoprotein ligand-1 (PSGL-1) of a human 
promyeloid cell line. A glycosyltransferase reaction library was constructed based on the 
substrate specificity reported previously in the literature [85]. Using this reaction library, a 
repertoire of possible glycan structures was predicted from the set of glycosyltransferases 
expressed in a human carcinoma cell line.  More recently, [86] introduced a pattern-
matching algorithm to generate the O-glycosylation networks based on 25 common 
glycosyl- and sulfotransferase activities. Through in-silico enzyme knockouts, the authors 
demonstrated the roles of each enzyme in the O-glycoform micro-heterogeneity.  
Here, we report a framework for generation and analysis of O-glycosylation network using 
RING (Rule Input Network Generator) and O-GlycoVis, a newly developed visualization 
program. RING was previously used for studies of chemical systems [87, 88]. A unique 
feature of RING is its use of an English-like reaction language to describe substrate 
specificity and additional constraints on the formation of glycan products. Based on this 
user-input information, RING can predict all possible O-glycosylation reactions and glycan 
structures generated from thereof. O-GlycoVis then uses these inputs to display the 
network topology and overlay it with glycan structure information. O-GlycoVis can also 
predict possible glycan structures in the network from an input monosaccharide 
composition, identify the reaction paths leading to those glycans, and then map the relative 
abundance of glycans in an input profile to the reaction paths. O-GlycoVis is a Windows-
based program, written in MATLAB® and freely available upon request.  
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Table 1. Classification of glycans in the O-glycosylation network of four cell lines based on 
the epitopes borne. 
5.3 MATERIALS AND METHODS 
The program consists of three main modules: reaction network generator (RING), glycan 
structure builder, and network visualizer as described below (Figure 15). 
Epitope SNFG representation 
Percentage of glycan species bearing the epitope (%) 
CHO HUVEC T47D MCF7 
Core 1 (and extended core 1) 
(a.k.a. Type 3  LacNAc chain)  5.1 1.2 96.6 2.8 
Core 2 (and extended core 2) 
 
94.1 98.3 0 96 
Type 1 LacNAc chain 
 
7.8 0 0 0 
Type 2 LacNAc chain 
 
47 92.6 0 76.7 
i antigen  68.6 90 48.3 82.2 
I antigen 
 
0 70.7 0 0 
Blood group O/H 
 
0 84.9 55.2 85.4 
Blood group A  
 
0 0 0 0 
Blood group B 
 
0 0 0 0 
Sda/cad 
 
49 0 13.8 0 
LeA 
 
0 0 0 0 
LeB 
 
0 0 0 0 
LeX 
 
19.6 53.2 6.9 35.1 
LeY 
 
0 15 6.9 18.9 
SLeX 
 
38.4 0 0 0 
LacdiNAc 
 
20.4 0 6.9 20 
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Figure 15. Input and output schematic for the platform used for mucin-type O-glycosylation 
network generation and visualization. 
5.3.1 Rule Input Network Generator (RING) 
For the generation of the O-glycosylation network, the inputs to the network generator are 
information on (1) initial reactants, (2) substrate specificity of all enzymes (reaction rules), 
(3) global constraints on glycans being formed, and (4) other post-processing instructions. 
These inputs are written in an English-like reaction language. Based on these inputs, the 
network generator then iteratively applies all the rules to the initial reactants and the 
products generated thereof. The output from the network generator is a list of all possible 
glycans and reactions consistent with the rules supplied by the user.  
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The initial reactants in the O-glycosylation model include a Ser/Thr residue on a 
polypeptide backbone and five nucleotide sugars (UDP-GalNAc, UDP-GlcNAc, UDP-Gal, 
CMP-Neu5Ac, and GDP-Fuc). The five nucleotide sugars provide the monosaccharides to 
be added to the extending O-glycans. An extending glycan on the protein may have more 
than one terminal monosaccharide that can receive a nucleotide sugar and form a glycosidic 
bond. The extending monosaccharide may have more than one carbon available for 
glycosidic bond formations. Furthermore, multiple nucleotide sugars may be capable of 
forming a glycosidic bond with the same hydroxyl carbon of the recipient monosaccharide. 
For example, UDP-Gal can be transferred to c3 or c4 of the GlcNAc residue on extending 
glycans to form β1-3 or β1-4 bond, respectively. The carbon c3 of GlcNAc can receive 
GDP-Fuc, UDP-GalNAc, UDP-Gal to form α1-3 or β1-3 bond. To deal with this 
complexity, each nucleotide sugar was represented as the sugar designator, plus designators 
for the type(s) of glycosidic bond that its carbonyl carbon can form as well as the carbons 
that are available for further glycan extension (Figure 16A).  
 
Figure 16. Illustration of an enzyme rule implemented in the O-glycosylation network 
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(A) Graphical and pseudo-chemical representations of nucleotide sugars. (B) An example of 
rule implementation in the O-glycosylation model. The rule describes structural 
requirements for the glycan to be extended (GlycanSubstrate) and the incoming nucleotide 
sugar (NucleotideSugar) in a reaction catalyzed by β1,4 N-acetylgalactosaminyltransferase 4 
(B4GALNT4) enzyme. The Glycan Substrate must contain a terminal GlcNAc and the Tn 
antigen (GalNAcα-Ser/Thr) substructure.  The Nucleotide Sugar must be UDP-GalNAc, 
shortened as GalNAc with an overhanging β-glycosidic “bond” connected to the carbonyl 
carbon c1 of GalNAc. The hydroxyl carbons c3 and c6 of GalNAc must not be linked with 
any other sugar. If all the requirements are satisfied, a β-glycosidic bond will be formed 
between s5 (hydroxyl carbon c4) of the Glycan Substrate and s6 (the overhanging β-glycosidic 
“bond”) of the Nucleotide Sugar as stated in the “form bond” module. The product glycan will 
contain the GalNAcβ1-4GlcNAc substructure. (C) and (D) Pseudo-chemical and graphical 
representations of a reaction following the enzymatic rule defined in 2A. The pseudo-
chemical representation was generated using the output from RING. 
A reaction rule defines the structure requirements for two substrates, the receiving glycan 
to be extended and the incoming nucleotide sugar. The rule also specifies the carbon 
position of the glycosidic bond formed. The model consists of 32 reaction rules that 
describe the substrate specificity of common mammalian O-glycosyltransferases. 
Sulfotransferases were not considered in this work. The rules were derived from previous 
studies reported in the literature (see Appendix Table 3). Isozymes with similar substrate 
specificities were considered as one enzyme. For example, ST3GAL1 and ST3GAL2 were 
lumped because they both prefer the Gal residue of Galβ1-3GalNAc. Similarly, ST3GAL4 
and ST3GAL6, both of which preferentially act on the Gal residue of type 2 chains, were 
also combined. All the isozymes that were combined are listed in Appendix Table 4. The 
effects of peptide sequence and charge on enzyme activity were neglected. Therefore, all 
the ppGalNAcTs were considered as having the same enzyme activity [89]. Figure 16B-D 
illustrates the implementation of one rule in the O-glycosylation model, whereby the 
structural requirements for two substrates are defined. One substrate is a glycan to be 
extended and the other is a nucleotide sugar.  
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Global constraints were implemented to restrict the formation of glycans to be within 
certain size or pattern. Most of these constraints prevent glycans with repetitive units to 
populate the network since they do not provide additional structural information. Five 
global constraints were imposed in the model (Appendix Table 5): (1) the maximal length 
of LacNAc chains on any glycan is two repeats; (2) a hybrid structure between type 1 and 
type 2 chains cannot be formed; (3) two consecutive I-antigens are not allowed in the 
system; (4) each monosaccharide can be linked to at most three other monosaccharides; (5) 
any carbon of a monosaccharide is connected with only one other monosaccharide. 
Other post-processing instructions: Using the input, the program generates the reaction 
network and a list of all possible glycans. Each glycan is represented as a SMILES string 
[90], assigned a unique identification number (ID) and classified based on the borne 
epitopes (or structural patterns) defined in the post-processing instructions. All the glycan 
strings and their IDs are used as inputs of the glycan structure builder module. The 
relationship between glycans is stored in a matrix. Each row of the matrix corresponds to 
one reaction that occurred in the O-glycosylation network. Four columns of the matrix 
provide the IDs of the substrate and product glycans, the names and indices of rules 
involved in that reactions. The relationship matrix is an input of the network visualizer, 
aiding synthesis pathway identification. 
5.3.2 Glycan Structure Builder  
The SMILES format of output glycan strings from RING is not commonly used for glycan 
representation. We developed an algorithm to translate SMILES strings to the standard 
IUPAC-condensed nomenclature (Appendix Figure 3). The DrawGlycan-SNFG software 
[91] then converts all the output strings to graphical representations of glycans and store 
60 
 
them as image files. Each image file is automatically named according to the ID of the 
glycan it bears. ImageMagick then post-processes these image files for better visualization 
(e.g. crop and convert to background-transparent images). 
5.3.3 Network Visualizer (O-GlycoVis)  
O-GlycoVis is a Matlab based program developed for visualization of the O-glycosylation 
network. Using the glycan classification results as the input, O-GlycoVis interfaces with 
GraphViz to display the distribution of glycan epitopes in the O-glycosylation network. In 
the network display, each node represents a glycan and each edge depicts a reaction. Node 
colors (except for white) represent the epitopes that a glycan bears. If a glycan carries 
multiple epitopes, the node will be segmented into parts, each of which will be colored 
accordingly. Edges are colored by enzyme activities unless otherwise specified.  
O-GlycoVis also predicts the synthesis pathway of input glycans. In this application, the 
module first retrieves the user-input information on the glycans and their abundances. 
Based on the monosaccharide composition of input glycans, the program identifies their 
IDs. A back-stepping algorithm is then used to identify all the immediate reactants leading 
to the input glycans (Figure 17). This process is repeated until the algorithm reaches the 
initial reactant glycan of the network. All the input glycans and their reactants are stored 
in a matrix whose two columns are the IDs of the substrate and product glycans. Each row 
of the matrix is one reaction step leading to the input glycan profiles. The matrix is used to 
create a pathway map, in which edges are labeled by the responsible reaction rules and 
nodes are colored by glycan abundances (percentages of the total glycan input).  
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Figure 17. Backward-stepping Algorithm used in the program to identify all potential 
reaction pathways to synthesize an O-glycan (e.g. glycan #9).  
gs and gp refer to substrate and product glycans of each glycosylation reaction. 
5.4 RESULTS 
5.4.1 O-Glycan Distribution in Chinese Hamster Ovary (CHO) Cells 
The O-glycosyltransferase enzymes expressed in CHO cells were compiled using the 
RNA-Seq data of CHO-DG44 and CHO-K1 lines (Appendix Table 4). The enzymes that 
are expressed at the transcript level in both cell lines were used to construct the O-
glycosylation network. The network generated consists of 255 glycan species and 557 
reactions. The epitope(s) borne in each glycan was then identified using the program.  
Table 1 summarizes the results of glycan classification by epitopes. A total of nine common 
epitopes were found in glycans: (1) core 1 or extended core 1, (2) core 2 or extended core 
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2, (3) type 1 LacNAc, (4) type 2 LacNAc, (5) LacdiNAc structure or one of the following 
antigens: (6) Sda/Cad, (7) Lewis X (LeX), (8) Sialyl-Lewis X (SLeX) and (9) i antigen. 
Figure 18 displays the distribution of epitopes over the network. Glycans bearing more 
than one epitopes are represented as nodes with multiple colors (e.g. the terminal glycan 
gT, as indicated by the circled nodes in Figure 18A-F. Its structure is shown in Appendix 
Figure 4). Core 3 and core 4 structures are not present in the network because CHO cells 
do not express β3-GnT6 enzyme. Similarly, I antigen was not formed because IGnT 
enzymes (GCNT2 and GCNT3) are not expressed.  Lewis Y (LeY),  blood groups ABO, 
LeA, LeB, and SLeA were also absent because α2-FucTs (FUT1 and FUT2) and α4-FucT 
(FUT3) are not expressed.  
Core 1 glycans constitute about 5% of the total number of species generated. The extension 
of core 1 glycan to core 2 vastly increases the glycan diversity (Figure 18A). Over 90% 
glycan species in the network have core 2 structure.  Far more glycans have type 2 chain 
than type 1 chain (Figure 18B). The number of glycans that have type 1 chains is smaller 
because of the narrow substrate specificity of β3-GalT5, which only acts on the GlcNAc 
residues of core 2 (GlcNAcβ1-6GalNAc) and core 3 (GlcNAcβ1-3GalNAc) structures to 
form type 1 chains [92]. In comparison, β4-GalT, which catalyzes the formation of Galβ1-
4GlcNAc of type 2 chains, has a broader substrate specificity. It accepts the GlcNAc 
residues of core 2/3 structures and β1,3GlcNAc  residues of type 2 chains. 
The representation of other epitopes in O-glycosylation network 
The number of glycans with i antigen generated in the network far exceeds that with 
LacdiNAc structure (Figure 18C). The i antigen is formed by the addition of a β1,4Gal to 
GlcNAc residues of glycans through B4GALT enzymes catalyzed reactions. LacdiNAc 
63 
 
structure, however, is formed by the addition of a β1,4GalNAc to GlcNAc residues, 
catalyzed by B4GALNACT3,4. Interestingly, although B4GALNACT3,4 has a broader 
substrate specificity than B4GALT, the number of glycans bearing LacdiNAc is far less 
than those having i antigen. After GalNAc is added to the GlcNAc residue to form 
LacdiNAc, the chain growth is terminated. However, once the i antigen is formed, the 
newly added Gal residue can be further extended with another GlcNAc, Neu5Ac or 
GalNAc by B3GNT, ST3GAL, and B4GALNACT2, respectively. This increases the 
number of glycans having i antigen.  
The program generated fewer glycans bearing LeX antigen than that with SLeX based on 
the O-glycosylation enzymes expressed in CHO cells, possibly due to the narrow substrate 
specificity of FUT4 (Figure 18D). FUT4 preferentially fucosylates the inner GlcNAc 
residue of type 2 chains to form LeX [93, 94]. In other words, the enzyme prefers glycans 
having at least two consecutive LacNAc motifs (Galβ1-4GlcNAcβ1-). Less than 20% of 
glycans in the network satisfy this requirement because the global constraints restrict the 
length of LacNAc chains to only two repeats (see Materials and Methods). On the other 
hand, FUT7, which catalyzes SLeX formation, accepts substrates with at least one LacNAc. 
The enzyme fucosylates the distal GlcNAc residues of sialylated glycans [citation]. Nearly 
50% of glycans in the network comply with these structural requirements.   
The number of glycans bearing Sda/Cad antigen is equivalent to that having type 2 chain 
and far exceeds that with type 1 chain (Figure 18E-F). Interestingly, about half of the 
Sda/Cad carrying glycans also have type 2 chain and vice versa, represented by nodes 
colored with both pink and yellow. On the other hand, less than 5% of glycans having 
Sda/Cad carry type 1 chain, indicated by dual-color nodes in Figure 18F. It should be noted 
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that all the glycans having both Sda/Cad and type 1 or type 2 chain are core 2 glycans with 
two arms (β1-6 and β1-3) on its structure. Sda/Cad is usually formed on one arm while type 
1 or type 2 chain is on the other arm.  
 
Figure 18. O-glycosylation network for CHO cells. 
Highlighted nodes represent glycans bearing (A) core 1 (orange) and core 2 (blue) structures, 
(B) type 1 (teal) and type 2 (pink) chains, (C) LacdiNAc (purple) and i antigen (green), (D) 
Lewis X (red) and sialyl-Lewis X (aqua), (E) type 2 chain and Sda/Cad antigen (yellow), (F) 
type 1 chain and Sda/Cad antigen. Boxed nodes represent the reported O-glycans on the 
65 
 
recombinant MUC1(1.7TR)-IgG2a fusion protein produced in CHO cells. The circled node 
represents a terminal glycan gT in the network. This node has multiple colors, indicating that 
the corresponding glycan carries more than one epitopes. The interactive network graph 
allows zooming in on the circled node to display its glycan structure (as shown in Appendix 
Figure 4). 
Comparing the generated network with literature 
We compared the O-glycosylation network generated for CHO cells to the reported O-
glycans on the recombinant MUC1(1.7TR)-IgG2a fusion protein [95] produced in CHO 
cells. The detected glycans are noted by the boxed nodes in Figure 18A. Although a large 
number of glycans were predicted, only core 1, mono- and di-sialyl core 1 glycans were 
seen in the reported profile. Notably, core 2 glycans were not detected. However, 
importantly, all reported detected glycans were predicted in the network generated by the 
program. Although the glycosylation network generates a large number of intermediate 
glycans, not all accumulate to a detectable level and get excreted with the glycoprotein. 
Thus the number of predicted glycans is much larger than that detected. CHO cells express 
three core 2 enzymes. Two of them (C2GnT1 and 2) are expressed only at low levels. The 
other, C2GnT3, is expressed at a high level only in CHO-DG44. The absence of core 2 
glycans could possibly be caused by several factors.  The local protein structure may not 
be favorable for C2GnT3, or the enzyme may not be expressed at a high level in the CHO 
cell line used. It is also possible that the glycan was present at a low level but was not 
detected in glycan analysis.  
5.4.2 O-Glycan Distribution in Human Umbilical Vein Endothelial Cells 
(HUVEC)  
The O-glycosylation network for HUVEC was constructed based on the gene expression 
(RNAseq) data of glycosylation enzymes in the HUVEC TERT2 cells available from the 
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Human Protein Atlas version 18 [96]. The list of enzymes is shown in Appendix Table 4. 
The program generated a network of 515 glycans in 1210 reactions. Glycans in the network 
cover eight epitopes: (1) core 1 and (2) core 2 structures, (3) type 2 chain and other antigens 
including (4) LeX, (5) LeY, (6) i, (7) I, and (8) blood group O/H. Similar to the O-
glycosylation network of CHO cells, this network did not contain core 3 or 4 structure, 
blood group A or B, LeA, and LeB antigens because the responsible enzymes were not 
expressed. In addition, type 1 chain, blood group Sda/Cad, sLeX, extended core 1 and 
LacdiNAc structures were not present because B3GALT5, B4GALNT2, FUT7,  B3GNT3 
and B4GALNT3,4 enzymes were not expressed. The abundance levels of predicted glycans 
harboring various epitopes are compared to networks predicted for other cells (Table 1). 
Similar to CHO cells, core 2 glycans are much more abundantly represented than core 1.   
We compared the generated network with the reported O-glycan profile of HUVEC [97] 
(Appendix Table 6). Again, the program predicted far more glycans than detected. The 
program predicted 38 out of the 50 reported glycan structures (including isomers). We used 
O-Glycovis to identify the reaction paths from the starting glycan to the detected products 
along the generated a network (Figure 19A). Nodes along the reaction paths are colored 
yellow, and the edges are colored by the enzyme catalyzing the reaction step. The program 
generates an interactive graph that allows zooming in on a particular region of the network 
(Figure 19B), and visualizing the reactions that traverse a particular node with the 
structures of substrate and product glycans being displayed (Figure 19C).  
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Figure 19. The program output using the HUVEC O-glycome profiling data. 
(A) The O-glycosylation network predicted for HUVEC cells. Pathways proceed from left to 
right. The reaction paths leading to the reported glycans are highlighted. Nodes along the 
reaction paths are colored yellow, and the edges are colored by the enzyme catalyzing the 
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reaction step. (i.e. Gal-transferase: yellow; GlcNAc-transferase: blue; Fuc-transferase: red; 
Neu5Ac-transferase: purple). (B) Magnification view of the rectangular region B in A. (C) 
Magnification view of the rectangular region in B. 
Among the twelve glycans that were not predicted by O-Glycovis, nine carries poly-
LacNAc chains with three repeats of Galβ1-4GlcNAc, that exceeded the maximal length 
of two repeats imposed in the global constraints. Glycan #3 and #5 (Appendix Table 6, 
Appendix Figure 5) are formed by the transfer of Neu5Ac to GalNAc of asialylated core 1 
structures, catalyzed by ST6GALNAC1,2 [98]. These two enzymes were not expressed in 
HUVEC TERT2 cells whose transcript profile was used to construct the network. All the 
reactions leading to glycan #30 were represented as the enzyme input into RING. The 
glycan is formed by sequential sialylation and fucosylation of the β1-6 arm of an extended 
core 2 structure (Appendix Figure 5). The glycan is absent in the predicted network because 
of the specification of reaction rules. Two synthesis routes lead to its formation with the 
reversed order of the two responsible enzymes: (1) FUT4-ST3GAL4, and (2) ST3GAL4-
FUT4 (Appendix Figure 5).  In our input rules, the route 1, sialylation of the terminal Gal 
residue by ST3GAL4, was blocked by prior fucosylation of the sub-terminal GlcNAc by 
FUT4 [96]. Another rule blocks route 2 because FUT4 activity toward the extending short 
sialyl-LacNAc chain was reported to be very weak [93]. By relaxing those rules glycan 
#30 can be generated. 
5.4.3 O-Glycan Distribution in Breast Cancer Cells (T47D and MCF7) 
Using the program, the O-glycosylation networks of two breast cancer cell lines T47D and 
MCF7 were predicted based on the glycosylation enzymes expression profile as revealed 
by the RNA-Seq data available from the Human Protein Atlas version 18 [96] (Appendix 
Table 4). The predicted network for T47D only consists of 29 glycans and 30 reactions. 
On the other hand, that for MCF7 has 858 glycans and 1906 reactions. The epitope 
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distribution of the O-glycans predicted in the two networks is shown in Table 1. The vast 
difference in the number of glycans generated between the two cell lines is also reflected 
in their epitope distribution.  
The glycan profiles of secretory MUC1 reported for these two cell lines were also 
compared to the network prediction (Table 2). The program predicted all the reported 
glycan structures (4 and 11 for T47D and MCF7, respectively) and identified all possible 
pathways leading to such glycans. Figure 20A shows the enormous network predicted for 
MCF7, highlighting only the route leading to the reported glycans in T47D and MCF7 
cells. Figure 20B and C show a simplified version of the output from O-Glycovis for T47D 
and MCF7 cells, respectively. The abundance level of the glycans is indicated by colors. 
The difference between the two networks is mainly due to the presence of core 2 enzymes, 
GCNT1, and GCNT3 in MCF7 cells line. Elimination of core 2 enzymes significantly 
reduced the size of the MCF7 network to somewhat similar to that of the T47D (i.e. 25 
glycans and 26 reactions).  
Table 2. Glycan profiles of secretory MUC1 reported for T47D and MCF7 cell lines. 
Glycan ID Used in Structure % of the total profile [99] Current work T47D MCF7 
1 6  6.9 12.9 
2 340 
 
0 54.3 
4 790  45.9 2.3 
5 88 
 
24.6 2.9 
8 807 
 
22.7 0 
9 528 
 
0 7.9 
10 101 
 
0 4.6 
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10’ 342 
 
0 4.6 
11 34 
 
0 1.1 
11’ 534 
 
0 1.1 
12 177 
 
0 2.5 
12’ 339 
 
0 2.5 
5.1 DISCUSSION 
In this study, we employed RING to generate an O-glycosylation reaction network and 
integrate the output into O-GlycoVis for network visualization and analysis. The user 
inputs into RING are rules on the substrate specificity and the reaction of the glycosylation 
enzymes involved. We used the transcriptome data to decide on the enzymes to be included 
for each cell type evaluated. This is easily modified by users for any new cell line. RING 
predicts possible glycan structures generated in the O-glycosylation networks.  Using the 
output from RING, O-GlycoVis generates network graphs that allow zooming into 
particular regions and nodes and displaying reactions that traverse one node with the 
structures of substrate and product glycans being shown. From an input monosaccharide 
composition, O-GlycoVis predicts the associated glycan structures and identifies the 
synthetic routes leading to each glycan. The abundance level of each glycan from an input 
profile can be overlaid onto the pathway map, assisting users to perform quantitative 
analysis of the glycan profile. 
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Figure 20. The program output using O-glycan profiling data from two breast cancer cell 
lines T47D and MCF7. 
(A) The O-glycosylation network predicted for MCF7 cells. Pathways proceed from left to 
right. The reaction paths leading to the reported glycans in T47D and MCF7 cells are 
highlighted. Nodes along the reaction paths are colored yellow, and the edges are colored by 
the enzyme catalyzing the reaction step. (B) & (C) Pathway maps of cellular O-glycan 
biosynthesis in T47D and MCF7 cells, respectively. Glycan structures are highlighted 
according to their abundance levels in the glycan profile. The numbers below glycan 
structures are their corresponding IDs listed in the first column of Table 2. 
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The program bears some degree of similarity to GlycoVis, the visualization tool for N-
glycosylation network [100]. However, there is a major difference between the two 
programs. N-glycosylation of recombinant therapeutic proteins follows a relatively fixed 
pathway of fix number of enzymes and reactions. Although some enzymes are represented 
by many isozymes with different substrate specificity, the basic network structure is not 
affected by those isoforms. In O-glycosylation, the number of enzymes is very large and 
the network generated in different cells or tissues can be vastly different as we have seen 
in the examples presented above.  Hence, the O-GlycoVis is integrated with RING to 
facilitate O-glycosylation network generation and visualization in a tissue or cell-specific 
fashion.  
A number of computational tools have been developed for the generation of glycosylation 
networks. A reaction pattern library was developed, which specifies the acceptor and donor 
monosaccharides and the linkage formed between them for a number of 
glycosyltransferases [85]. GNAT uses class-based inheritance to describe the enzyme 
substrate specificity [83]. Specifically, structural requirements on the substrate and product 
glycans of each glycosylation reaction are defined in different fields of an enzyme class or 
sub-class. O-Glycologue utilizes a set of pattern-matching rules to describe enzyme 
substrate specificity [86]. The program generates O-glycosylation networks by iterative 
application of such rules upon glycan strings. Glycan strings are represented using a one-
letter code for monosaccharide and linkage. A similar approach was used to generate N-
glycosylation networks, in which glycan structures are represented using modified 
LinearCode nomenclature [101]. RING can perform network generation with a similar 
capability to the aforementioned tools. Importantly, the English-like reaction language 
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used by RING allows simple description of glycan structures and substrate specificity of 
glycosylation enzymes. Like other network generating tools, the network generation step 
of RING may require a long computational time for a very large network that has a large 
number of global constraints imposed.  
O-glycans are implicated in a variety of biological processes and human diseases. The 
structure of O-glycans affects the quality of therapeutic proteins. Better O-glycan 
characterization and a better control of O-glycosylation in protein and cell production will 
help generate high-quality products. The integrated platform reported here can help predict 
glycans generated in any particular cell line or tissue to facilitate the identification of 
glycans. Its versatility in projecting the network and tracing the reaction path will facilitate 
the development of strategies in glycoengineering.   
6 CONCLUSION AND FUTURE DIRECTIONS 
Energy metabolism has a profound impact on the outcome of cell culture processes. 
Elevated lactate production has a negative effect on cells’ growth, viability, and 
productivity; reducing lactate production is thus of high importance to achieving desired 
process performance. This thesis presents mathematical modeling approaches to 
understand different behaviors energy metabolism. Insights from this study may provide 
new means for robust control of metabolism in mammalian cells culture.   
In this study, we have demonstrated that the bistable behavior in glycolysis flux is 
implicated in several complex metabolic phenomena including the multiplicity of steady 
state in continuous culture, the metabolic switch to high lactate production in fed-batch 
culture and the switch to low flux state during hepatocyte differentiation. In fed-batch 
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cultures, the stimulation of PFKFB kinase activity due to AMPK activation under stress 
conditions affects the steady state topology of glycolysis flux. Lactate inhibition on 
glycolysis activity, to a certain extent, reverses the change in the steady state topology. 
Using the model, we investigated strategies to divert the culture from such undesired 
switch, which includes controlling glucose at low levels, adding lactate to the culture, 
inhibiting AMPK, and suppressing kinase activity of PFKFB. In continuous culture, 
bistability in glycolysis flux can be exploited to achieve a desired low flux state with high 
cell concentration. Two alternative approaches were proposed to guide a continuous culture 
towards this steady state. In hepatocyte differentiation, switch in isoform composition of 
key glycolysis enzymes alters the bistable behavior of steady state. Certain compositions, 
which are present in more differentiated counterparts of human embryonic stem cells 
(hESCs), cause a loss in the bistable behavior of glycolysis flux. Cells that possess such 
isoform compositions can only operate a low flux state for a wide range of glucose 
concentration. Model prediction was shown to be in agreement with experimental 
observations on changes of hESCs metabolism during differentiation.  
Another challenge in cell culture process is to obtain proper and consistent glycosylation 
of the protein products. While N-glycans have been known to affect the biologics efficacy, 
(mucin-type) O-glycans have profound effects on the structure and stability of 
glycoproteins. The synthetic pathway of O-glycans in mammalian cells involves a large 
number of enzymes with cell-specific expression pattern. To facilitate the analysis of the 
pathway in a cell-specific fashion, we developed an integrated platform to generate the O-
glycosylation networks of different cell lines. Using the generated networks, the synthetic 
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routes for input glycans were predicted. The platform holds potentials to facilitate the 
development of glycoengineering strategies. 
The link between glucose metabolism and glycosylation patterns has been long known. 
Both N- and O-glycosylation (mucin-type) utilize nucleotide sugars that are synthesized 
from glucose-6-phosphate and fructose-6-phosphate, two metabolites of the glycolysis 
pathway. The concentration of these metabolites varies according to the glycolysis flux 
states. The kinetic model of energy metabolism presented in the current study can be linked 
with a model of nucleotide sugar pathways and eventually a glycosylation model to study 
the effects of glucose metabolism on the output glycan profile. Insights from this modeling 
effort can serve as a guideline for modulating metabolism to achieve desired glycosylation 
patterns. 
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8 APPENDIX 
8.1 APPENDIX TABLES 
Appendix Table 1. Fixed parameter values in the metabolic model 
Reproduced from: Mulukutla, B.C., et al., Multiplicity of Steady States in Glycolysis and 
Shift of Metabolic State in Cultured Mammalian Cells. Plos One, 2015. 10(3). 
Parameter 
Symbol Parameter Description Value Units 
Ccadp Cytosolic ADP concentration 0.54 mM 
Cmadp Mitochondrial ADP concentration 0.1 mM 
Ccatp Cytosolic ATP concentration 0.31 mM 
Cmatp Mitochondrial ATP concentration 0.1 mM 
Ccamp Cytosolic AMP concentration 0.03 mM 
Cmamp Mitochondrial AMP concentration 0.1 mM 
Cmgtp Mitochondrial GTP concentration 0.1 mM 
Cmgdp Mitochondrial GDP concentration 0.1 mM 
pHm Mitochondrial pH 8  
pHi Intracellular pH 7.3  
Mg Cytosolic magnesium concentration 0.7 mM 
MgADP Cytosolic MgADP concentration 0.46 mM 
MgATP Cytosolic MgATP concentration 2.69 mM 
Ncd Total cytosolic NAD concentration 0.32 mM 
Ndp Total cytosolic NADP concentration 0.065 mM 
Ccpi Cytosolic phosphate concentration 2.5 mM 
Cmpi Mitochondrial phosphate concentration 2.5 mM 
Cc23p2g Cytosolic 2,3-bisphosphoglycerate concentration 3.1 mM 
Ccg16p Cytosolic glucose 1,6-bisphosphate concentration 0.1 mM 
Ccala Cytosolic alanine concentration 1 mM 
Cmcoq Mitochondrial oxidized ubiquinol concentration 1.08 mM 
Cmqh2 Mitochondrial reduced ubiquinol concentration 0.27 mM 
Ccco2 Cytosolic CO2 concentration 1.2 mM 
Cmco2 Mitochondrial CO2 concentration 21.4 mM 
Cccoash Cytosolic Coenzyme A concentration 0.02 mM 
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Ccaccoa Cytosolic Acetyl-Coenzyme A concentration 0.001 mM 
Cmcoash Mitochondrial Coenzyme A concentration 0.04 mM 
Cmnad Mitochondrial NAD concentration 2.87 mM 
Cmnadh Mitochondrial NADH concentration 0.1 mM 
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Appendix Table 2. Changes in the steady state behavior of glycolysis flux at different stages of HLC differentiation  
Each row represents one set of steady state simulations that consider the changes in the transcript levels of isoforms of a single glycolysis enzyme. 
The last row shows the resulting steady state behavior of glycolysis flux under changes in the isoform levels of GLUT, HK, PFK, PK, and LDH, 
altogether.  
 Day 6 (Stage 1) Day 10 (Stage 2) Day 14 (Stage 3) Day 20 (Stage 4) 
GLUT 
    
HK 
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PFK 
    
PK 
    
LDH 
    
Combined 
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Appendix Table 3. Structural requirements for glycan substrates of all enzymes implemented in O-glycosylation network. 
Enzyme (Short Name) Gene symbol Substrate → Product Requirement/restriction implemented in the model 
polypeptide N-
acetylgalactosaminyltr
ansferase  
(ppGalNAcT) 
GALNTs 
 
→ 
 
Tn antigen 
Requirement: No specific sequon 
is required although the 
presence of Pro near Ser/Thr 
seems to favor the initiation of 
mucin-type O-glycosylation, 
[102] 
N-acetyl-β-
glucosaminyl-
glycoprotein 4-β-N-
acetylgalactosaminyltr
ansferase 2 (Cad β4-
GalNAcT2) 
B4GALNT2 
 
→ 
 
Requirement: Gal residues of 
Neu5Acα2-3Gal (of type 1, type 
2 and type 3 chains). Type 3 
chains are less preferred than 
type 1 and 2 chains. [103] 
Restriction: Prior fucosylation of 
the Gal residue was reported to 
preclude this reaction.[104] 
 
→ 
 
N-acetyl-β-
glucosaminyl-
glycoprotein 4-β-N-
acetylgalactosaminyltr
ansferase 3 and 4 (β4-
GalNAcT3,4) 
B4GALNT3, 4 
 
→ 
 
Requirement: Non-reducing 
terminal GlcNAcβ residue [105] 
α-1,3-N-
acetylgalactosaminytra
nsferase 
A3GALNT 
 
→ 
 
Requirement: prior α2-
fucosylation of the target Gal 
residue [106]. 
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Enzyme (Short Name) Gene symbol Substrate → Product Requirement/restriction implemented in the model 
N-acetylgalactosaminide 
β-1,3-
galactosyltransferase 
(C1β3-GalT-I) 
C1GALT1 
 
→ 
 
Core 1 (T antigen) 
Requirement: Free 3- and 4-
hydroxyls of GalNAc [107]. 
 
 
 
Restriction: Sialyl Tn antigen is 
not a substrate [102] 
β-N-acetylglucosaminyl-
glycopeptide β-1,4-
galactosyltransferase 
(β4-GalT) 
B4GALT1, 2, 3, 4 
 
→ 
 
Requirement: Free 4-hydroxyl of 
GlcNAc [108].  
 
 
→ 
 
Note: β4GalT4 is the most 
efficient enzyme for 
galactosylation of core 2. 
β4GalT1 is the most efficient 
enzyme for galactosylation of 
core 3. Both β4GalT1 and 
β4GalT4 are efficient in forming 
type 2 poly-N-acetyllactosamine 
structures (Galβ1-4GlcNAc-)n 
of core 2 and 3 [109]. β4GalT1 
is the most efficient enzyme for 
galactosylation of GlcNAcβ1-6 
of I antigen [110] 
 
→ 
 
 →  
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Enzyme (Short Name) Gene symbol Substrate → Product Requirement/restriction implemented in the model 
  
 
Restriction: Prior addition of Gal 
or GalNAc to the GlcNAc 
residue via β1,3-linkage 
precludes this reaction.1 
β-N-acetylglucosaminyl-
glycopeptide β-1,3-
galactosyltransferase 
(β3-GalT) 
B3GALT5 
 
→ 
 
Requirement: Free 3-hydroxyl of 
GlcNAc; Substrates include 
core 2 and 3 O-glycans [92].  
Note: Because core 3 structures 
are not formed in the network, 
the model only considers core 2 
glycans as substrates of 
B3GALT5. 
 
 
 
Restriction: Prior addition of Gal 
or GalNAc to the GlcNAc 
residue via β1,4-linkage 
precludes this reaction.23 
 
 
 
α-1,3-
galactosyltransferase 
A3GALT 
 
→ 
 
Requirement: prior α2-
fucosylation of the target Gal 
residue [106]. 
                                                 
1 Assumed to simplify the model. 
2 Assumed to simplify the model. 
3 Assumed to simplify the model. 
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Enzyme (Short Name) Gene symbol Substrate → Product Requirement/restriction implemented in the model 
β-1,3-galactosyl-O-
glycosyl-glycoprotein 
β-1,6-N –
acetylglucosaminyltran
sferase (C2β6-GnT) 
GCNT1, 3, 4 
 
→ 
 
Core 2 
Requirement: Free 4- and 6-
hydroxyls of Gal and GalNAc 
[111]; free 2-acetamido group of 
GalNAc [102]. The latter 
requirement is not necessary for 
the current model. 
 
 
 
Restriction: Gal of core 1 must not 
be O-3-sulfated [112] or 
connected with Neu5Ac via α2-
3 linkage [102] 
N-acetyllactosaminide β-
1,6-N-
acetylglucosaminyl-
transferase 
GCNT2 
 → 
 
Requirement: Non-terminal 
Galβ1-4 residue on poly-
LacNAc chain (mainly type 2). 
Sub-terminal Galβ1-4 residue is 
most preferred substrate [113]. 
β-1,3-galactosyl-O-
glycosyl-glycoprotein 
β-1,6-N-
acetylglucosaminyltran
sferase 3 
GCNT3 
 
→ 
 
Requirement: Free 4- and 6-
hydroxyls of GalNAc and the 6-
hydroxyl of Gal [102]. Core 1, 
core 3, and GlcNAcb1-3Gal- are 
substrates for the synthesis of 
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Enzyme (Short Name) Gene symbol Substrate → Product Requirement/restriction implemented in the model 
 
→ 
 
core 2, core 4, and I antigen, 
respectively [114, 115] 
Restriction: Extended core 3 
structures (Galβ1-3/4GlcNacβ1-
3GalNAcαSer/Thr) are not 
substrate for core 4 synthesis 
[116]. In order to simplify the 
network, it was assumed that 
only unmodified core 3 structure 
is the substrate.  
 
→ 
 
      
N-acetyllactosaminide β-
1,3-N-
acetylglucosaminyltran
sferase  (β3-GnT) 
B3GNT1, 2, 3, 4 
 
→ 
 
Requirement: Free 3-hydroxyl of 
Gal on (poly)-N-
acetyllactosamine chains [117, 
118] 
 
 
 
Restriction: type 1 and type 2 
chains with the inner GlcNAc 
being α1,4- and α1,3-
fucosylated are not substrates 
[118].   
 
 
 
N-acetyllactosaminide β-
1,3-N-
acetylglucosaminyltran
B3GNT3 
 
→ 
 
Requirement: Free 3-hydroxyl of 
Gal; Substrates include core 1 
and core 2 O-glycans [119]  
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Enzyme (Short Name) Gene symbol Substrate → Product Requirement/restriction implemented in the model 
sferase  3 (core 1 
extension) 
Extended core 1 
 
→ 
 
 
 
 
Restriction: α6-sialyl core 1 is not 
a substrate. 
 
N-acetyllactosaminide β-
1,3-N-
acetylglucosaminyltran
sferase  6 (core 3 
synthase) 
B3GNT6 
 
→ 
 
 
N-acetyl-β-
glucosaminyl-
glycoprotein 4-β-N-
acetylgalactosaminyltr
ansferase 3 and 4 (β4-
GalNAcT3,4) 
B4GALNT3, 4 
 
→ 
 
Requirement: Non-reducing 
terminal GlcNAcβ residue [105] 
β-galactoside α-2,3-
sialyltransferase 
(ST3O) 
ST3GAL1, 2 
 
→ 
 
Requirement: Free 3-hydroxyl of 
Gal; Galβ1-3 residue of core 1 
and 2 (Galβ1-3GalNAc) [120, 
121]. 
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Enzyme (Short Name) Gene symbol Substrate → Product Requirement/restriction implemented in the model 
 
 
 
Restriction: Sialyl T and Tn 
antigens are not substrates. Prior 
sialylation of the Gal residue by 
ST6Gal precludes this reaction4. 
β-galactoside α-2,3-
sialyltransferase 4 and 
6 (STZ and ST3GalVI) 
ST3GAL4, 6 
 →  
Requirement: Free 3-hydroxyl of 
Gal 
Restriction: Type 2 N-
acetyllactosamine extensions 
(Galβ1-4GlcNAc-)n [120, 122]. 
I-branched chains were assumed 
to be substrates although they 
are not formed in the network. 
 
 
 
Restriction: type 2 chains with the 
inner GlcNAc being α1,3-
fucosylated are not substrates 
[121]. 
β-galactoside α-2,3-
sialyltransferase 3 
(ST3N) 
ST3GAL3 
 →  
Requirement: Free 3-hydroxyl of 
Gal 
Restriction: Type 1 N-
acetyllactosamine extensions 
(Galβ1-3GlcNAc-)n are 
substrates [123]. I-branched 
chains were assumed to be 
                                                 
4 Assumed to simplify the model. 
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Enzyme (Short Name) Gene symbol Substrate → Product Requirement/restriction implemented in the model 
substrates although they are not 
formed in the network. 
 
 
 
Restriction: type 1 chains with the 
inner GlcNAc being α1,4-
fucosylated are not substrates 
[121]. 
α-N-
acetylgalactosaminide 
α-2,6-sialyltransferase 
(ST6GalNAc) 
ST6GALNAC1 
 
→ 
 
Sialyl Tn antigen 
Requirement: Free 6-hydroxyl of 
GalNAc; Tn antigen, core 1, and 
α3-sialyl-T antigen are 
substrates [102]. 
Note: Because ST6GALNAC1 is 
primarily responsible for Sialyl-
Tn antigen synthesis, the model 
only consider this activity of the 
enzyme [102]. 
 
→ 
 
 
→ 
 
ST6GALNAC2, 1 
 
→ 
 
Requirement: Free 6-hydroxyl of 
GalNAc. Core 1 is the preferred 
substrate [124, 125]. 
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Enzyme (Short Name) Gene symbol Substrate → Product Requirement/restriction implemented in the model 
 
 
 
Restriction: Tn antigen is not a 
substrate. Low activity toward 
α3-sialyl-T antigen [124, 125]. 
Note: Because ST6GALNAC2 is 
not expressed in CHO-DG44 
cells, this rule was disabled in 
the model. 
 
 
 
ST6GALNAC3,4 and 
1,2 
 
α3-sialyl-T antigen 
→ 
 
Requirement: Free 6-hydroxyl of 
GalNAc 
Restriction: α3-sialyl-T antigen is 
a preferred substrate [126, 127] 
 
 
 
Restriction: very low or no 
activity toward Tn antigen [126, 
127] 
 
 
 
Restriction: very low or no 
activity toward core 1 [126, 127] 
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Enzyme (Short Name) Gene symbol Substrate → Product Requirement/restriction implemented in the model 
α-(1,2)-
fucosyltransferase (α2-
FucT) 
FUT1, 2 
 → 
 
Requirement: type 1, 2 and 3 
LacNAc chain. [128, 129]. 
Note: For type 3 LacNAc 
substrate, the activity was 
restricted to unmodified core 1 
structure to simplify the model. 
 
 → 
 
 → 
 
 
 
 
Restriction: α2-FUTs act before 
α3/4-FUTs [102]. 
 
 
 
α-(1,3/4)-
fucosyltransferase 
(α3/4-FucT) 
FUT3  
 → 
 
Requirement: type 1 and 2 chain. 
Restriction: Prior α2,3/6-
sialylation of the outer Gal 
residue precludes the α3-FucT 
activity and prior α1,2-
fucosylation of this Gal 
suppresses it [130].  
 → 
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Enzyme (Short Name) Gene symbol Substrate → Product Requirement/restriction implemented in the model 
Note: Gal residues connected to 
the I-branched GlcNAc are not 
substrates.5 
α-(1,3)-
fucosyltransferase (α3-
FucT) 
FUT4 
 → 
 
Requirement: The inner and distal 
GlcNAcβ residues of poly-N-
acetyllactosamine (type 2 
chains) [94, 131]. I-branched 
chains were assumed to be 
substrates. 
Restriction: The inner GlcNAcβ 
residue of neutral chains are 
preferred substrates [131]. 
FUT7,4 
 → 
 
Requirement: The distal GlcNAcβ 
residue of sialylated poly-N-
acetyllactosamine (type 2 
chains) [94, 131, 132]. I-
branched chains were assumed 
to be substrates. 
  
 
 Restriction: Type 2 chains 
terminated with Neu5Acα2-3 
(i.e. Neu5Acα2-3Galβ1-
4GlcNAcβ1-) are substrates. 
Neutral chains are NOT 
substrates [94]. 
                                                 
5 Assumed to simplify the model. 
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Appendix Table 4. List of O-glycosyltransferases expressed in four different cell lines and the 
enzymatic activities considered in the O-glycosylation network. 
ENZYMATIC 
ACTIVITY GENE 
Expressed (Y) or Not Expressed (N) 
CHO HUVEC T47D MCF7 
β3-GalT B3GALT5 Y N N N 
β3-GlcNAcT 
B4GAT1 (B3GNT1) Y Y Y Y 
B3GNT2 Y Y Y Y 
B3GNT3 
(Core 1 extension) Y N Y Y 
B3GNT4 Y N Y Y 
B3GNT6 
(Core 3 GnT) N N N Y (very low) 
B3GNT7 Y Y (very low) Y (very low) Y (very low) 
B3GNT8 Y Y N Y (very low) 
Cad β4-GalNAcT B4GALNT2 Y N Y Y 
β4-GalNAcT 
B4GALNT3 Y N Y Y (very low) 
B4GALNT4 Y Y (very low) Y Y 
β4-GalT 
B4GALT1 Y Y Y Y 
B4GALT2 Y Y Y Y 
B4GALT3 Y Y Y Y 
B4GALT4 Y Y Y Y 
Core 1 β3-GalT C1GALT1 Y Y Y Y 
α2-FucT 
FUT1 N/A Y Y Y 
FUT2 N/A N Y (very low) Y 
α4-FucT FUT3 N/A N N N 
α3-FucT 
FUT4 Y Y Y Y 
FUT5 N/A N N Y (very low) 
FUT6 N/A N N N 
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FUT7 Y N Y (very low) Y (very low) 
FUT9 N/A N Y (very low) Y 
Polypeptide GalNAc-T GALNT1-18 Y Y Y Y 
Core 2 β6-GlcNAcT 
GCNT1 Y Y N Y 
GCNT3 N N N Y (very low) 
GCNT4 Y N N N 
IGnT GCNT2 N Y Y (very low) N 
α3-SiaT 
ST3GAL1 Y Y Y Y 
ST3GAL2 Y Y Y Y 
ST3GAL3 Y Y Y Y 
ST3GAL4 Y Y Y Y 
ST3GAL6 Y Y Y N 
α6-SiaT 
ST6GALNAC1 Y N N N 
ST6GALNAC2 N N Y Y 
ST6GALNAC3 N Y N N 
ST6GALNAC4 Y Y Y Y 
A-transferase 
B-transferase ABO Y N N N 
 
108 
 
Appendix Table 5. Some examples of glycan structures that violate global constraints. 
Constraint # SNFG representation Causes of violation 
1 
 
GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc 
Extends beyond two repeats of Type 2 chain. 
 
 
GlcNAc(β1-3)Gal(β1-3)GlcNAc(β1-3)Gal(β1-3)GlcNAc 
Extends beyond two repeats of Type 1 chain. 
 
 
GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-3)GalNAc 
Extends beyond Type 2 + Type 3 chain. 
 
 
GlcNAc(β1-3)Gal(β1-3)GlcNAc(β1-3)Gal(β1-3)GalNAc 
Extends beyond Type 1 + Type 3 chain. 
 
 
GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-6)Gal(β1-4)GlcNAc 
Extends beyond two repeats of Type 2 chain with I antigen. 
2 
 
Galβ1-4GlcNAcβ1-3Galβ1-3GlcNAc 
A hybrid structure between Type 2 and Type 1. 
 
Galβ1-3GlcNAcβ1-3Galβ1-4GlcNAc 
A hybrid structure between Type 1 – Type 2. 
 
Galβ1-4GlcNAcβ1-6Galβ1-3GlcNAc 
A hybrid structure between Type 2 and Type 1, linked via I-
antigen. 
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3 
 
GlcNAcβ1-6Galβ1-4GlcNAcβ1-6Gal 
Two consecutive I-antigens linked via type 2 chain. 
 
GlcNAcβ1-6Galβ1-3GlcNAcβ1-6Gal 
Two consecutive I-antigens linked via type 1 chain. 
4 
 
GlcNAc(β1-3)[Fuc(α1-2)][Neu5Ac(α2-3)]Gal(β1-4)GlcNAc 
A galactose is linked to four other monosaccharides including 
Neu5Ac, Fuc, and two GlcNAc 
5 
 
Gal(β1-4)[GalNAc(β1-4)]GlcNAc 
C4 of the GlcNAc is linked to two other monosaccharides (Gal 
and GalNAc) 
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Appendix Table 6. List of O-glycans secreted from Human Umbilical Vein Cells (HUVEC). 
Composition 
Glycan ID 
Structure(6) 
 
[91](7) Current work 
GalNAc1GlcNAc0Gal1Neu5Ac0Fuc1 1 299 
 
GalNAc1GlcNAc0Gal1Neu5Ac1Fuc0 2 474  
GalNAc1GlcNAc0Gal1Neu5Ac1Fuc0 3 n/a(8) 
 
GalNAc1GlcNAc1Gal2Neu5Ac0Fuc0 4 166 
 
GalNAc1GlcNAc0Gal1Neu5Ac1Fuc1 5 n/a 
 
GalNAc1GlcNAc1Gal2Neu5Ac0Fuc1 7 265 
 
GalNAc1GlcNAc1Gal2Neu5Ac0Fuc1 8 168 
 
GalNAc1GlcNAc0Gal1Neu5Ac2Fuc0 10 502 
 
                                                 
(6) Shaded structures were not predicted by the program. 
(7) The ID sequence is not continuous because only IDs of glycans detected in HUVEC cells were shown. The IDs of glycans only detected in other cells were 
omitted. 
(8) Not predicted by the program 
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GalNAc1GlcNAc1Gal2Neu5Ac0Fuc2 11 267 
 
GalNAc1GlcNAc1Gal2Neu5Ac1Fuc0 13 172 
 
GalNAc1GlcNAc1Gal2Neu5Ac1Fuc0 14 82 
 
GalNAc1GlcNAc2Gal3Neu5Ac0Fuc0 16 103 
 
GalNAc1GlcNAc1Gal2Neu5Ac1Fuc1 18 173 
 
GalNAc1GlcNAc1Gal2Neu5Ac1Fuc1 19 171 
 
GalNAc1GlcNAc2Gal3Neu5Ac0Fuc1 22 94 
 
GalNAc1GlcNAc2Gal3Neu5Ac0Fuc1 23 214 
 
GalNAc1GlcNAc1Gal2Neu5Ac2Fuc0 24 491 
 
GalNAc1GlcNAc2Gal3Neu5Ac0Fuc2 26 217 
 
GalNAc1GlcNAc2Gal3Neu5Ac1Fuc0 28 100 
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GalNAc1GlcNAc2Gal3Neu5Ac1Fuc0 29 89 
 
GalNAc1GlcNAc1Gal2Neu5Ac2Fuc1 30 n/a 
 
GalNAc1GlcNAc2Gal3Neu5Ac1Fuc1 33 211 
 
GalNAc1GlcNAc2Gal3Neu5Ac1Fuc1 34 163 
 
GalNAc1GlcNAc2Gal3Neu5Ac2Fuc0 38 495 
 
GalNAc1GlcNAc3Gal4Neu5Ac1Fuc0 41 
 
71 
 
 
75 
 
 
GalNAc1GlcNAc3Gal4Neu5Ac1Fuc0 42 
 
160 
 
 
 
 
 
n/a 
 
 
 
 
(9) 
GalNAc1GlcNAc3Gal4Neu5Ac1Fuc0 43 n/a  
(9) 
GalNAc1GlcNAc2Gal3Neu5Ac2Fuc1 44 481 
 
                                                 
(9) The length of LacNAc chain in this structure exceeds the maximal length imposed in the global constraints. 
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GalNAc1GlcNAc3Gal4Neu5Ac1Fuc1 47 
67 
 
 
279 
 
 
GalNAc1GlcNAc3Gal4Neu5Ac1Fuc1 48 
157 
 
 
 
179 
 
 
n/a 
 
 
 
(9) 
GalNAc1GlcNAc3Gal4Neu5Ac1Fuc1 49 
156 
 
 
181 
 
 
GalNAc1GlcNAc3Gal4Neu5Ac1Fuc2 56 400 
 
GalNAc1GlcNAc3Gal4Neu5Ac1Fuc2 57 210 
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GalNAc1GlcNAc3Gal4Neu5Ac2Fuc0 58 
182 
 
 
158 
 
 
 
GalNAc1GlcNAc3Gal4Neu5Ac2Fuc0 59 70 
 
GalNAc1GlcNAc4Gal5Neu5Ac1Fuc0 62 n/a  
(9) 
GalNAc1GlcNAc3Gal4Neu5Ac2Fuc1 63 213 
 
GalNAc1GlcNAc4Gal5Neu5Ac1Fuc1 65 n/a 
 
(9) 
GalNAc1GlcNAc4Gal5Neu5Ac1Fuc1 66 n/a  
(9) 
GalNAc1GlcNAc3Gal4Neu5Ac3Fuc0 70 501 
 
GalNAc1GlcNAc4Gal5Neu5Ac2Fuc0 73 n/a 
 
(9) 
GalNAc1GlcNAc4Gal5Neu5Ac2Fuc1 74 n/a 
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(9) 
GalNAc1GlcNAc4Gal5Neu5Ac3Fuc0 76 n/a 
 
(9) 
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8.2 APPENDIX FIGURES 
 
Appendix Figure 1. Strategies for guiding continuous culture to steady state with a low 
glycolysis flux.  
Two strategies for directing a continuous culture to low flux state are depicted. (A-D) Cells cultured 
in fed-batch with glucose maintained at 0.5 mM undergo a metabolic shift to low flux state. Once 
a low flux state is reached, the culture can be switched to a continuous mode with a dilution rate 
located in the bistable region (0.033 h-1 in this example). The continuous culture will remain at low 
flux state and reaches steady state with a low metabolic flux and higher cell concentration. (E-D) 
Without controlling glucose at a low level, the continuous culture will reach steady state with low 
glycolysis flux only when it is operated at a low dilution rate (<0.021 h-1). In the low dilution rate 
region, the only existing steady states are those with low glycolysis flux. The dilution rate can then 
be incrementally increased to a final dilution rate that is located in the bistable region (0.033 h-1 in 
this example). The culture will remain at low flux state and settles to steady state with a low flux 
and higher cell concentration. (Courtesy of Dr. Andrew Yongky) 
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Appendix Figure 2. Directing continuous culture to steady state with a low glycolysis flux by 
controlling dilution rate.  
The culture was started in batch mode and exhibits high metabolic flux.  The culture is then 
switched to a continuous mode with a dilution rate of 0.021 h-1 and feed glucose concentration of 
7 mM. By operating at a low dilution rate, the culture reaches a steady state with low metabolic 
flux. Incrementally increasing the dilution rate to a final rate of 0.033 h-1 allows the culture to 
remain at low flux and reaches a final steady state with higher cell concentration (compared to 
Figure 6.3A). Arrow (↑) indicates the time at which continuous mode is initiated (courtesy of Dr. 
Andrew Yongky). 
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Appendix Figure 3. Demonstration of the algorithm used to translate glycan strings from 
their SMILES format into the modified IUPAC condensed nomenclature. 
Blue text indicates the portions of the input string that have been processed. Asterisks (*) 
indicate parentheses recorded by the algorithm. Underlined text indicates the paused 
position in the string. 
Description of the algorithm:  
The algorithm first preprocesses the SMILES format of a glycan to remove brackets 
enclosing monosaccharides, monosaccharide carbons, glycosidic bonds and polypeptide 
backbone. Next, the algorithm identifies the Ser/Thr residue of the polypeptide backbone 
and sets it as the starting point (step 1). It then steps from right to left in the SMILES string, 
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and at the same time, adds processed monosaccharides to the growing output string (step 
2).  
Branch search process: The algorithm pauses once a branch point of the glycan 
structure is reached, as indicated by an open parenthesis (step 2). The first monosaccharide 
on the left of the open parenthesis is the parent of upcoming branches (e.g. GalNAc in step 
3).  The algorithm then steps from left to right in the SMILES string to identify all the 
monosaccharides that are branched off from the parent monosaccharide (step 3, 4, 5 and 
6). This process hereinafter will be referred to as “branch search”. The branch search 
terminates when the corresponding close parenthesis is encountered. After the branch 
search finishes, all the processed branches are added to the output string.  Any branch that 
was previously added to the output string while the algorithm stepped from right to left 
will be skipped (e.g. c1a SerThr-pp-Pro in step 3).  The algorithm then returns to the parent 
monosaccharide and continues to step from right to left in the SMILES string (step 7). 
Another open parenthesis is encountered, indicating a potential branch point (e.g. GlcNAc 
in step 8). Here, the algorithm performs another branch search for GlcNAc (step 8, 9 and 
10).  
The branch search is carried out based on a recursive algorithm. During a branch 
search, if the algorithms identify any sub-branch point, indicated by another open 
parenthesis (step 4), the current search is paused, and another nested search begins to 
identify all sub-branches. After all the sub-branches are identified, the paused search 
resumes.  
In addition to monosaccharides, monosaccharide carbons that are involved in 
glycosidic bonds formation are also added to the output string following the modified 
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IUPAC condensed nomenclature. Monosaccharide carbons that are not involved in 
glycosidic bond formations (i.e. not adjacent to ‘a’ or ‘b’, which represents for alpha or 
beta glycosidic bond) are ignored (e.g. carbons c3 and c6 of Gal in step 6). 
The algorithm terminates after the leftmost monosaccharide (e.g. GlcNAc in step 
10) in the SMILES string is added to the output string.  
 
Appendix Figure 4. An example of an O-glycan that carries multiple epitopes on its structure. 
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Appendix Figure 5. Potential reaction paths leading to the three glycans that were not 
predicted by the program. 
The number under each glycan structure is the glycan ID used by Kudelka et al. 2016 (see Appendix 
Table 6). Glycan structures without IDs are those not reported in the paper. Solid arrows indicate 
reactions that were predicted by O-GlycoVis and dashed arrows represent unpredicted reactions. 
The red cross mark indicates enzymes that are not expressed in the HUVEC TERT2 cells. 
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8.3 APPENDIX MATERIALS 
8.3.1 Rate Equations 
Reproduced from: Mulukutla, B.C., et al., Multiplicity of Steady States in Glycolysis and 
Shift of Metabolic State in Cultured Mammalian Cells. Plos One, 2015. 10(3). 
GLYCOLYSIS 
Hexokinase (HK):   The rate equation for HK was taken from Mulquiney et al. [133]. The 
kinetic constants which correspond to those of the isozyme HK2 were adopted from 
previous literature [134-138]. The rate equation employs the partial rapid equilibrium 
random bi-bi mechanism with the assumption that all the steps in the mechanism, except 
for the reactive-ternary complexes, are fast reactions. The inhibitions by g6p, glucose-1,6-
phosphate (g16bp), 2,3-bisphosphoglycerate (2,3bpg) and glutathione (gsh) were modeled 
as a mixed type of inhibition affecting both the activity (Vmax) as well as the affinity (KM) 
of the enzyme for glucose. 
Equation S1. Hexokinase (HK) 
6
, 6
6 6
, , 6 , ,
1
1
c c c c
MgATP glc MgADP g pHK HK
HK mf mrHK HK HK HK
MgATP glc i MgADP g p HK
c c c c c c c c
MgATP g p glc MgATP glc MgADP MgADP g P
HK HK HK HK HK HK HK HK
i MgATP i g p glc MgATP glc i MgADP i MgADP g
C C C C
r V V
K K K K N
C C C C C C C C
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K K K K K K K K
 
= −  
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= + + + + + +
6
6 16 2,3
6 , 16 ,2,3 ,
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c c c c c c c c
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2 -1
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g p
HK
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−
=
=
=
=
=
=
=
=
=
 
The rate equations and kinetic constants for hexokinase isoforms. Isoform-specific parameters are 
colored blue. 
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6
, 6
6 6
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, , 6 , ,
1
1
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i i
i ii
c c c c
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 iHKglcK [139] 6 i
HK
g p glcK − [139] 
HK1 0.47 0.021 
HK2 0.26 0.016 
HK3 0.007 0.092 
HK4  
(GCK) 7.7 No inhibition 
 
 iHK
ρ  
D6 D10 D14 D20 
HK1 0.60 0.26 0.42 0.51 
HK2 0.25 0.26 0.23 0.32 
HK3 0.07 0.08 0.08 0.07 
HK4 (GCK) 0.08 0.08 0.08 0.07 
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Glucose Phosphate Isomerase (GPI): The rate equation for GPI was taken from 
Mulquiney et al. [133]. The kinetic constants were adopted from previous literature [140-
142]. The rate equation employs the steady state uni uni reaction kinetics. 
Equation S2. Glucose Phosphate Isomerase (GPI) 
6 6
6 6
 
1
c c
g p f p
GPI GPI
f r
GPI c c
g p f p
GPI GPI
f r
GPI GPI
mrmf
C C
K K
r
C C
K K
V V
=
−
+ +
           
3 -1
3 -1
1
1
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9.6*10
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f
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−
−
=
=
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=
 
Phosphofructokinase (PFK): The rate equation for PFK was taken from Mulquiney et al. 
[133]. The kinetic constants were adopted from previous literature [143-147]. The rate 
kinetics was based on the two-state allosteric model using ordered bi bi mechanism.  The 
two-state model considers that the enzyme can exist in the active or the non-active state as 
determined by the levels of the activity modulators. These include activators (f16bp, f26bp, 
g16bp, AMP etc) and inhibitors (ATP, Mg etc).  These activity modulators are isozyme-
specific.  For example, f16bp only stimulates PFKM and PFKL. The fraction of the enzyme 
in the active state is represented by the nonlinear term NPFK which is a function of the levels 
of the activity modulators.  LPFK represents the equilibrium constant between the two states 
of the enzyme in the absence of any substrates.  The initial velocity expression for the 
enzyme fraction in the active state was modeled as partial rapid equilibrium random bi bi 
steady state equation similar to the HK kinetics. 
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Equation S3. Phosphofructokinase (PFK) 
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The rate equations and kinetic constants for phosphofructokinase isoforms. Isoform-specific 
parameters are colored blue. 
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 16
PFK
f bpK [148] 26
PFK
f bpK [149] 
PFKL 0.65 5.5*10-3 
PFKM 0.35 5.5*10-3 
PFKP N.A. 4.5*10-2 
 
 iPFK
ρ  
D6 D10 D14 D20 
PFKL 0.17 0.18 0.15 0.19 
PFKM 0.46 0.36 0.34 0.30 
PFKP 0.37 0.51 0.96 1.11 
 
6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase (PFKFB):  The rate equation 
for PFKFB and the kinetic constants were taken from previously reported studies [150, 
151]. PFKFB is a bi-functional enzyme with kinase and bisphosphatase activities, each 
localized to either terminals of the enzyme and are independent of each other’s activity.  
The kinase domain catalyzes the synthesis of fructose-2,6-bisphosphate (f26bp) from 
fructose-6-phoshate (f6p) and the bisphosphatase domain mediates the hydrolysis of f26bp 
to f6p.  The reaction kinetics for the kinase domain (rPFK2) follows the ordered bi bi steady 
state kinetics, with phosphoenolpyurvate (pep) inhibition of the kinase domain modeled as 
non-competitive inhibition.  The bisphosphatase reaction kinetics (rF2,6BPase) was modeled 
as simple Michaelis-Menten kinetics with non-competitive product inhibition by f6p. 
Isozymes of PFKFB vary in their kinase to bisphosphatase activity (K/P) [152]. The effect 
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of isozyme (or K/P) was modeled by changing the Vmax of rPFK2 and holding rF2,6BPase 
constant. 
Equation S4. 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase (PFKFB) 
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 
+ +  
 
                                   
-1 -1
2,6
3
3
2,6
, 26
2,6
, 6
13.86 
10  
25*10  
F BPase
F BPase
m f bp
F BPase
i f p
V mM h
mM
mM
K
K
−
−
=
=
=
 
 
Aldolase (ALDO):  The rate equation for ALDO was taken from Mulquiney et al. [133]. 
The kinetic constants were adopted or estimated from previous literature [153-162]. The 
reaction kinetics of ALDO follows the ordered uni bi steady state kinetics.  Inhibition due 
to 2,3bpg as described in the original expression was retained in this study. However, since 
2,3bpg is not a reaction intermediate considered in the model, its concentration was held 
constant for the purpose of this study. 
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Equation S5. Aldolase (ALDO) 
16
16 ,
2,3 16 2,3
,2,3 16 , ,2,3 ,
1,6
1 1
ALD c ALD c c
mf f bp mr gap dhap
ALD ALD ALD
f bp gap i dhap
ALD c c ALD c c c
bpg f bp dhap gap bpg dhap
ALD ALD ALD ALD ALD ALD
i bpg f bp gap i dhap i bpg i dhap
ALD c
dhap F P
V C V C C
K K K
r
C C K C C C
K K K K K K
K C C
−
=
  
+ + + + +     
+
, 16 , ,
c c c
gap dhap gap
ALD ALD ALD ALD ALD
i f bp gap i dhap gap i dhap
C C
K K K K K

+ 

              
2 -1
2 -1
2
16
2
, 16
2
2
,
,2,3
1.33*10  
 4.57*10  
5*10
1.98*10
3.5*10
1.1*10
0.189
1.5
ALD
mf
ALD
mr
ALD
f bp
ALD
i f bp
ALD
dhap
ALD
i dhap
ALD
gap
ALD
i bpg
V mM h
V mM h
K mM
K mM
K mM
K mM
K mM
K mM
−
−
−
−
=
=
=
=
=
=
=
=
 
Triose Phosphate Isomerase (TPI): The rate equation for TPI was taken from Mulquiney 
et al. [133]. The kinetic constants were adopted from previous literature [154, 163-165]. 
The rate kinetics of TPI follows a simple steady state uni uni reaction kinetics. 
Equation S6. Triose Phosphate Isomerase (TPI) 
1
c c
dhap gapTPI TPI
mf mrTPI TPI
f r
c c
dhap gap
TPI TPI
f r
TPI
C C
V V
K K
C C
K K
r
−
+ +
=                                                                        
2 -1
3 -1
1
1
5.10*10  
2.76*10  
1.62*10
4.30*10
TPI
mf
TPI
mr
TPI
f
TPI
r
V mM h
V mM h
K mM
K mM
−
−
=
=
=
=
 
Glyceraldehyde 3-Phosphate Dehydrogenase (GAPDH): The rate equation for GAPDH 
was taken from Mulquiney et al. [133]. The kinetic constants were adopted from previous 
literature [166-169]. The rate kinetics of GAPDH follows the ter ter (bi uni uni bi ping 
pong) steady state kinetics. 
129 
 
Equation S7. Glyceraldehyde 3-Phosphate Dehydrogenase (GAPDH) 
1,3
, , ,1,3
1,31,3
' '
, , ,1,3 ,
1 1
c c c c c c
Pi gap bpg NADHGAPD GAPDNAD H
mf mrGAPD GAPD GAPD GAPD GAPD
i Pi i gap i bpg NADHNAD
GAPD Gc c c c
bpggap gap bpg gap
GAPD GAPD GAPD GAPD
i gap i gap i bpg i GAP
C C C C C C
V V
K K K K K
r
KC C C C
K K K K
+ +
+
−
=
   
+ + + +        ,1,3 , ,
1,3
'
, , , , ,1, ,
1
GAPD c cAPD c c
gap PiNADH NADH
GAPD GAPD GAPD GAPD GAPD
i bpg NADH i Pi i gapNAD
c c c cc c c
gap bpgPi gap gapNAD NAD
GAPD GAPD GAPD GAPD GAPD GAPD
i gap i Pi i gap i gap ii NAD i NAD
K C CC C
K K K K K
C C C CC C C
K K K K K K K
++
+
+ +
+ +
+
 
+ + + +  
 
1,3
,3 , ,1,3
1,3
, , ,1,3 , ,
GAPD c c c
bpg Pi NADH H
GAPD GAPD GAPD GAPD
bpg i Pi i bpg NADH
c c c GAPDc c c c c c
Pi gap gapgap NADH bpg NADH NAD NAH H
GAPD GAPD GAPD GAPD GAPD GAPD GAPD
i gap i NADH i bpg NADH i Pi i gapNAD
K C C C
K K K
C C C K CC C C C C C
K K K K K K K
+
++ +
+
+
+ + + + 1,3'
, , ,1,3
1,3
'
, , , ,1,3 , ,1,3
c c c
Pi bpgD
GAPD GAPD GAPD GAPD
i gap i Pi i bpgNAD
c c c c c c c c
Pi gap NADH Pi bpg NADHH H
GAPD GAPD GAPD GAPD GAPD GAPD GAPD
i Pi i gap i NADH i bpg NADH i Pi i bpg
C C
K K K K
C C C C C C C C
K K K K K K K
+
+
+ ++ +
         
,
,
,
5.317*
3.919*
.
.
.
.
.
.
GAPD 3 1
mf
GAPD 3 1
mr
GAPD
NAD
GAPD
i NAD
GAPD
Pi
GAPD
i Pi
GAPD
NADH
GAPD
i NADH
V 10 mMh
V 10 mMh
K 0 045mM
K 0 045mM
K 2 5mM
K 2 5mM
K 0 0033mM
K 0 01mM
+
+
−
−
=
=
=
=
=
=
=
=
,
'
,
,
, ,
'
, ,
.
. *
.
.
. *
.
. *
GAPD
gap
GAPD 16
i gap
GAPD
i gap
GAPD
1 3bpg
GAPD 18
i 1 3bpg
GAPD
i 1 3bpg
GAPD 8
eq
K 0 095mM
K 1 59 10 mM
K 0 031mM
K 0 000671mM
K 1 52 10 mM
K 0 001mM
K 1 9 10
−
−
−
=
=
=
=
=
=
=
 
 
Phosphoglycerate Kinase (PGK): The rate equation for PGK was taken from Mulquiney 
et al. [133]. The kinetic constants were adopted from previous literature [170-173]. The 
rate kinetics of PGK follows the partial rapid equilibrium random bi bi steady state kinetics.  
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Equation S8. Phosphoglycerate Kinase (PGK) 
,
, , ,
, ,
, , , , , , ,
c c c c
1 3bpg MgADP 3 pg MgATPPGK PGK
mf mrPGK PGK PGK PGK
i MgADP 1 3bpg i MgATP 3 pg
PGK c c c c c c
1 3bpg MgADP 1 3bpg MgADP 3 pg MgATP 3 p
PGK PGK PGK PGK PGK PGK
i 1 3bpg i MgADP i MgADP 1 3bpg i 3 pg i MgATP
C C C C
V V
K K K K
r
C C C C C C C
1
K K K K K K
−
=
+ + + + + +
,
c c
g MgATP
PGK PGK
i MgATP 3 pg
C
K K
    
4
4
,
,
, ,
,
,
5.96*10 /
. *10 /
.
.
.
.
.
.
.
. *
PGK
mf
PGK
mr
PGK
MgADP
PGK
i MgADP
PGK
1 3bpg
PGK
i 1 3bpg
PGK
MgATP
PGK
i MgATP
PGK
3 pg
PGK
i 3 pg
PGK 3
eq
V mM h
V 2 39 mM h
K 0 1mM
K 0 08mM
K 0 002mM
K 1 6mM
K 1mM
K 0 186mM
K 1 1mM
K 0 205mM
K 3 2 10
=
=
=
=
=
=
=
=
=
=
=
 
Phosphoglycerate Mutase (PGM): The rate equation for PGM was taken from Mulquiney 
et al. [133]. The kinetic constants were adopted from previous literature [174, 175]. The 
rate kinetics of PGM follows the uni uni steady state kinetics. 
Equation S9. Phosphoglycerate Mutase (PGM) 
c c
3 pg 2 pgPGAM PGAM
mf mrPGAM PGAM
3 pg 2 pg
PGAM c c
3 pg 2 pg
PGAM PGAM
3 pg 2 pg
C C
V V
K K
r
C C
1
K K
−
=
+ +
                                                     .
.
.
PGAM 5 1
mf
PGAM 5 1
mr
PGAM
3 pg
PGAM
2 pg
PGAM
eq
V 4.894*10 mM h
V 4.395*10 mM h
K 0 168mM
K 0 0256mM
K 0 17
−
−
=
=
=
=
=
 
Enolase (ENO): The rate equation for ENO was taken from Mulquiney et al. [133]. The 
kinetic constants were adopted from previous literature [176-178]. The rate kinetics of 
ENO follows the partial rapid equilibrium random bi bi steady state kinetics. 
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Equation S10. Enolase (ENO) 
, ,
, ,, , , ,
2 2
2 2
2 2 2 2
2 2 2 2
c c c c
2 pg pepMg MgENO ENO
mf mrENO ENO ENO ENO
2 pg pepi Mg i Mg
ENO c c c c c cc c
2 pg pep2 pg Mg Mg pep Mg Mg
ENO ENO ENO ENO ENO ENO ENO ENO
i 2 pg 2 pg i pep pepi Mg i Mg i Mg i Mg
C C C C
V V
K K K K
r
C C C C C CC C
1
K K K K K K K K
+ +
+ +
+ + + +
+ + + +
−
=
+ + + + + +
       
2 2
4 1
3 1
,
2 2
 2.106*10
5.542*10
0.14
0.11
.046
3.0
ENO
mf
ENO
mr
ENO ENO
i Mg Mg
ENO ENO
pep PEP
ENO ENO
pg PG
ENO
eq
V mM h
V mM h
K K mM
K K mM
K K mM
K
+ +
−
−
=
=
= =
= =
= =
=
 
Pyruvate Kinase (PK): The rate equation for PK was taken from Mulquiney et al. [133]. 
The kinetic constants were adopted from previous literature [179-184]. Like PFK, the rate 
kinetics of PK was based on the two-state allosteric model using the ordered bi bi 
mechanism.  The two-state model considers that the enzyme can exist in the active or non-
active state determined by the levels of the activity modulators. These include activators 
(f16bp, pep, pyr etc) and inhibitors (ATP, ala etc).  The fraction of the enzyme in the active 
state is represented by the nonlinear term NPK which is a function of levels of activity 
modulators. LPK represents the equilibrium constant between enzymes at the two states in 
the absence of any substrates.  The initial velocity expression for the enzyme fraction in 
the active state is modeled as partial rapid equilibrium random bi bi steady state equation. 
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Equation S11. Pyruvate Kinase (PK) 
   
 
c c c c
pep MgADP pyr MgATPPK PK
mf mrPK PK PK PK
pep MgADP pyr MgATP
PK c c c c
PKpep MgADP pyr MgATP
PK PK PK PK
pep MgADP pyr MgATP
c
ATP
PK PK
C C C C
V V
K K K K 1r
NC C C C
1 1 1 1 1
K K K K
C1
N 1 L
 
 −
 
=        + + + + + −                 
+
= +
44 c
ala
PK PK
ATP ala
4 4c c c c
pep pyr f 16bp g16bp
PK PK PK PK
pep pyr f 16bp g16bp
C1
K K
C C C C
1 1
K K K K
  
+  
   
   
+ + + +      
   
       
3 -1
-1
1
1
3
16
16
2.02*10   
4.75  
2.25*10
4.74*10
3 
3.39 
4 
5.0*10
0.1 
0.398
0.02 
PK
mf
PK
mf
PK
pep
PK
MgADP
PK
MgATP
PK
ATP
PK
pyr
PK
f bp
PK
g bp
PK
PK
ala
V mM h
V mM h
K mM
K mM
K mM
K mM
K mM
K mM
K mM
L
K mM
−
−
−
=
=
=
=
=
=
=
=
=
=
=
 
The rate equations and kinetic constants for pyruvate kinase isoforms. Isoform-specific parameters 
are colored blue. 
 
 
 
 
 
 
   
 
c c c c
pep MgADP pyr MgATPPK PK
mf mrPK PK PK
MgADP pyr MgATP
PK c c c c
PKpep MgADP pyr MgATP
PK PK PK
MgA
PK
pep
PK
pep DP pyr MgATP
c
ATP
PK PK
C C C C
V V
K K K 1r
NC C C C
1 1 1 1 1
K K K
C1
N 1
K
K
L
 
 −
 
=        + + + + + −                 
+
= +
i i
44 c
ala
PK
ala
4 4c c c c
pep pyr f 16bp g16bp
PK PK
pyr g16bp
4
PK PK PK
i 1
PK
ATP
PK PK
pep f 16bp
C1
K
C C C C
1 1
K K
r
K
K K
rρ
=
  
+  
   
   
+ + + +      
   
= ∑
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3 -1
-1
1
1
6
1
3
6
1
2.02*10   
4.75  
4.74*10
3 
2.25*10
3.39 
5.0*
4 
0.1 
0.398
0.02
0
 
1
PK
mf
PK
mf
PK
MgADP
PK
MgATP
PK
pyr
PK
g bp
PK
PK
PK
pep
PK
ATP
PK
f bp
ala
V mM h
V mM h
K mM
K mM
K
K mM
K m
mM
K mM
L
K m
M
K mM
M
−
−
−
=
=
=
=
=
=
=
=
=
=
=
 
 PK
pepK [185] 
PK
ATPK [185] PKf 16bpK [185] 
PKM2 0.4 2.5 0.25 
PKM1 0.08 3.25 N.A. 
PKL 0.6 0.125 0.08 
PKR 1.2 0.05 0.4 
 
 iPK
ρ  
D6 D10 D14 D20 
PKM1 0.46 0.24 0.29 0.51 
PKM2 0.46 0.24 0.29 0.51 
PKL 0.08 0.09 0.09 0.08 
PKR 0.08 0.09 0.09 0.08 
 
Lactate Dehydrogenase (LDH): The rate equation for LDH and the kinetic constants were 
adopted from previous literature [133, 186-188]. The kinetics of LDH was modeled as 
ordered bi bi steady state kinetics, with substrate inhibition by pyruvate. 
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Equation S12. Lactate Dehydrogenase (LDH) 
, ,
"
,, , , ,
1 1
c c c c
NADH pyr NAD lac
LDH LDH LDH LDH
i NADH pyr i NAD lac
LDH LDH
mrmf
LDH LDH c cLDH c c c
pyr pyrNADH NAD lac NADH NAD
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. *  
. *  
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3
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LDH
pyr
LDH
i pyr
LDH
NAD
LDH
i NAD
LDH
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LDH
i lac
LDH
i NADH
LDH
NADH
LDH
i pyr
V 10 mM h
V 2 17 10 mM h
0 2 mM
0 228 mM
0 107 mM
0 503 mM
10 1 mM
30 mM
2 45 10 mM
8 44 10 mM
0 101 mM
K
K
K
K
K
K
K
K
K
−
−
=
=
=
=
=
=
=
=
=
=
=
 
The rate equations and kinetic constants for lactate dehydrogenase isoforms. Isoform-specific 
parameters are colored blue. 
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−
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= ∑
 
 LDHpyrK  ,
LDH
i pyrK  LDHlacK  ,
LDH
i lacK  LDHNADK  ,
LDH
i NADK  LDHNADHK  
LDH-A4 (LDH-5) [189, 190] 0.35 0.280 23 130 0.085 0.467 0.00743 
LDH-B4 (LDH-1) [191] 0.1 0.180 9.340 26 0.169 0.5028 0.00844 
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 iLDH
ρ  
D6 D10 D14 D20 
LDHA 0.51 0.17 0.20 0.65 
LDHB 0.48 0.50 0.41 0.47 
 
PENTOSE PHOSPHATE PATHWAY 
Glucose 6-phosphate Dehydrogenase (G6PD) 
G6PD is part of oxidative pentose phosphate pathway.  Kinetics of G6PD was modeled as 
ordered bi bi steady state kinetics [192]. The rate equation for G6PD was taken from [193]. 
The kinetic constants were adopted from previous literature [194, 195]. 
Equation S13. Glucose 6-phosphate Dehydrogenase (G6PD) 
( )
15 20 20
6
19 24 24
17 24 22
6 6
6 6
6
6
6
6
1.45*10 2.04*10  1.83*10 +
4.29*10  6.01*10  6.84*10
 5.74*10 5.01*10 7.26*10
G PD
G PD c c G PD c c
mf NADP g p mr pg NADPH
G PD
G PD
c c
NADPH NADP
c c c
g p NADPH NADP
c c c
pg NADPH NADP g
D
V C C V C C
r
D
C C
C C C
C C C C
= + +
+ + +
−
=
+ + + ( )( )29 276 1.10*10 8.65*10c c cp NADPH NADPC C+
 
6 20 -1
6 19 -1
-1
-1
*
*
4.39 10
7.48 10
G PD
mf
G PD
mr
V mM h
V mM h
=
=
 
6-Phosphogluconate Dehydrogenase (6PGD): 
6PGD is part of oxidative pentose phosphate pathway.  Kinetics of 6PGD was modeled as 
ordered sequential bi ter steady state kinetics [196]. The rate equation for 6PGD was taken 
from [193]. The kinetic constants were adopted from previous literature [197, 198]. 
Equation S14. 6-Phosphogluconate Dehydrogenase (6PGD) 
( )
2
15 19 18
18 23 21
18 23 23
6 6
6
6
6
6
5
6
5
5.38*10 7.86*10 6.97*10
1.04*10 3.99*10 3.03*10
7.26*10 2.40*10 4.46*10
PGD c c PGD c c
mrNADP pg NADPHmf
PGD
PGD
c c
PGD NADPH NADP
c c c
ru p NADPH NADP
c c c
pg NADPH NADP
ru pV COC C V C Cr
D
D C C
C C C
C C C C
=
−
=
+ + +
+ + +
+ + + ( )( )27 275 2.63*10 3.19*10
 
c c c
ru p NADPH NADPC C+
  
6 -1
6 -1
19 -1
19 -2
*
*
1.83 10
9.0 10
PGD
mf
PGD
mr
V mM h
V mM h
=
=
 
136 
 
Ribulose Phosphate Epimerase (RPE)  
RPE is part of non-oxidative pentose phosphate pathway.  Kinetics of RPE was modeled 
as steady state uni uni mechanism. The kinetic constants were adopted from previous 
literature [199-202]. 
Equation S15. Ribulose Phosphate Epimerase (RPE) 
5 5
5 51
cc
ru p xyl pRPE RPE
mrmf RPE RPE
rf
RPE cc
ru p xyl p
RPE RPE
rf
CC
V V
K K
r
CC
K K
−
=
+ +
                                                             
4 -1
4 -1
1
1
4.642*10  
6.667*10  
1.90*10
5.00*10
RPE
mf
RPE
mr
RPE
f
RPE
r
V mM h
V mM h
K mM
K mM
−
−
=
=
=
=
 
Ribose Phosphate Isomerase (RPI)   
RPI is part of non-oxidative pentose phosphate pathway.  Kinetics of RPI was modeled as 
steady state uni uni mechanism. The kinetic constants were adopted from previous 
literature [199, 200, 203, 204]. 
Equation S16. Ribose Phosphate Isomerase (RPI)   
5 5
5 51
c c
ru p r pRPI RPI
mrmf RPI RPI
rf
RPI c c
ru p r p
RPI RPI
rf
C C
V V
K K
r
C C
K K
−
=
+ +
                                                                
4 -1
4 -1
1
2.56*10  
1.09*10  
7.80*10
2.20 
RPI
mf
RPI
mr
RPI
f
RPI
r
V mM h
V mM h
K mM
K mM
−
=
=
=
=
 
Phosphoribosylpyrophosphate Synthetase (PRPPS)   
PRPPS channels ribose-5-phosphate (r5p) towards nucleotide synthesis. The rate is a 
relatively small portion of total PPP flux.  Kinetics of PRPPS was modeled as a rapid 
equilibrium random bi reactant system. The kinetic constants were adopted from previous 
literature [205]. 
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Equation S17. Phosphoribosylpyrophosphate Synthetase (PRPPS)   
( )( )
5
5 5
c c
MgATP r pPRPPS
PRPPS m PRPPS c PRPPS c
MgATP MgATP r p r p
C C
r V
K C K C
=
+ +
                                  
-1
5
25.3  
0.01 
0.57 
PRPPS
m
PRPPS
MgATP
PRPPS
r p
V mM h
K mM
K mM
=
=
=
 
Transketolase1 (TK1)  
TK1 is part of non-oxidative pentose phosphate pathway.  Kinetics of TK1 was modeled 
as steady state bi bi ping pong mechanism. The kinetic constants were adopted from 
previous literature [199, 200, 206]. 
Equation S18. Transketolase1 (TK1) 
( )
( )
16 16 16 16
1
16 16 17 17
1 1
5 75
1
1
7 5 7
7 55
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TK
TK
c c c c
gaps p r p s p
c c c c c
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V
D
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D
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+
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=
+ +
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18 -1
18 -1
1 -1
1 -1
5.3210
2.58*10
TK
mf
TK
mr
V mM h
V mM h
=
=  
Transaldolase (TA) 
TA is part of non-oxidative pentose phosphate pathway.  Kinetics of TA was modeled as 
steady state bi bi ping pong mechanism. The rate equation for TA was taken from [199]. 
The kinetic constants were adopted from previous literature [200, 207-209]. 
Equation S19. Transaldolase (TA) 
16 16 17 15 17
7 4 6 7
16 16 18
4 6 6 7 4
7 46
3.4*10 2.38*10 1.64*10 2.72*10 4.41*10
7.83*10 2.21*10 2.1*10
c c c c c c
TA s p gap e p f p s p gap
c c c c c c
e p F P gap f p s p e p
TA c c TA c c
gap mrs p e pmf f p
TA
TA
V
D C C C C C C
C C C C C C
V C C C C
r
D
−
= + + + +
+ + +
=
      
20 -1
19 -1
-1
-1
1.36*10
7.53*10
TA
mf
TA
mr
V mM h
V mM h
=
=  
Transketolase2 (TK2)  
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TK2 is part of non-oxidative pentose phosphate pathway.  Kinetics of TK2 was modeled 
as steady state bi bi ping pong mechanism. The kinetic constants were adopted from 
previous literature [199, 200, 206, 210]. 
Equation S20. Transketolase2 (TK2) 
( )( )
( )
17 16 16 17 16
2
16 18 17
2 2
45 6
2
2
4 46
45
3.01*10 5.96*10 1.25*10 1.60*10 3.31*10
7.35*10 1.67*10 3.38*10  
TK
TK c c TK c c
mr gape pmf xyl p f p
TK
TK
c c c c c
gap gape p e pf p
c c c
gape pxyl p
V
D
C C V C C
r
D
C C C C C
C C C
= +
−
=
+ + + +
+ +
        
2 19 -1
2 18 -1
-1
-1
*
*
3.64 10
1.23 10
TK
mf
TK
mr
V mM h
V mM h
=
=  
Glutathione Peroxidase (GPX)  
GPX oxidizes the reduced form of glutathione (gsh) into glutathione disulfide (gssg) while 
hydrogen peroxide (H2O2) is reduced into the water. Thus this reaction plays an important 
role in preventing cells from oxidative stress. The kinetics of GPX was modeled as first-
order reaction kinetics. 
Equation S21. Glutathione Peroxidase (GPX) 
GPX c
f gshGPX V Cr =                              
4 -1-1*1.56 10GPXfV mM h=  
Glutathione Reductase (GSSGR)  
The enzyme GSSGR converts gssg back into gsh while NADPH produced in the pentose 
phosphate pathway is oxidized into NADP. The kinetics of GSSGR was modeled as 
ordered sequential steady state kinetics [211]. The rate equation for GSSGR was taken 
from [193]. The kinetic constants were adopted from previous literature [212, 213]. 
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Equation S22. Glutathione Reductase (GSSGR) 
40 42 41 35 41
43 38 42
1.73*10 2.88*10 3.43*10 7.77*10 2.47*10
4.02*10 1.3*10 4.90*10
c c c c
NADPH gssg gsh NADP
c c c c c c
NADPH gssg NADPH gsh gssg NADP
GSSGR
GSSGR c c GSSGR c c
gssg mrNADPH NADPmf gsh
GSSGR
GSSGR
V
C C C C
C C C C C C
D
C C V C C
r D
+ + + +
+ + +
=
−
=
36
37 40 39
41 38 41
39
5.55*10
1.11*10 1.24*10 3.26*10
2.08*10 9.25*10 2.45*10
1.78*10 2
c c
gsh gsh
c c c c c c c
gsh NADP gsh NADP NADPH gssg gsh
c c c c c c c c c
NADPH gssg gsh NADPH gsh gsh gssg gsh NADP
c c c
gsh gsh NADP
C C
C C C C C C C
C C C C C C C C C
C C C
+
+ + +
+ + +
+ + 40 40.32*10 2.74*10c c c c c c c cNADPH gssg gsh gsh gssg gsh NADP gshC C C C C C C C+
    
44 -1
40 -1
-1
-1
*
*
5.5 10
1.05 10
GSSGR
mf
GSSGR
mr
V mM h
V mM h
=
=  
TCA CYCLE 
Pyruvate Dehydrogenase (PDH) 
The rate equation for PDH was taken from [214].  The kinetics of PDH was modeled as 
hexa uni ping pong mechanism. The kinetic constants were adopted from previous 
literature [215, 216].  
Equation S23. Pyruvate Dehydrogenase (PDH) 
2
,
,
, 2 , 1
m m m
AcCoA NADH COm m m
f PDH pyr CoASH NAD
eq PDH
PDH PDH m m PHD m m PDH m m m m m
PDH i pyr CoASH CoASH PDH i pyr pyr CoASH pyr CoASHNAD NAD NAD NAD
C C C
V C C C
K
r
K C C K C C K C C C C Cα α
+
+ + + +
 
−  
 =
+ + +
  
, 1
,
, 2
,
1
1
m
AcCoA
PDH i c
i AcCoA
m
NADH
PDH i PDH
i NADH
C
K
C
K
α
α
 
= +  
 
 
= +  
 
                                                                                                                                      
,
,
,
,
.
. *
. *
. *
. *
. *
. *
1
f PDH
4
eq PDH
PDH 3
pyr
PDH 3
CoASH
PDH 3
NAD
PDH 3
i AcCoA
PDH 3
i NADH
V 189 7mMh
K 1 2 10
K 38 8 10 mM
K 9 9 10 mM
K 60 7 10 mM
K 40 0 10 mM
K 40 2 10 mM
+
−
−
−
−
−
−
=
=
=
=
=
=
=
 
Citrate Synthase (CS) 
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The rate equation for CS was taken from [214]. The kinetic constants were adopted from 
previous literature [217-220]. The kinetics of CS was modeled as an ordered bi bi 
mechanism. 
Equation S24. Citrate Synthase (CS) 
,
,
, , , 1 , 1 , 2
, 1
,
, 2
, ,
1
1
m m
m m CoASH cit
f CS OAA AcCoA
eq CS
CS CS CS CS m CS m m m
i OAA i AcCoA CS i OAA CS i AcCoA AcCoA CS i OAA OAA AcCoA
m
cit
cit
CS i CS
i cit
m m
ATP ADP
ATP ADP
CS i CS
i ATP i
C CV C C
K
r
K K K C K C C C
C
P
K
C C
P P
K K
α α α
α
α
 
−  
 =
+ + +
 
 
= + 
 
 
= + +
, , ,
m
AMP m m
CoASH scoaAMP
CS CS CS CS
ADP i AMP i CoASH i scoA
C
C CP
K K K
 
 
+ + + 
 
 
     
,
,
,
,
,
,
,
,
,
 
. *
*
. *
. *
*
*
*
*
*
*
1
f CS
0 12
eq CS
CS 3
OAA
CS 3
AcCoA
CS 3
i OAA
CS 3
i cit
CS 3
i ATP
CS 3
i ADP
CS 3
i AMP
CS 3
i CoASH
CS
i scoa
V 1804 mMh
K 6 22 10
K 4 10 mM
K 1 4 10 mM
K 3 33 10 mM
K 1600 10 mM
K 900 10 mM
K 1800 10 mM
K 6000 10 mM
K 67 10 mM
K 140
−
−
−
−
−
−
−
−
−
=
=
=
=
=
=
=
=
=
=
= 310 mM−
  
 
Aconitase (ACON)  
The rate equation for ACON was taken from [214].  The kinetics of ACON employs the 
steady state uni uni reaction kinetics. The kinetic constants were adopted from previous 
literature [217, 218, 221]. 
Equation S25. Aconitase (ACON) 
,
,
m
m icit
f ACON cit
eq ACON
ACON ACON m
ACON m cit icit
cit cit ACON
icit
CV C
K
r
K CK C
K
 
−  
 =
+ +
                                                                  
,
,
*
. *
*
*
5 1
f ACON
2
eq ACON
ACON 3
cit
ACON 3
icit
V 1 10 mMh
K 2 7 10
K 1161 10 mM
K 434 10 mM
−
−
−
−
=
=
=
=
\ 
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Isocitrate Dehydrogenase (IDH) 
The rate equation for IDH was taken from [214].  The kinetics of IDH was modeled as 
ordered bi ter mechanism. The kinetic constants were adopted from previous literature 
[217, 218, 222, 223]. 
Equation S26. Isocitrate Dehydrogenase (IDH) 
2
,
,
, , ,
, 1 , 1 , 1
,
,
, 1
11
1 1
1
H H
m m m
akg NADH CO
f IDH m m
eq IDH icitNAD
IDH n nIDHIDH IDH m
m icit m NAD i icit NADH
IDH i IDH i IDH im m m IDH
icit icit i NADHNAD
IDH
a ADP ADP
IDH i m
ADP
C C C
V
K C C
r
KK K C
C C C K
K P
C
α α α
α
+
+
+
 
−  
 =
    
 + + + +        
= +
,
1
m
ATP fATP
IDH
fADP i ATP ATP
C P
P K P
  
+      
    
,
,
,
,
,
,
,
,
. *
.
*
*
*
*
. *
*
4 1
f AKG
eq IDH
IDH 3
m NAD
IDH 3
m icit
IDH 3
a ADP
IDH 3
i ATP
IDH 3
i icit
IDH 3
i NADH
H
V 2 75 10 mMh
K 30 5
K 74 10 mM
K 183 10 mM
K 50 10 mM
K 91 10 mM
K 23 8 10 mM
K 29 10 mM
n 3
+
−
−
−
−
−
−
−
=
=
=
=
=
=
=
=
=
 
α-Ketoglutarate Dehydrogenase (AKGD) 
The rate equation for AKGD was taken from [214].  The kinetics of AKGD was modeled 
as hexa uni ping pong ter ter mechanism. The kinetic constants were adopted from previous 
literature [217, 218, 224, 225]. 
142 
 
Equation S27. α-Ketoglutarate Dehydrogenase (AKGD) 
2
,
,
, , ,
, 1
, ,
, 1
11
1 1 1
1
m m m
SCoA NADH CO
f AKGD m m m
eq AKGD akg CoASH NAD
AKGD AKGDAKGD AKGD m m
m akg m CoASH m NADSCoA NADH
AKGD im m AKGD m AKGD
akg CoASH i SCoA i NADHNAD
AKGD i
C C C
V
K C C C
r
KK K C C
C C K C K
K
α
α
+
+
+
 
−  
 =
     
+ + + + +           
= + ,
,
1
mAKGD
ATP fATPa ADP ADP
m AKGD
ADP fADP i ATP ATP
C PP
C P K P
  
+      
      
,
,
,
,
,
,
,
,
,
 
. *
*
*
*
*
*
. *
. *
1
f AKGD
8
eq AKGD
AKGD 3
m akg
AKGD 3
m CoaSH
AKGD 3
m NAD
AKGD 3
a ADP
AKGD 3
i ATP
AKGD 3
i SCoA
AKGD 3
i NADH
V 2495 mMh
K 1 66 10
K 120 10 mM
K 55 10 mM
K 21 10 mM
K 100 10 mM
K 50 10 mM
K 6 9 10 mM
K 0 60 10 mM
+
−
−
−
−
−
−
−
−
=
=
=
=
=
=
=
=
=
 
 
 
Succinyl-CoA Synthetase (SCOAS) 
The rate equation for SCOAS was taken from [214].  The kinetics of SCOAS follows the 
ordered ter ter mechanism. The kinetic constants were adopted from previous literature 
[217, 218, 226]. 
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Equation S28. Succinyl-CoA Synthetase (SCOAS) 
,
,
, , , , , , , , ,
m m m
m m m CoASH suc GTP
f SCoAS GDP SCoA Pi
eq SCoAS
SCoAS SCoAS SCoAS SCoAS SCoAS SCoAS m SCoAS SCoAS m SCoAS m m SCoAS m m
i GDP i SCoA m Pi i SCoA m Pi GDP i GDP m SCoA Pi m Pi GDP SCoA m SCoA GDP Pi
C C CV C C C
K
r
K K K K K C K K C K C C K C C
 
−  
 =   
+ + + +
(, , ,, , , , ,
, , ,
SCoAS SCoAS SCoAS
SCoAS m m m m m i GDP i SCoA m Pi SCoAS SCoAS m SCoAS SCoAS m
m GDP SCoA Pi GDP SCoA Pi i GTP m suc CoASH i suc m CoASH GTPSCoAS SCoAS SCoAS
i suc i GTP m CoASH
K K K
K C C C C C K K C K K C
K K K
K
 
 
            + + + +  
 
            , ,, , ,
, ,
,
,
SCoAS SCoAS m m m
SCoAS m m SCoAS m m SCoAS m m m m m m suc i GTP GDP SCoA suc
m GTP CoASH suc m suc CoASH GTP m CoASH suc GTP CoASH suc GTP SCoAS SCoAS
i GDP i SCoA
SCoAS m m m
m GTP GDP CoASH suc
SCo
i GDP
K K C C C
C C K C C K C C C C C
K K
K C C C
K
+ + + +
            + , , , ,
, , , ,
, ,
, ,
SCoAS SCoAS m m m m SCoAS SCoAS m m
i GTP m suc GDP SCoA Pi CoASH m suc i GTP GDP CoASH
AS SCoAS SCoAS SCoAS SCoAS
i GDP i SCoA i Pi i GDP
SCoAS SCoAS m m m m
i CoASH m GTP GDP SCoA Pi suc
SCoAS
i GDP i SCo
K K C C C C K K C C
K K K K
K K C C C C
K K
+ +
            + , ,
, , , , , ,
, ,
SCoAS m m m m SCoAS m m m m m
m GTP GDP SCoA CoASH suc m GTP GDP SCoA Pi CoASH suc
SCoAS SCoAS SCoAS SCoAS SCoAS SCoAS SCoAS
A i Pi i GDP i SCoA i GDP i SCoA i Pi
SCoAS SCoAS m m m
i GDP m SCoA Pi suc GTP
K C C C C K C C C C C
K K K K K K
K K C C C

+ + 

            + , , , ,
, , , , , , , ,
,
SCoAS SCoAS m m m m SCoAS SCoAS m m m m
m GDP i Pi SCoA CoASH suc GTP i GDP m SCoA Pi CoASH suc GTP
SCoAS SCoAS SCoAS SCoAS SCoAS SCoAS SCoAS SCoAS
i suc i GTP i CoASH i suc i GTP i CoASH i suc i GTP
m
K K C C C C K K C C C C
K K K K K K K K
K
+ + +
             + , , , ,
, , , , , , ,
SCoAS m m m SCoAS SCoAS m m SCoAS m m m m SCoAS m m m m m
GDP SCoA Pi GTP i GDP m SCoA Pi GTP m GDP SCoA Pi suc GTP m GDP SCoA Pi CoASH suc GTP
SCoAS SCoAS SCoAS SCoAS SCoAS SCoAS S
i GTP i GTP i suc i GTP i GDP i SCoA i Pi
C C C K K C C K C C C C K C C C C C
K K K K K K K
+ + + CoAS    
                                                                                                                      
,
,
,
,
,
,
,
.
*
*
. *
*
*
1
f SCoAS
eq SCOAS
SCoAS 3
m GDP
SCoAS 3
m SCoA
SCoAS 3
m Pi
SCoAS 3
m CoaSH
SCoAS 3
m suc
V 362 mMh
K 7 43
K 16 10 mM
K 55 10 mM
K 660 0 10 mM
K 20 10 mM
K 880 10 mM
−
−
−
−
−
−
=  
=
=
=
=
=
=
            
,
,
,
,
,
,
,
. *
. *
*
*
*
*
. *
SCoAS 3
m GTP
SCoAS 3
i GDP
SCoAS 3
i SCoA
SCoAS 3
i Pi
SCoAS 3
i CoaSH
SCoAS 3
i suc
SCoAS 3
i GTP
K 11 1 10 mM
K 5 5 10 mM
K 100 10 mM
K 2000 10 mM
K 20 10 mM
K 3000 10 mM
K 11 1 10 mM
−
−
−
−
−
−
−
=
=
=
=
=
=
=
 
  
Succinate Dehydrogenase (SDH) 
The rate equation for SDH was taken from [214].  The kinetics of SDH was modeled as 
Theorell-Chance bi bi mechanism. The kinetic constants were adopted from previous 
literature [217, 218, 227-229]. 
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Equation S29. Succinate Dehydrogenase (SDH) 
2
2
,
,
,
, , , 1 , , , 1
,
, ,
, ,
m m
QH fumm m
f SDH suc COQ
eq SDH
SDH SDH
SDH SDH SDH m SDH m m m m mm suc
i suc m COQ SDH i m COQ suc m suc SDH i COQ suc COQ COQ fumSDH
i fum
SDH SDH
i suc m COQ
SDH SDH
i fum m QH
C C
V C C
K
r
K
K K K C K C C C C C
K
K K
K K
α α
 
−  
 =
+ + + +
 
         + 

2 2 2 2
,
, , 1 ,
,
, , ,
, 1
, ,
1
1
SDH
m fumSDH m SDH m m m m m
m fum SDH i QH m QH fum suc QH QH fumSDH
i suc
mm m
fumOAA suc
SDH SDH SDH
i OAA a suc a fum
SDH i mm
fumsuc
SDH SDH
a suc a fum
K
K C K C C C C C
K
CC C
K K K
CC
K K
α
α
 
+ + +   
        
 
+ + +  
 =
 
+ +  
 
   
,
,
,
,
,
,
,
,
,
,
. *
.
*
*
. *
*
*
*
. *
*
2
4 1
f SDH
eq SDH
SDH 3
m suc
SDH 3
m COQ
SDH 3
m QH
SDH 3
m fum
SDH 3
i suc
SDH 3
i fum
SDH 3
i OAA
SCoAS 3
a suc
a
V 5 81 10 mMh
K 1 21
K 467 10 mM
K 480 10 mM
K 2 45 10 mM
K 1200 10 mM
K 120 10 mM
K 1275 10 mM
K 1 5 10 mM
K 450 10 mM
K
−
−
−
−
−
−
−
−
−
=  
=
=
=
=
=
=
=
=
=
, *
SCoAS 3
fum 375 10 mM
−=
 
 
Fumarase (FUM) 
The rate equation for FUM was taken from [214].  The kinetics of FUM was modeled as 
ordered uni uni mechanism. The kinetic constants were adopted from previous literature 
[217, 218, 227, 230, 231]. 
Equation S30. Fumarase (FUM) 
,
,
,
, , 1
,
, 1
, , , , ,
1
m
m mal
f FUM fum
eq FUM
FUM FUM m
m fum malFUM m
m fum FUM i fum FUM
m mal
m m m mm
ATP fATP ADP fADP GTP fGTP GDP fGDPcit
FUM i FUM FUM FUM FUM FUM
i cit i ATP ATP i ADP ADP i GTP GTP i GDP
CV C
K
r
K C
K C
K
C P C P C P C PC
K K P K P K P K P
α
α
 
−  
 =
+ +
= + + + + +
GDP
       
,
,
,
,
,
,
,
,
,
. *
.
. *
. *
*
*
*
*
*
4 1
f FUM
eq FUM
FUM 3
m fum
FUM 3
m mal
FUM 3
i cit
FUM 3
i ATP
SDH 3
i ADP
SDH 3
i GTP
SDH 3
i GDP
V 2 21 10 mMh
K 4 56
K 44 7 10 mM
K 197 7 10 mM
K 3500 10 mM
K 40 10 mM
K 400 10 mM
K 80 10 mM
K 330 10 mM
−
−
−
−
−
−
−
−
=  
=  
=
=
=
=
=
=
=
 
Malate Dehydrogenase 2 (MDH2) 
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MDH2 is the isoform that is present in the mitochondria. The rate equation for MDH2 was 
taken from [214].  The kinetics of MDH2 employs the ordered bi bi mechanism. The kinetic 
constants were adopted from previous literature [217, 218, 232, 233]. 
Equation S31. Malate Dehydrogenase 2 (MDH2) 
, 2
, 2
2 2
2 2 2 2 ,
, 2, , 2, 2 2, ,
, ,
,
m m
m m OAA NADH
f MDH malNAD
eq MDH
MDH MDH m m m m m
mal NADH mal OAAMDH MDH MDH m MDH m m m m NAD NAD
m mal MDH i m mal MDH i mal mal MDH MDHi NAD NAD m NAD NAD
i NADH i OAA
i NA
C CV C C
K
r
K C C C C C
K K K C K C C C
K K
K
α α
+
+ +
+ + + +
 
−  
 =
+ + + + + +
2 2 2
, 2 2
, 2, ,2 2 2 2
, , ,,
2, 2
,
1
MDH MDH MDH m m m
m mal MDH m MDH m m m m mD mNADH mal OAA NADH
m NADH MDH i OAA m OAA NADH OAA OAA NADHMDH MDH MDH MDHNAD
i NADH m OAA i mali NAD
m
ATP fATP
MDH i MDH
i ATP ATP
K K C C CK C K C C C C C
K K K K
C P
K P
α
α
+
+
+
  
+ + + +      
= + + 2 2
, ,
m m
ADP fADP AMP fAMP
MDH MDH
i ADP ADP i AMP AMP
C P C P
K P K P
 
+  
 
   
                                                                                         
,
,
,
,
,
,
,
. *
. *
. *
*
. *
. *
*
8 1
f MDH 2
4
eq MDH 2
MDH 2 3
m NAD
MDH 2 3
m mal
MDH 2 3
m OAA
MDH 2 3
m NADH
MDH 2 3
i NAD
V 3 53 10 mMh
K 4 02 10
K 90 55 10 mM
K 250 10 mM
K 6 128 10 mM
K 2 58 10 mM
K 279 10 mM
+
+
−
−
−
−
−
−
−
=  
=
=
=
=
=
=
            
,
,
,
,
,
,
*
. *
. *
. *
. *
. *
MDH 2 3
i mal
MDH 2 3
i OAA
MDH 2 3
i NADH
MDH 2 3
i ATP
MDH 2 3
i ADP
MDH 2 3
i AMP
K 360 10 mM
K 5 5 10 mM
K 3 18 10 mM
K 183 2 10 mM
K 394 4 10 mM
K 420 0 10 mM
−
−
−
−
−
−
=
=
=
=
=
=
 
NAD/NADH SHUTTLES 
Glutamate Oxaloacetate Transaminase 2 (GOT2) 
GOT2 is the isoform that is present in the mitochondria. The rate equation for GOT2 was 
taken from [214].  The kinetics of GOT2 is modeled as ping pong bi bi mechanism. The 
kinetic constants were adopted from previous literature [234]. 
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Equation S32. Glutamate Oxaloacetate Transaminase 2 (GOT2) 
, 2
, 2
2 2
,2 2
, , 2, 2
,
2 2
, , ,
2 2
, ,
m m
OAA glum m
f GOT asp akg
eq GOT
GOT GOT m m
m asp akg gluGOT m GOT m m m
m akg asp m asp GOT i akg asp akg GOT
i glu
GOT GOT GOT m m
i asp m akg m glu asp OAA
GOT GOT
m OAA i glu i
C C
V C C
K
r
K C C
K C K C C C
K
K K K C C
K K K
α
 
−  
 =
+ + + +
 
  
 
2 2
, 2, ,2
,
2, 2
,
1
m m GOT m GOT m
OAA glu m glu GOT i OAA m OAA gluGOT
asp
m
akg
GOT i GOT
i akg
C C K C K C
C
K
α
α
 
+ + +  
 
 
= +  
 
 
,
,
,
,
,
,
,
,
,
,
,
. *
.
.
.
*
.
.
.
*
.
.
6 1
f GOT
eq GOT
GOT
m asp
GOT
m akg
GOT 3
m OAA
GOT
m glu
GOT
i asp
GOT
i akg
GOT 3
i OAA
GOT
i glu
GOT
i AKG
V 3 87 10 mMh
K 1 56
K 0 89 mM
K 3 22 mM
K 88 10 mM
K 32 5 mM
K 3 9 mM
K 0 73 mM
K 48 10 mM
K 10 7 mM
K 26 5 mM
−
−
−
=  
=
=  
=  
=
=  
=  
=  
=
=  
=  
 
Malate Dehydrogenase 1 (MDH1)  
MDH1 is the isoform that is present in the mitochondria. The rate equation and kinetic 
constants for MDH1 were taken from [235].  The kinetics of MDH1 was modeled as 
ordered bi bi mechanism. 
Equation S33. Malate Dehydrogenase 1 (MDH1) 
, 1
, 1
1
,1 1 1 1
, , , , 1 1
,,
1
, ,
1
c c
malc c NAD
mf MDH OAA NADH
eq MDH
MDH c c c c c
m NADH OAAMDH MDH MDH c MDH c c c OAA NADH malNAD
i NADH m OAA m OAA NADH m NADH OAA OAA NADH MDH MDH
i mali NAD
MDH M
i NADH m OAA
MDH
C C
V C C
K
K C C C C CK K K C K C C C
K K
K K
r
+
+
+
 
−  
 
+ + + + +
+
=
11
1 1 ,
,1 1 1 1,
, , ,,
MDH c c c c cDH
Mal NADH Mal OAAMDH c MDH c m NAD c c NAD
mal m mal MalMDH MDH MDH MDHm NAD NAD NAD
m mal i NADH i OAAi NAD
K C C C C C
K C K C C C
K K K K
+ +
+ + +
+
 
+ + + +  
 
      
                                                              
7 -1
, 1
4
, 1
1
,
1
,
1
,
3.59*10  
2.67*10
0.114 
1.1 
0.088 
mf MDH
eq MDH
MDH
m NAD
MDH
m mal
MDH
m OAA
V mM h
K
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K mM
K mM
+
=
=
=
=
=
       
1
,
1 3
,
1 3
,
1
,
1
,
0.026 
4.9*10  
63*10  
7.1 
0.94 
MDH
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MDH
i NADH
MDH
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MDH
i mal
MDH
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K mM
K mM
K mM
K mM
K mM+
−
−
=
=
=
=
=
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Glutamate Oxaloacetate Transaminase 1 (GOT1)  
GOT1 is the isoform that is present in the cytosol. The rate equation for GOT1 was taken 
from [214].  The kinetics of GOT1 was modeled as ping pong bi bi mechanism. The kinetic 
constants were adopted from previous literature [234]. 
Equation S34. Glutamate Oxaloacetate Transaminase 1 (GOT1) 
, 1
, 1
1 1
,1 1
, , 1, 1
,
1 1 1
, , ,
1 1
, ,
c c
OAA gluc c
mf GOT asp akg
eq GOT
GOT GOT c c
m asp akg gluGOT c GOT c c c
m akg asp m asp GOT i akg asp akg GOT
i glu
GOT GO GOT c c
i asp m akg m glu asp OAA
GOT GOT
m OAA i glu
C C
V C C
K
r
K C C
K C K C C C
K
K K K C C
K K K
α
 
−  
 =
+ + + +
 
  
 
1 1
, 1, ,1
,
1, 1
,
1
c c GOT c GOT c
OAA glu m glu GOT i OAA m OAA gluGOT
i asp
c
akg
GOT i GOT
i akg
C C K C K C
C
K
α
α
 
+ + +  
 
 
= +  
 
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3 1
mf GOT 1
eq GOT
GOT
m asp
GOT
m akg
GOT 3
m OAA
GOT
m glu
GOT
i asp
GOT
i akg
GOT 3
i OAA
GOT
i glu
GOT
i akg
V 2 36 10 mMh
K 1 56
K 4 4mM
K 0 38mM
K 95 10 mM
K 9 6mM
K 3 9mM
K 0 73mM
K 48 10 mM
K 8 4mM
K 26 5mM
−
−
−
=  
=
=
=
=
=
=
=
=
=
=
 
α-Ketoglutarate –Malate shuttle (AKGMAL) 
The rate equation for AKGMAL was taken from [214].  The kinetics of AKGMAL was 
modeled as rapid equilibrium random bi bi mechanism. The kinetic constants were adopted 
from previous literature [236]. 
Equation S35. α-Ketoglutarate –Malate shuttle (AKGMAL) 
( ),
, ,
, , , , , , ,
2
c m m c
mf AKGMAL akg mal akg mal
AKGMAL c m c m m cc m
akg akg mal akg mal akgiAKGMAL AKGMAL mal mal
m akgi m malx AKGMAL AKGMAL AKGMAL AKGMAL AKGMAL AKGMAL AK
m mali m malx m akgi m akgx m mali m akgx m malx
V C C C C
r
C C C C C CC CK K
K K K K K K K
−
=
+ + + + + +
,
GMAL AKGMAL
m akgiK
 
  
 
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6 -1
,
,
,
,
,
3.19*10  
0.4 
10 
1.3 
0.17 
mf AKGMAL
AKGMAL
m mali
AKGMAL
m malx
AKGMAL
m akgi
AKGMAL
m akgx
V mM h
K mM
K mM
K mM
K mM
=
=
=
=
=
 
Aspartate –Glutamate shuttle (ASPGLU) 
The rate equation for ASPGLU was taken from [214].  The kinetics of ASPGLU was 
modeled as rapid equilibrium random bi bi with charge translocation mechanism. The 
kinetic constants were adopted from previous literature [237]. 
Equation S36. Aspartate –Glutamate shuttle (ASPGLU) 
( ), ,
, , ,
, , , ,
(2
c m m m c c
mf ASPGLU eq ASPGLU asp glu asp gluH H
ASPGLU c m m m cc
asp glu aspaspASPGLU ASPGLU ASPGLU H H
eq ASPGLU i aspi i glux ASPGLU ASPGLU ASPGLU ASPGLU ASPGLUH
i aspi i aspi i glux i aspxH
V K C C C C C C
r
C C C C CC
K K K K m m m
K K K K K K
+ +
+ +
+
+
−
=
+ + +
,
, , , , ,
m
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ASPGLU ASPGLU
i aspxH
m c c c m m c c c m m
asp glu asp glu gluH H H H H H
ASPGLU ASPGLU ASPGLU ASPGLU ASPGLU ASPGLU ASPGLU ASPGLU ASPGLU ASPGLU
i aspx i glui i aspi i glui i gluxH H H H H H
C
m
K
C C C C C C C C C C C
m m m m m
K K K K K K K K K K K
+
+ + + + + +
+ + + + +
+ +
+ + + + + )ASPGLU
+
       
                                                                                                                          
4 -1
,
,
,
,
,
,
6.5
2.49*10  
0.6
0.028 
2.8 
0.18 
1.6 
10
1.8
mf ASPGLU
eq ASPGLU
ASPGLU
i aspi
ASPGLU
i aspx
ASPGLU
i glui
ASPGLU
i glux
ASPGLU
H
V mM h
K
K mM
K mM
K mM
K mM
K mM
m
+
−
=
=
=
=
=
=
=
 = 
 
 
TRANSPORTERS 
Glucose Transporter (GLUT):  Glucose transporters mediate transport of glucose across 
plasma membranes.  Till date, fourteen glucose transporters (isozymes) have been 
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identified which perform the same function but have very different kinetic properties [238]. 
Kinetics of the GLUT1 isozyme was considered in the model and was modeled as uni uni 
steady state kinetics. 
Equation S37. Glucose Transporter (GLUT): 
1
GlcTr GlcTr
mf mr
e c
glc glc
GlcTr GlcTr
glc glc
GlcTr e c
glc glc
GlcTr GlcTr
glc glc
V
C C
V
K K
r
C C
K K
−
+
=
+
                                                        
-1
-1
7.67 mM
0.767 mM
1.50 
GlcTr
mf
GlcTr
mr
GlcTr
glc
V h
V h
mMK
=
=
=
 
The rate equations and kinetic constants for GLUT isoforms. Isoform-specific parameters are colored 
blue. 
4
1
7.27 
7.27 
i
i
i
i i
i
i
e c
glc glc
mf mr
e c
glc g
GLUT GLUT
GLUT
GL
GLUT GLUT
e,glc c,gl
lc
-1
mf
-1
mr
GLUT
i
c
GLUT GLUT
e,gl
UT
GLUT
GLUT GLUT
c c,glc
C C
V -V
r = 
C C
1+ +
V = mM h
V = mM h
r r
K K
K K
ρ
=
= ∑
 
 ,
i
e glc
GLUTK  ,
i
c glc
GLUTK
10 
Refs. 
GLUT1 3 0.3 [239] 
GLUT2 17 1.7 [239, 240] 
GLUT3 1.411 0.14 [241] 
GLUT4 6.6 0.66 [239] 
 
 iGLUT
ρ  
D6 D10 D14 D20 
GLUT1 0.13 0.08 0.12 0.30 
GLUT2 0.005 0.005 0.007 0.008 
GLUT3 0.86 0.85 0.73 0.68 
                                                 
10 ,
i
c glc
GLUTK was estimated as 10% of , ie glc
GLUTK  
11 For deoxyglucose 
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GLUT4 0.006 0.005 0.005 0.005 
 
Pyruvate –Hydrogen shuttle (PYRH)  
PYRH was modeled as reversible mass action kinetics. The rate equation was taken from 
[246]. 
Equation S38. Pyruvate –Hydrogen shuttle (PYRH) 
( ), c c m mPYRH m PYRH pyr pyrH Hr V C C C C+ += −                                                           -1, 13=   1*10m PYRHV mM h  
Citrate –Malate shuttle (CITMAL)  
CITMAL was modeled as reversible mass action kinetics. The rate equation was taken 
from [246]. 
Equation S39. Citrate –Malate shuttle (CITMAL) 
( ), c m m cCITMAL m CITMAL cit mal cit malr V C C C C= −                                                       -1, 296.6  m CITMALV mM h=   
Malate-Phosphate shuttle (MALPi)  
MALPi was modeled as reversible mass action kinetics. The rate equation was taken from 
[246]. 
Equation S40. Malate-Phosphate shuttle (MALPi) 
( ), c m m cMALPi m MALPi mal Pi mal Pir V C C C C= −                                                               -1, 17.3  m MALPiV mM h=   
Glutamate-Hydrogen shuttle (GLUH)  
GLUH was modeled as reversible mass action kinetics. The rate equation was taken from 
[246]. 
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Equation S41. Glutamate-Hydrogen shuttle (GLUH) 
( ), c c m mGLUH m GLUH glu gluH Hr V C C C C+ += −                                                    
8 -1
, 3.87*10  m GLUHV mM h=   
OTHER REACTIONS 
Glutaminase (GLS)  
The kinetics of GLS was modeled as simple Michaelis-Menten kinetics with non-
competitive inhibition by glutamate. The kinetic constants for GLS were taken from [242]. 
Equation S42. Glutaminase (GLS) 
,
,
,
,
1
m
gluc
m GLS gln
eq GLS
GLS m
gluGLS c
m gln glnGLS
i glu
C
V C
K
r
C
K C
K
 
−  
 =
 
+ +  
 
                                                                  
-1
,
,
,
,
38.8  
1
12
55
m GLS
eq GLS
GLS
m gln
GLS
i glu
V mM h
K
K mM
K mM
=  
=
=  
=  
 
Glutamate Dehydrogenase (GDH) 
The kinetic constants for GDH were taken from [243, 244].  The kinetics of GDH was 
modeled as random bi bi mechanism.  
Equation S43. Glutamate Dehydrogenase (GDH) 
3
,
,
, ,3
, , ,
, ,
, 3
, 3
m m m
m m AKG NADH NH
f GDH NAD Glu
eq GDH
GDH GDH GDH mm m m
GDH GDH GDH m GDH m m m i NAD m Glu NADHGlu NAD NH
i NAD Glu m Glu NAD m NAD Glu Glu NAD GDH GDH
i AKG i NADH
GDH m m
m Glu NAD NH
GDH
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C C CV C C
K
r
K K CC C CK K K C K C C C
K K
K C C
K
 
−  
 =
+ + + + +
+ + , , , 3 , 3
, 3 , , , , 3 ,
, , , 3
, 3 , ,
GDH GDH GDH m m GDH m m m m m m
i NAD m Glu m NADH AKG NH m NAD Glu NADH Glu AKG NAD NH
GDH GDH GDH GDH GDH GDH
m NH i AKG i NADH i NADH i NH i AKG
GDH GDH GDH m m
i NAD m Glu m AKG NADH NH
GDH GDH
m NH i AKG i NADH
K K K C C K C C C C C C
K K K K K K
K K K C C
K K K
+ +
+ , , , 3
, 3 , , ,
, , , 3 , ,
, 3 , , ,
GDH GDH GDH m m m m m m
i NAD m Glu m AKG NH AKG NADH Glu NAD AKG
GDH GDH GDH GDH GDH
m NH i AKG i NADH i AKG
GDH GDH GDH m GDH GDH m m m
i NAD m Glu m AKG NH i NAD m Glu Glu NADH AKG
GDH GDH GDH
m NH i AKG i Glu i AK
K K K C C C C C C
K K K K
K K K C K K C C C
K K K K
+ +
+ + , ,
, , ,
, , 3 , , 3
, 3 , , , 3 , , ,
GDH GDH m m
i NAD m Glu AKG NADH
GDH GDH GDH GDH
G i NADH i AKG i NADH
GDH GDH m m m GDH GDH m m m m
m NADH m Glu NH AKG NAD i NAD m Glu Glu AKG NADH NH
GDH GDH GDH GDH GDH GDH
m NH i AKG i NADH m NH i Glu i AKG i NADH
K K C C
K K K
K K C C C K K C C C C
K K K K K K K
+
+ + GDH
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3 -1 -1
,
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0.04 
1.1 
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0.25 
f GDH
GDH
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K
K
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=
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,
, 3
,
,
,
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0.004 
1 
0.003eq GDH
GDH
i NH
GDH
i Glu
GDH
i NADH
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mM
mM
mM
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K
K
K
K
K
=
=
=
=
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ATP-Citrate Lyase (CLY)  
The kinetics of CLY was modeled as ordered bi bi mechanism. The kinetic constants were 
adopted from previous literature [245-248]. 
 
Equation S44. ATP-Citrate Lyase (CLY) 
,
,
, , , ,
, ,
, ,
,
, ,
c c
m CLY cit CoASH
CLY CLY c c c c c
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V C C
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K
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+ + + + +
+ ,,
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CLY c c c c c
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=
 
 
Mitochondrial Malic Enzyme (MMALIC)  
The rate equation and kinetic constants for CMALIC were adopted from [249]. The 
kinetics of CMALIC was modeled as ordered bi ter mechanism. 
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Equation S45. Mitochondrial Malic Enzyme (MMALIC) 
2
,
,
1
m m m
pyr NADH COm m
mmalic mal NAD
eq mmalic
mmalic m
mmalic m mmalic m mmalic mmalicATP
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Cytosolic Malic Enzyme (CMALIC)  
The rate equation and kinetic constants for CMALIC were taken from [250]. The kinetics 
of CMALIC was modeled as ordered bi ter mechanism. 
Equation S46. Cytosolic Malic Enzyme (CMALIC) 
2
2
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, , , ,
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c c c
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CO i CO mal mal COm mal m NADPH NADP pyri NADP m mal NADPH
cmalic cmalic cmalic cmalic cmalic cmalic cmalic
i NADPH i pyr i NADPH m CO i mal m CO i mal
C K C C CK K C CK K C
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Glutamate Alanine Transaminase (GPT) 
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The rate equation and kinetic constants for GPT were taken from [251].  The kinetics of 
GPT was modeled as ping pong bi bi mechanism.  
Equation S47. Glutamate Alanine Transaminase (GPT) 
,
,
,
,
, ,
m m
Pyr Glum m
f GPT Ala AKG
eq GPT
GPT GPT m m GPT m m GPT m m
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Pyruvate Carboxylase (PC)  
The kinetics of PC was modeled as bi uni mechanism. The kinetic constants for PC were 
taken from [252]. 
Equation S48. Pyruvate Carboxylase (PC) 
2
2 2 2 2
,
, , , ,
m
m m OAA
PC pyr CO
eq PC
PC PC PC PC m PC m m m
m pyr m CO m pyr CO m CO pyr pyr CO
CV C C
K
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K K K C K C C C
 
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2
-1 -1
,
,
,
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m pyr
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K
K
=
=
=
=
                            
Mono Carboxylate Transporter (MCT)  
The kinetics of MCT was modeled as ordered bi bi mechanism. The kinetic constants for 
MCT were adopted from [253, 254]. 
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Equation S49. Mono Carboxylate Transporter (MCT) 
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m laci lac m laci lac m laci laci H m H H m H H H
MCT c e MCT e c c c e
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cit
Hcit Mgcit Kcit
C C CP
K K K
+
= + + +  
1
m
H
scoa
Hscoa
C
P
K
+
= +  
1
m m
H K
fATP
HATP KATP
C C
P
K K
+ +
= + +  
7
4
2
2.57*10
1.51*10
1.35*10
HATP
MgATP
KATP
K M
K M
K M
−
−
−
=
=
=
 
7
3
2
3.8*10
1.62*10
2.95*10
HADP
MgADP
KADP
K M
K M
K M
−
−
−
=
=
=
 
7
2
2
6.03*10
1.38*10
8.91*10
HAMP
MgAMP
KAMP
K M
K M
K M
−
−
−
=
=
=
 
 
 
 
97.41*10HCoASHK M
−=  
6
4
1
2.34*10
4.27*10
4.58*10
Hcit
Mgcit
Kcit
K M
K M
K M
−
−
−
=
=
=
 
41.1*10HscoaK M
−=  
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1
m m
H K
fADP
HADP KADP
C C
P
K K
+ +
= + +  
1
m m
H K
fAMP
HAMP KAMP
C C
P
K K
+ +
= + +  
fGTP fATPP P=  
fGDP fGDPP P=  
 
 
 
 
 
 
 
8.3.2 Differential Equations 
Mulukutla, B.C., et al., Multiplicity of Steady States in Glycolysis and Shift of Metabolic 
State in Cultured Mammalian Cells. Plos One, 2015. 10(3). 
GLYCOLYSIS 
1. Glucose: 
c
glc
GlcTr HK
dC
r r
dt
= −  
2. Glucose 6-phosphate: 6 6
c
g p
HK GPI G PD
dC
r r r
dt
= − −  
3. Fructose 6-phosphate: 6 2 2 2,6
c
f p
PGI TA TK PFK F BPase PFK
dC
r r r r r r
dt
= + + − + −  
4. Fructose 1,6-bisphosphate: 16
c
f bp
PFK ALD
dC
r r
dt
= −  
5. Fructose 2,6-bisphosphate: 26 2 2,6
c
f bp
PFK F BPase
dC
r r
dt
= −  
6. Dihydroxyacetone phosphate: 
c
dhap
ALD TPI
dC
r r
dt
= −  
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7. Glyceraldehyde 3-phosphate: 1 2
c
gap
ALD TPI TK TK TA GAPDH
dC
r r r r r r
dt
= + + + − −  
8. 1,3-bisphosphoglycerate: 1,3
c
bpg
GAPDH PGK
dC
r r
dt
= −  
9. 3-phosphoglycerate:     3
c
pg
PGK PGM
dC
r r
dt
= −  
10. 2-phosphoglycerate: 2
c
pg
PGM EN
dC
r r
dt
= −  
11. Phosphoenolpyruvate: 
c
pep
EN PK
dC
r r
dt
= −  
12. Pyruvate: 
c
pyr
PK LDH PYRH CMALIC
dC
r r r r
dt
= − − +    
13. Lactate: 
c
lac
LDH MCT
dC r r
dt
= −  
PENTOSE PHOSPHATE PATHWAY 
14. 6-phosphogluconate: 6 6 6
c
pg
G PD PGD
dC
r r
dt
= −  
15. Ribulose 5-phosphate:  5 6
c
ru p
PGD RPE RPI
dC
r r r
dt
= − −   
16. Xylulose 5-phosphate: 5 1 2
c
xyl p
RPE TK TK
dC
r r r
dt
= − −  
17. Ribose 5-phosphate: 5 1
c
r p
RPI PRPPS TK
dC
r r r
dt
= − −  
18. Erythrose 4-phosphate: 4 2
c
e p
TA TK
dC
r r
dt
= −  
19. Sedoheptulose 7-phosphate: 7 1
c
s p
TK TA
dC
r r
dt
= −  
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20. Glutathione: 
c
glutathione
GSSGR GSHOX
dC
r r
dt
= −  
TCA CYCLE 
21. Mitochondrial pyruvate: 1
m
pyr c
PYRH PDH mmalic PC GPT
m
dC Vr r r r r
dt V
= ∗ − + − +  
22. Mitochondrial Acetyl-CoA: 
m
AcCoA
PDH CS
dC r r
dt
= −  
23. Mitochondrial Citrate: 
m
cit
CS ACON CITMAL
dC r r r
dt
= − +  
24. Mitochondrial Isocitrate: 
m
icit
ACON IDH
dC r r
dt
= −  
25. Mitochondrial Alpha-ketoglutarate: 2 1
m
akg
IDH AKGD AKGMAL GOT GDH GPT
dC
r r r r r r
dt
= − + − + −  
26. Mitochondrial Succinyl-CoA: 
m
SCoA
AKGD SCOAS
dC r r
dt
= −  
27. Mitochondrial Succinate: 
m
suc
SCOAS SDH
dC r r
dt
= −  
28. Mitochondrial Fumarate: 
m
fum
SDH FUM
dC
r r
dt
= −  
29. Mitochondrial Malate: 2
m
mal
FUM mmalic MDH AKGMAL CITMAL MALPi
dC r r r r r r
dt
= − − − − +  
30. Mitochondrial Oxaloacetate: 2 2
m
OAA
CS MDH GOT PC
dC r r r r
dt
= − + + +  
NAD/NADH SHUTTLES 
31. Mitochondrial Aspartate: 2
m
asp
ASPGLU GOT
dC
r r
dt
= −  
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32. Mitochondrial Glutamate: 2 1
m
glu
GOT ASPGLU GDH GLUH GPT
dC
r r r r r
dt
= − − − +  
33. Aspartate: 1
c
asp m
GOT ASPGLU
c
dC Vr r
dt V
= − − ∗  
34. Glutamate: 1
c
glu m m
GOT ASPGLU GLUH GLS
c c
dC V Vr r r r
dt V V
= + ∗ − ∗ +  
35. Oxaloacetate: 1 1
c
OAA
GOT MDH CLY
dC r r r
dt
= − +  
36. Malate: 1
c
mal m m m
MDH AKGMAL CITMAL MALPi cmalic
c c c
dC V V Vr r r r r
dt V V V
= + ∗ + ∗ − ∗ −  
37. Alpha-ketoglutarate: 1
c
akg m
AKGMAL GOT
c
dC Vr r
dt V
= − ∗ −  
OTHER EQUATIONS 
38. Citrate: 
c
cit m
CITMAL CLY
c
dC Vr r
dt V
= − ∗ −  
39. NAD: 1
c
NAD
LDH GAPDH MDH
dC r r r
dt
= − +  
40. NADP: 6 6
c
NADP
GSSGR G PD PGD cmalic
dC r r r r
dt
= − − −  
 
